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INTRODUCTION: inflammation increases the production of pro-inflammatory 
cytokines, that, on binding to their respective receptors in the liver, stimulate 
the synthesis of native CRP (nCRP). nCRP can be dissociated into sub-units 
or monomeric CRPs (mCRPs) and can be locally accumulated with 
macrophages in the same chronic inflamed tissue. Therefore, the goal of the 
present project was to investigate the potential of mCRP pro-inflammatory 
activity and the potential of new effective small molecule inhibitors (SMIs) in 
blocking mCRP effects. MATERIALS AND METHODS: differentiated human 
U937 macrophage-like cells were stimulated by mCRP in the presence or 
absence of small molecular compounds, such as Acetylcholine (ACh) and 
Nicotine or the 3H12 antibody. The levels of tumour necrosis factor-α (TNF-α), 
Interleukin-6 (IL-6); and IL-10 were determined by enzyme-linked 
immunosorbent (ELISA) assay. Western Blotting was used to evaluate the 
intrinsic pro-inflammatory pathway. The RT-PCR was used to determine 
mCRP RNA gene expression. RESULTS: mCRP increased TNF-α and IL-6 
concentrations. ACh significantly inhibited the mCRP induced TNF-α and IL-6 
release. Western blotting confirmed that ACh blocks mCRP-induced cell 
signalling phosphorylation of ERK, JNK, and NF-KB. The RT-PCR results 
showed that mCRP increases cytokine RNA expression, whereas ACh was 
unable to reduce it. CONCLUSIONS: this study demonstrated that mCRP had 
a robust pro-inflammatory activity, whilst the use of ACh inhibited its pro-
inflammatory activity, therefore reducing TNF-α, IL-6 and IL-10 release. 
Indeed, it is likely that the monomeric CRP could be a promising new target for 
the prevention and treatment of chronic inflammation tissue associated with 
chronic kidney diseases, arteriosclerosis and stroke. 
 
Keywords: Inflammation, monomeric C-reactive protein; inflammation; 
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1.1.1 Inflammation. 
Injury can interfere with the fundamental equilibrium (homeostasis) necessary 
for the survival of the organism. After homeostasis disruption, inflammation 
steps in as the first phase of the wound healing process (WHP) (Serra et al., 
2017). The word inflammation comes from the Latin term, “inflammare” (to set 
on fire) and was first designated by Cornelius Celsus, who described this 
phenomenon using adjectives such as swelling, redness, heat, and pain 
(Freire and Dyke, 2013). Inflammation is a natural mechanism, with the primary 
aim of protecting the host from any factors that could potentially interfere with 
normal homeostasis (Chen et al., 2018). A brief summary of the inflammation 
phase will be given for the purpose of the studies described in this thesis.  
1.1.2 Acute Inflammation. 
 
The most commonly example used to explain the inflammation phase is that 
of Acute Skin Wound Healing (Eming et al., 2007; Larouche et al., 2018; 
Canedo-Dorantes and Canedo-Ayala, 2019). This process starts when the 
components of the coagulation cascade and immune system cells are 
attracted to the injured site to avoid substantial blood and fluid loss (Weiss, 
2008). This mechanism is triggered to prevent potential and hazardous 
infections and to eliminate dead tissues (Gurtner et al., 2008). That is, the first 
bacterial pathogens to penetrate the injury are identified by the Toll-like 
receptors (TLRs), which are trans-membrane-spanning receptors normally 
expressed in sentinel cells, such as tissue resident macrophages, dendritic 
cells, neutrophils and monocytes (Gerold et al., 2007; Hemmi and Akira, 2005; 
Prince et al., 2011). Once the pathogens have been recognized, this process 
allows their elimination through the production of pro-inflammatory cytokines, 
chemokines and prostaglandins (Freire and Dyke, 2013). At the beginning of 
the inflammatory stage, endothelial cells (ECs) increase the expression of both 
chemokines and cell adhesion molecules (CAMs) on the surface of their 
membrane (Martin, 1997; P et al., 2003). Both chemokines and CAMs allow 
for the recruitment of neutrophils from the circulation to the wound site (Pate 
et al., 2010). Once recruited, neutrophils eliminate invading agents and/or 
other potentially hazardous microorganisms, by increasing the concentration 
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of chemokines, cytokines and active antimicrobial substances, such as 
reactive oxygen species (ROS) (Gonzalez et al., 2016). The exponential 
increase of several chemotactic cytokines (Deshmane et al., 2009) is followed 
by an invasion of mononuclear phagocyte cells (monocytes) through vascular 
leakage (Rodero et al., 2014). Once monocytes have differentiated into 
macrophages (Yang et al., 2014a), they increase the concentration of several 
pro-inflammatory cytokines and eliminate any potentially harmful microbicidal 
activity (Thuraisingam et al., 2010; Rodero and Khosrotehrani, 2010).  
1.1.3 Cytokines. 
 
Cytokines are specifically secreted proteins, such as lymphokines, monokines, 
chemokines and interleukins with autocrine, paracrine and/or endocrine 
activity (Zhang and An, 2007). These proteins are released by several cells 
during the inflammatory response to activate and regulate the immune system 
response (Kany et al., 2019).  
 
1.1.3.1 Tumor Necrosis Factor-α (TNF-α). 
 
TNF-α is a pleotrophic polypeptide, which plays a pivotal role during 
inflammation, cell proliferation, differentiation and apoptotic activities 
(Feuerstein et al., 1994; Baud and Karin, 2001). This 26 kDa homotrimer 
transmembrane protein is synthesised by several immune system cells (T-
lymphocytes, natural killer cells and macrophages) when they are stimulated 
by Lipopolysaccharides (LPS) or in the presence of other pathological medical 
conditions (Van Deventer, 1997; van der Bruggen et al., 1999; Zelová and 
Hošek, 2013; Bokhari et al., 2014). After being synthesised, TNF-α remains 
attached to the cell surface until the TNF-converting enzyme modifies it into a 
soluble TNF form with a molecular mass of 17 kDa (Ramana, 2010). Once 
converted, this pro-inflammatory cytokine is released into the bloodstream 
(Black et al., 1997). Under normal physiological conditions, there is a low TNF-
α level (Mirzaei and Mahmoudi, 2018). However, during infection or traumatic 
events, there is a significant rise in the TNF-α concentration (Robak et al., 
1998; B. Johnston and Conly, 2006). When TNF is released into the 
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bloodstream, this pro-inflammatory cytokine mediates its activity through the 
activation of TNF receptors (TNFR1 or TNFR2) that are expressed in all 
tissues (Yang et al., 2018). Both TNFR1 and/or TNFR2 are capable of 
stimulating the nuclear factor kappa-light-chain-enhancer of activated B cells 
(also known as a Nuclear Factor-KB or NF-KB) which leads to a cell death 
(TNFR1) or cell survival (TNFR2) response (Yang et al., 2018). Once TNF-α 
is released, together with interleukin-6 (IL-6), it triggers several acute-phase 
protein (APPs) secretions (Moshage, 1997), such as the pentameric or native 
C-reactin protein (nCRP) and or alpha 1-acid glycoprotein (alpha 1AG) (Meijer 
et al., 1993). Evidence of the capacity TNF-α has to increase nCRP production 
has been reported by Calabro et al. (2003) who observed that there is an 
increase in nCRP synthesis when human coronary artery smooth muscle cells 
(HCASMCs) are exposed to TNF-α.  
 
1.1.3.2 Interleukin-1β (IL-1β). 
 
IL-1β is a pro-inflammatory cytokine belonging to the IL-1 family (Allan et al., 
2005). IL-1β is secreted when extra cellular stimuli, such as Damage 
Associated Molecular Pattern molecules (DAMPs), Pathogen Associated 
Molecular Pattern (PAMPs) viruses, LPS, UV light, oxidative stresses, 
inflammatory stimuli and cytokines (Shih et al., 2015), bind to pattern 
recognition receptors (PRRs) (Lopez-Castejon and Brough, 2011). When 
PRRs activate the mitogen-activated protein kinase (MAPK) this allows NF-KB 
to translocate into the nucleus and to up-regulate the IL-1β gene expression 
(de Oliveira et al., 2017). The up-regulation of the IL-1β gene expression 
increases the synthesis and release of IL-1β pro-inflammatory cytokines, 
which, once released into the circulation, bind to the IL-1 receptor (IL-1R) 
(Jensen et al., 2000; Meier et al., 2019). When IL-1β and IL-6 bind to their 
respective receptors on hepatocyte cells, these two pro-inflammatory 
cytokines trigger the release of several APPs, such as nCRP (Szalai et al., 
1998b; Calabro et al., 2003; Kramer et al., 2008). This process triggers Acute 
Phase Response (APR) activity (Dinarello, 2009; Dinarello et al., 2012; 
Garlanda et al., 2013).  
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1.1.3.3 Interleukin-6 (IL-6). 
 
IL-6 is a pro-inflammatory mediator which was first discovered in 1986 as a B-
cell differentiation factor-2 (BSF-2) (Hirano et al., 1986). This pro-inflammatory 
cytokine is secreted by several cells, such as ECs, neurons and macrophages 
(Chi et al., 2001; Li et al., 2009; Erta et al., 2012). IL-6 synthesis occurs when 
viruses, LPS, UV light, oxidative stresses, inflammatory stimuli or cytokines 
(Shih et al., 2015) bind to the PRRs (Pires et al., 2018). This allows the NF-KB 
to translocate into the nucleus and up-regulate the IL-6 mRNA gene 
expression (Lawrence, 2009; Tanaka et al., 2014). Once released into the 
bloodstream, IL-6 binds to hepatocyte cells (Schmidt-Arras and Rose-John, 
2016). This bond allows the CCAAT/enhancer binding protein ! (C/EBP!) and 
the C/EBP# transcription factors to enhance the amount of nCRP released into 
the bloodstream (Kushner and Feldmann, 1978; Heinrich et al., 1990; Zhang 
et al., 1996; Szalai et al., 1998a; Du Clos and Mold, 2004). Literature has 
reported a strong correlation between the amount of IL-6 released during 
inflammation activity and the increase in nCRP concentration (Szalai et al., 
1998a). A linear correlation between elevated IL-6 and nCRP levels has been 
confirmed in several patients with different types of infections (Sahbudak Bal 
et al., 2017; Herold et al., 2020) or medical diseases such as obesity, cancer, 
chronic kidney disease (CKD), atherosclerosis and stroke (Khaodhiar et al., 
2004; Béténé A Dooko et al., 2014; Luna et al., 2014). 
1.1.4 Acute-phase response (APR). 
 
When the inflammation phase increases the pro-inflammatory cytokine 
release, these pro-inflammatory markers bind to hepatocyte cells (Szalai et al., 
1998b; Calabro et al., 2003; Kramer et al., 2008; Schmidt-Arras and Rose-
John, 2016) and stimulate the liver to produce APPs (Fig 1.1) which are 
released into the circulation (Zhang and An, 2007; Zhou et al., 2016). Amongst 
the several pro-inflammatory cytokines, IL-6 has been identified as a the major 
stimulator of numerous APP proteins (Heinrich et al., 1990). When IL-6 binds 
to the IL-6R present on hepatocyte cells (Tanaka et al., 2014), this pro-
inflammatory cytokine activates the signal transducer and activator of 
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transcription-3 (STAT3) factor, C/EBP transcription factors and the NF-KB the 
transcription factors (Agrawal et al., 2003). The activation of these intrinsic 
pathways regulates the transcription of APR genes (Lowenstein and 
Matsushita, 2004). Activation of APR genes decreases the transthyretin, 
retinol binding protein (RBP), albumin and transferrin circulation protein but 
increases the nCRP, serum amyloid A (SAA), haptoglobin (Hp), alpha-1-
acidglycoprotein (A1GP), ceruloplasmin (Cp) and fibrinogen blood 
concentration (Ceron et al., 2005; Khalil and Al-Humadi, 2020). The increase 
in the aforementioned APPs are categorised as major when the APP increase 
is 10- to 100-fold, moderate when the APP increase is 2- to 10-fold, or minor 
when the APP increase is minimal (< 2-fold) (Cray et al., 2009). When there is 
a high concentration of both pro-inflammatory cytokines and APPs in blood, a 
wide range of biological, physiological, metabolic, immunological and neuro-
endocrinal changes take place (Gruys et al., 2005; Jain et al., 2011). This 
response is also known as an APR (Cray et al., 2009). Both inflammation and 
APR are identified by the presence of some pro-inflammatory mediators, such 
as nCRP (Jain et al., 2011; Ahmed et al., 2012). 
 
Fig 1.1. Acute-phase response. A schematic summary of how trauma, stress, injury and/or 
infection trigger the acute phase response. These factors increase the production of pro-
inflammatory cytokines, that, on binding to their respective receptor in the liver, they induce the 
synthesis of several APPs (nCRP has been recognised as a one of the most important). Adapted 
from: Cray, C., Zaias, J. and Altman, N. H. (2009) 'Acute phase response in animals: a review.' 
Comp Med, 59(6), Dec, 2009/12/26, pp. 517-526. 
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1.1.5 The pentameric or native C-reactive protein (nCRP). 
 
Particular attention has been paid to the study of nCRP, due to its capacity to 
rise exponentially in reaction to both infection and/or tissue damage (Gans et 
al., 2015). Various cell types can synthesize and secrete nCRP, such as 
peripheral blood lymphocytes (Kuta and Baum, 1986), respiratory epithelium 
(Sattar et al., 1999), neurons (Yasojima et al., 2000) , endothelial cells (Pasceri 
et al., 2000a), smooth muscle cells (Calabro et al., 2003), macrophages 
(Devaraj et al., 2009) and mainly hepatocytes (Hurlimann et al., 1966). The 
monomer of this protein has a molecular weight of 23 kDa (Osmand et al., 
1977) and composed of 206 amino acids aligned into two !-sheets (Shrive et 
al., 1996). Once synthesised, the monomers are assembled through disulfide 
bonds (Goodman et al., 1996). This process occurs in the endoplasmic 
reticulum and allows the nCRP to take on a pentameric form (Fig 1.2). 
Pentameric CRP is made up of five noncovalently associated protomers 
equally positionated around a central hole (Thompson et al., 1999; Du Clos 
and Mold, 2004). The pentameric or native-CRP (nCRP) forms remain inside 
the endoplasmic reticulum until the pro-inflammatory cytokine IL-6 (Szalai et 
al., 1998a; Du Clos and Mold, 2004) binds to the hepatocyte cells (Kushner 
and Feldmann, 1978; Zhang et al., 1996; Szalai et al., 1998a; Du Clos and 
Mold, 2004).  
Increased levels of nCRP have been reported in several types of infective 
mechanisms. Indeed, Póvoa et al. (2005) observed a substantial rise in the 
nCRP concentration (>8.7 mg/dL) in subjects with fungal infection with Gram-
positive and Gram-negative bacteria. Liu et al. (2010) reported that nCRP is a 
useful clinical biological marker, predictive of potential bacterial infection in the 
aging population. Haran et al. (2013) reported that there is also a rise in the 
nCRP protein (135.96 mg/L) in those affected by influenza and/or by a bacterial 
infection. 
nCRP is released into the circulation to discern pathogenic agents from 
damaged cells (Volanakis, 2001). Indeed, Ca2+-dependent binding enables 
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Fig 1.2. The pentameric or native C- reactive protein. This figure shows the native C- reactive protein (nCRP) in its typical annular pentameric form.  
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each monomer to bind to the phosphocholine (PCh) expressed in a lot of 
bacteria and/or fungus (Volanakis and Kaplan, 1971; Boncler and Watala, 
2009). When this binding occurs, nCRP triggers both the complement system 
and the phagocytosis activity which allows for the identification and elimination 
of bacteria (Mortensen, 2001; Chaplin, 2010). For example, an in vivo study 
reported that nCRP has a protective capacity when it binds to the PCh present 
in gram-positive pathogens such as Streptococcus pneumoniae through the 
activation of the complement system (Mold et al., 1981), Szalai et al. (2000) 
also reported that nCRP had protective proprieties against Salmonella enterica 
serovar typhimurium infection in transgenic CRPtg C57BL/6J congenic mice. 
Once the defensive activity of nCRP is concluded, this pentatrix is removed to 
the circulation and catabolized by hepatocytes (Hutchinson et al., 1994; 
Markanday, 2015). 
1.1.6 Chronic Inflammation. 
 
Under normal physiological conditions, a reduction in the level of nCRP is a 
sign that acute inflammation is progressing to the following stage (Kasapis and 
Thompson, 2005; North et al., 2009). However, sometimes the acute 
inflammation process does not progress and there is a continuous neutrophil 
and monocyte/macrophage recruitment (Motwani and Gilroy, 2015) alongside 
a substantial and consistent presence of: (I) several pro-inflammatory 
mediators (Histamine, Eicosanoids); (II) pro-inflammatory cytokines (TNF-α, 
IL-1β, IL-6); (III) and APPs, such as nCRP (Lawrence and Gilroy, 2007; Luan 
and Yao, 2018; Slevin and Molins, 2018). This chronic inflammation activity 
leads to tissue injury (Franceschi and Campisi, 2014) and is often associated 
with several noncommunicable chronic diseases (NCDs) (Camps and García-
Heredia, 2014) such as obesity, diabetes, cancer, Chronic Kidney Disease 
(CKD), Alzheimer’s disease (AD) and cardiovascular disease (CVD) (Akiyama 
et al., 2000; Kovesdy et al., 2017; Gupta et al., 2018). 
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1.1.7 nCRP and its association with noncommunicable 
chronic diseases (NCDs). 
 
As aforementioned in paragraphs 1.1.5 and 1.1.6, nCRP is a biological marker 
useful to indicate the potential ongoing event of acute infection and/or chronic 
inflammation. Indeed, the last two decades have witnessed the publication of 
studies that have reported an association between higher nCRP 
concentrations (>3μg/mL) and an increased risk of several NCDs, such as 
obesity, diabetes, cancer, stroke, atherosclerosis and AD (Black et al., 2004; 
Kushner et al., 2006; Luan and Yao, 2018).  
 
1.1.7.1 nCRP and Obesity. 
 
Obesity is an abnormal or excessive adipose tissue (AT) accumulation (Palou 
and Bonet, 2013). Under normal physiological conditions, the main role of AT 
is to store excess nutrients (Zwick et al., 2018). However, in the case of 
obesity, AT releases pro-inflammatory mediators, such as the monocyte 
chemoattractant protein-1 (MCP-1), the plasminogen activator inhibitor 1 (PAI-
1), the high-mobility group binding protein 1 (HMGB-1), angiotensin II, TNF-α, 
IL-6 and leptin (Makki et al., 2013; Guzmán-Ruiz et al., 2014). Both IL-6 and 
leptin are present in the circulation of obese people (Eder et al., 2009; DePaoli, 
2014). These two mediators bind to hepatocytes and stimulate both nCRP 
synthesis and release (Szalai et al., 1998a; Du Clos and Mold, 2004; Loffreda 
et al., 1998). A study by Visser et al. (1999) reported that young people with a 
high body mass index (BMI) had a high concentration of several pro-
inflammatory markers and nCRP (>0.22 mg/dL) (Visser et al., 1999). Another 
study reported a strong association between obesity, high nCRP levels (>10 
mg/L) and metabolic syndromes (MetS) (Aronson et al., 2004). Kahn et al. 
(2006) published similar results, confirming that obesity is the main factor 
associated to nCRP and MetS. Investigation on 493 obese patients, with a BMI 
from 31 to 91 kg/m2, showed that those with higher nCRP levels (>7.7 mg/L) 
ran a higher risk of suffering from depression (Dixon et al., 2008). Choi et al. 
(2013) reported that higher nCRP levels were associated to obesity, in 
particular in females. Paepegaey et al. (2015) reported on 674 obese patients 
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with a BMI from 47.4 ± 7.4 kg/m2 and stated that there was a higher nCRP 
level, especially in females. Elevated BMI levels, nCRP and HMGB-1 were 
also reported in a study by Guzmán-Ruiz et al. (2014).  
 
1.1.7.2 nCRP and Diabetes. 
 
Literature reports that there is an elevated serum HMGB-1 concentration in 
obese populations (Gunasekaran et al., 2013). When circulating HMGB-1 
dissociates into a HMGB1 biological active isoform, it is able to penetrate into 
the bone marrow and stimulate the release of monocytes into the circulation 
(Liesz et al., 2015). This release accounts for findings that there is a rise in the 
white blood cell (WBC) count in obese-type 2 diabetes mellitus (OT2DM) 
patients (Colberg et al., 2010; Gkrania-Klotsas et al., 2010; Milam, 2016; 
Colberg et al., 2016; Zhou et al., 2018). Once in the circulation, both 
monocytes and macropahges bind to the highly concentrated blood glucose 
(Al-Nuaim, 1997; Lafontan, 2005; Daniele et al., 2014; Malin et al., 2018). This 
binding activates both the aerobic glycolysis metabolism and the hypoxia-
inducible factor 1-α (HIF1-α) transcription factor, increasing the release of 
several pro-inflammatory cytokines (Galván-Peña and O'Neill, 2014). If this 
release continues, it leads to a systemic chronic low-grade inflammation 
(Tsalamandris et al., 2019). This systemic chronic low-grade inflammation then 
stimulates the release of nCRP (Ziv-Baran et al., 2017). A study reported that 
elevated fibrinogen, IL-6 and nCRP levels were associated with the risk of 
developing diabetes (Bertoni et al., 2010). Wang et al. (2013) studied 4,213 
Japanese subjects, age range 35 to 66 and stated that elevated nCRP (>10 
mg/L) levels preceded the onset of T2DM and that this result was not affected 
by their being either obese or smokers. de Rekeneire et al. (2006) reported 
elevated nCRP (34.5 mg/L) concentrations in subjects affected by diabetes. 
Alam et al. (2014) reported that elevated nCRP levels (5.290 mg/L) were also 
associated to high ferritin levels in 67 diabetic patients. El Boukhrissi et al. 
(2017) stated that significantly high nCRP levels (>5.94 mg/L) were also 
confirmed in 250 T2DM patients with a BMI from 27.2 ± 6.8 kg/m2. 
Furthermore, several studies have also reported that high nCRP 
concentrations in diabetic subjects were also associated to the risk of 
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developing other diabetic complications and/or diabetes-related diseases. 
Indeed, elevated nCRP concentrations have been associated with the risk of 
developing atherosclerosis (Mugabo et al., 2010). In a Japanese study on 
3,573 T2DM patients, aged 62 to 64 years, with a BMI from 24.6 ± 2 kg/m2 it 
was reported that high levels of nCRP were also associated with a higher 
incidence of depression (Hayashino et al., 2014). A recent study reported an 
association between nCRP levels and CVD in 40 diabetic patients (Ahmed et 
al., 2020). More recently, it has also been reported that elevated nCRP levels 
in OT2DM were associated with a higher risk of developing cancer (Lee et al., 
2011; Kolb and Zhang, 2020). 
 
1.1.7.3 nCRP and Cancer. 
 
Recently, some authors have reported that the low-chronic grade of 
inflammation caused by both obesity and diabetes also increases the risk of  
developing cancer (Lega and Lipscombe, 2020). The presence of nCRP has 
been observed in cancer (Lee et al., 2011; Shimura et al., 2012; Shrotriya et 
al., 2018). Indeed, Yang et al. (2007) reported that when nCRP binds to 
myeloma cells through FC-γ receptors (FCγRs), this pentameric protein 
phosphorylates the Akt, ERK and NF-KBp65 pathways and, in turn annuls the 
effects of therapeutic compounds, such as dexamethasone and melphalan. 
Paulsen et al. (2017) detected elevated IL-6 and nCRP levels in 49 advanced 
cancer patients. Agnoli et al. (2017) reported that high nCRP levels (1150 
ng/mL) were also associated to a higher risk of breast cancer (BC) in 
postmenopausal women. Pastorino et al. (2017) stated that higher nCRP 
concentration could be a predictor of immediate and/or long-term mortality in 
lung cancer (LC). Fang et al. (2017) on nasopharyngeal carcinoma reported 
that there was a linear association between nCRP concentration (≥1.96 mg/L) 
and a worse prognosis and higher mortality. 
 
1.1.7.4 nCRP and Stroke. 
 
A 2006 study reported that an obesity-associated low-chronic level of 
inflammation, also creates a predisposition for the development of CVD 
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(Poirier et al., 2006). Research, published in the New England Journal of 
Medicine evidenced the presence of higher baseline levels of serum amyloid 
A, sICAM-1, IL-6, total cholesterol, apolipoprotein B-100 and in particular 
nCRP and their association with cardiovascular accidents, such as stroke 
(Ridker et al., 2000).  
 
Stroke is a neurological medical condition of ischemic or haemorrhagic nature 
(intracerebral haemorrhage –ICH-, subarachnoid haemorrhage) due to a 
critical focal injury to the brain (Sacco et al., 2013). This neurological medical 
condition can induce long-term disability, or even death (Starosta et al., 2016; 
Ågesen et al., 2018). In 2011 an AHA report (Roger et al., 2011) confirmed 
that, of ≈610,000 people yearly suffering from a first stroke attack, ≈185,000 
had recurrent attacks, while of the remaining patients (≈425,000 people) 87% 
were affected by an ischemic stroke (IS) event and 13% by a haemorrhagic 
stroke event.  
 
Considering the strong correlation between nCRP and stroke one may 
speculate that this neurological medical condition could be predicted by 
evaluating the baseline nCRP levels (den Hertog et al., 2009). A study by Rost 
et al. (2001) reported that an excessive nCRP concentration (>5.4 ± 7.3 µg/mL) 
was associated to a higher risk of stroke in both genders, with a higher 
frequency in women. Similar results were also reported in another study, 
where nCRP and ICAM-1 serum levels were predictive of a higher stroke risk 
(Jiménez et al., 2016). Even a single stroke symptom, such as unilateral 
numbness, unilateral weakness and disability to communicate verbally or in 
writing form, was recently found to be correlated to anomalous levels of nCRP, 
NT-pro BNP, Factor VIII, Factor XI and D-dimer (Landry et al., 2017).  
 
Extensive studies have been carried out on ischemic stroke (IS) and its 
correlation with nCRP (Di Napoli et al., 2001b; Di Napoli et al., 2001a; Winbeck 
et al., 2002; den Hertog et al., 2009; Bakhshayesh-Eghbali et al., 2016). IS is 
characterised by vessel occlusion as a consequence of cardioembolic, 
atherothrombotic and/or lacunar events (Meschia and Brott, 2018). The 
occlusion leads to a significant decrease in cerebral blood flow (CBF) 
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associated with a cascade of biological activity and neural cell death (Meschia 
and Brott, 2018). It was observed that ROS generation (from the penumbra 
area) stimulated the surviving neurons to release cytokines and chemokines 
to activate the tissue-resident macrophage (TRM) microglia (Wang et al., 
2006; Qin et al., 2019). Once activated, microglia increase the level of several 
pro-inflammatory mediators, such as iNOS, IL-1β MCP-1, IL-6 and TNF-α 
(Gelosa et al., 2014; Zarruk et al., 2018). Therefore, the rapid and unexpected 
increase in this pro-inflammatory mediator, acting on TJs proteins (occluding, 
ZO-1, ZO-2 and claudin-5), lead to both TJs phosphorylation, destabilisation 
and nullification (Dörfel and Huber, 2012), which, in turn, facilitates blood brain 
barrier (BBB) disruption within the first 3 hours of IS onset (Dörfel and Huber, 
2012; Giraud et al., 2015). This process then promotes the release of several 
pro-inflammatory mediators into the circulation and their binding with 
hepatocyte cells increases the release of APPs, e.g., nCRP (Kushner and 
Feldmann, 1978; Zhang et al., 1996; Szalai et al., 1998a; Du Clos and Mold, 
2004). Therefore, nCRP is not only an indicator of first-onset stroke but may 
also be a neurological clinical marker immediately after an IS event (Hertog et 
al., 2009). A study, carried out in 2014, reported that higher nCRP (>10 mg/L) 
concentrations were independently associated to a worse initial clinical 
condition, haematoma growth, neurological worsening and eventually death 
(Di Napoli et al., 2014). Geng et al. (2017) observed that nCRP levels were 
significantly and dependently associated to early neurological deterioration in 
1,064 patients over 18 years of age, with a BMI between 17.7 and 36.3 kg/m2. 
Similar results were confirmed in another review where nCRP levels were 
associated to an unfavourable long-term clinical outcome, evaluated by the 
Barthel Index (BI), the Glasgow outcome scale (GOS), the modified Rankin 
Scale (mRS) and/or the NIH Stroke Scale (NIHSS) (VanGilder et al., 2014).  
 
Several studies have reported that neurological worsening is most likely 
associated to high nCRP concentrations leading to a larger brain lesion. For 
example, Jiang et al. (2017b) stated that stroke patients with an nCRP 
concentration of >6 pg/mL have a larger brain lesion volume three days after 
a stroke event. You et al. (2018) studied 146 IS patients and confirmed that 
elevated nCRP (5.4 ± 15.3 mg/L), LDL-C (4.7 ± 1.1 mmol/L) and homocysteine 
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(26.4 ± 6.3 µmol/L) concentrations were associated to larger white matter 
lesions (WMLs) and worst clinical cognitive outcomes when these were 
evaluated by the Montreal Cognitive Assessment scale, the mini-mental state 
examination and the BI. Kuhlmann et al. (2009) reported that the association 
between nCRP concentration, larger brain lesions and worse clinical cognitive 
outcomes probably depends on the capacity nCRP has to bind to ECs through 
both FcγRIII (CD16) and FcγRII (CD32). When binding takes place, the 
activation of the MAPKp38 pathways induce TJ protein (occluding and ZO-1) 
disorganisation, exacerbating BBB destruction (Kuhlmann et al., 2009). This 
phenomenon was reported to promote an intense leukocyte infiltration and 
also to induce a stronger, acute, initial pro-inflammatory response, with all the 
aforementioned negative neurological consequences (Ferrarese et al., 1999; 
Chiba and Umegaki, 2013; Lu et al., 2018).  
 
In stroke, nCRP may also be used as a middle and long-term neuro-cognitive 
clinical marker. Together with Erythrocyte Sedimentation Rate, IL-6 and IL-12, 
nCRP was found to be predictive of post-stroke cognitive impairment (PSCI) 
(Mijajlović et al., 2017). The relationship between nCRP, stroke and PSCI was 
also well-documented in a cohort study where a high baseline serum nCRP 
was associated to a higher risk of developing vascular dementia (Hsu et al., 
2017), which is known to be associated to stroke events (Desmond et al., 2002; 
Iadecola, 2013; O'Brien and Thomas, 2015; Venkat et al., 2015). 
 
1.1.7.5 nCRP and Alzheimer’s disease (AD). 
 
Obesity and stroke have often been linked to the risk of developing AD 
(Businaro et al., 2012; Murali Vijayan and Reddy, 2016; M. Vijayan et al., 
2017). AD is a neurological brain disease caused by involving an aggregation 
of the beta-amyloid protein (beta-amyloid plaques) outside neurons (Carter 
and Lippa, 2001), together with an aggregation of the tau protein (tau tangles) 
inside neurons (Murphy and LeVine, 2010). This abnormal protein 
accumulation interferes with both ordinary transport of neuron nutrients and 
neuron-to-neuron communication, leading to neural cell death (Niikura et al., 
2006) expressed clinically with by its well-known symptoms, i.e., cognitive 
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problems expressed, thinking/memory, depression, problem-solving and 
language difficulty (Tarawneh and Holtzman, 2012; Bature et al., 2017).  
 
A study on AD, carried out in 1994, reported that nCRP had been observed in 
senile plaques in AD patients (Iwamoto et al., 1994). K. Yasojima et al. (2000) 
that compared mRNA nCRP levels in AD patients and a control group, 
confirmed the presence of mRNA in the hippocampus of the AD group. Another 
study reported that elevated nCRP serum concentrations were associated to 
all causes of dementia when the population studied included subjects over 90 
years of age (Kravitz et al., 2009).  
 
1.1.7.6 nCRP and Chronic Kidney Disease (CKD). 
 
Several studies have already reported that the low-chronic grade of 
inflammation caused by obesity also facilitate the possibility to develop of CKD 
(Kovesdy et al., 2017). Therefore, it is not surprising that in these NCD 
elevated nCRP levels have been confirmed. For example, a recent study 
reported that higher nCRP levels (≥3.0 mg/L) were directly associated with an 
increased risk of CKD (Gao et al., 2020). Another study on 4,320 participants, 
average age 54 years, reported elevated nCRP levels (3.2 ± 1.1 mg/L) in CKD 
patients (Fox et al., 2010). Another study reported that elevated nCRP 
concentrations (5.40 ± 1.95 mg/L) were inversely proportional to the estimated 
glomerular filtration rate (eGFR) in 104 CKD patients (Lalramenga et al., 
2019).  
 
1.1.7.7 nCRP and atherosclerotic disease. 
 
CKD not only increases nCRP levels but is also a risk factor for atherosclerotic 
disease (Mathew et al., 2017). Under normal physiological conditions, 
endothelium cells play a critical role in maintaining the barrier function of the 
vasculature, by selecting the elements that may cross from blood to tissues 
(R. A. Vogel et al., 1998; Y. Zhang and Yang, 2016). However, when APR is 
chronically activated (Rodriguez-Hernandez et al., 2013), this acute-phase 
reaction may lead to the deterioration of the EC-tight junctions (Pant et al., 
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2014). Damage to EC-tight junctions activates both protein kinase C and NF-
KB (Willis et al., 2010; Aveleira et al., 2010). This activation increases the 
secretion of several pro-inflammatory mediators, such as angiotensin II, 
surface adhesion molecules, monocyte chemoattractant protein-1 (MCP-
1/CCL2) and IL-6 (Tousoulis et al., 2006; Xiao et al., 2014; Fatkhullina et al., 
2016; Reiss et al., 2017). When MCP-1 is released by ECs (Deshmane et al., 
2009), this chemotactic cytokine recruit monocyte cells through the 
CCR2/CCL2 pathway from the blood stream to the injury site (Sindrilaru and 
Scharffetter-Kochanek, 2013). This recruitment is facilitated by the presence 
of E-selectin, P-selectin and L-selectin (Jin et al., 2013), which enhance the 
rolling and recruitment of leukocyte cells to the injury site (Jin et al., 2013). 
Once at the site of injury, monocytes differentiate into macrophages (Malissen 
et al., 2014; Orekhov et al., 2019). The macrophages bind to PAMPs and 
DAMPs, increasing the secretion of TNF-α, IL-1β and IL-6 (Koh and DiPietro, 
2011; Liu et al., 2017a). As aforementioned in paragraph 1.1.3.3, when IL-6 
binds to hepatocyte cells (Szalai et al., 1998a; Du Clos and Mold, 2004) it 
increases nCRP concentration in the circulation (Lowenstein and Matsushita, 
2004; Ceron et al., 2005). This increase is followed by nCRP accumulation in 
the damaged endothelium tissue and if atherosclerotic plaques are present, it 
contributes to their progression (Paffen and DeMaat, 2006). Autoptic evidence 
on 302 human cadavers evidenced an nCRP concentration of 1.4 μg/mL in the 
healthy controls, 2.5 μg/mL in stable plaques, 2.9 μg/mL in plaque erosion and 
3.2 μg/mL in acute plaque ruptures (Burke et al., 2002).  
 
nCRP contributes to the evolution of atherosclerotic lesions and plaques in 
various ways (Paffen et al., 2004). For example, it has been reported that 
nCRP increases atherosclerosis development by increasing the superoxide 
and inducible NO (iNOS) concentration and reducing the platelet aggregation 
inhibitor prostacyclin (PGI2), the expression of endothelial nitric oxide 
synthase (or NOS3) and the Nitric Oxide (NO) synthesis (Venugopal et al., 
2002; Venugopal et al., 2003). When the nCRP reduces the NO concentration 
(Fig 1.3), this has a negative effect on EC survival and activity (Verma et al., 
2004). Devaraj et al. (2004) confirmed that when nCRP binds to ECs, this  
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Fig 1.3. nCRP biological activity. As herein reported, nCRP exercises a strong biological activity on several cell types, all of which are involved in cardiovascular disease 
pathogenesis. For example, nCRP can increase EC and macrophage activation, as well as activation of the complementary cascade. It can also, enhance PAI-1 activity 
and increase both MCP-1 and IL-8 concentration. Adapted From: Luan Y-Y, Yao Y-M. The Clinical Significance and Potential Role of C-Reactive Protein in Chronic 
Inflammatory and Neurodegenerative Diseases. Frontiers in immunology. 2018;9:1302 
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this pentatrix protein activates the NF-KB transcription factor, which promotes 
IL-8 mRNA and the respective protein translation. Another study corroborated 
that when nCRP binds to ECs there is an increase in the CD40 and CD40L 
cell surface expression (Lin et al., 2004), which has previously been proposed 
as potential markers of inflammation in cardiovascular events (Schonbeck and 
Libby, 2001). 
 
Two other studies reported that when nCRP binds to ECs there is an increase 
in the intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
protein 1 (VCAM-1), E- selection and MCP-1 levels (Pasceri et al., 2000b; 
Pasceri et al., 2001). 
 
An increase in MCP-1 promotes monocyte binding and rolling to the 
endothelium through CAMs (Libby, 2002; Hansson, 2005; Hansson and 
Hermansson, 2011; Jin et al., 2013). Once at the injury site, nCRP facilitates 
monocyte infiltration into the arterial wall (Torzewski et al., 2000). The nCRP 
then binds to the monocytes, increasing the production of mRNA and protein 
product of the macrophage marker CD11b (Yasojima et al., 2001) as well as 
other several pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1 (Ballou 
and Lozanski, 1992; Klouche et al., 1998; Paffen et al., 2004).  
 
Along with the recruitment, differentiation and activation of the monocytes, 
platelets are also stimulated, contributing to the development of an 
atherogenesis process (Gawaz et al., 2005; Nording et al., 2015). nCRP 
promotes platelets adhesion to the endothelium (Yaron et al., 2006). However, 
a study reported that when the nCRP binds to activated platelets it dissociates 
into the monomeric CRP (mCRP) form (Eisenhardt et al., 2009b). 
 
1.1.7.8 nCRP can be dissociated into a monomeric-CRP (mCRP) 
form.  
 
Under normal physiological conditions, nCRP maintains its original native 
pentameric conformational form (Eisenhardt et al., 2009a). However, several 
studies have also described a monomeric conformational form (mCRP) 
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originating from the initial nCRP (Fig 1.4), which may be obtained both in vitro 
and in vivo (Salazar et al., 2014). Two studies reported that nCRP can easily 
be dissociated by a buffer with 10 mM of EDTA and 8 M/L urea (Potempa et 
al., 2015; Potempa et al., 1983). Taylor and Van Den Berg (2007) documented 
how it was possible to dissociate nCRP into mCRP by heating the native 
protein (nCRP) at 70 °C for one hour. Ji et al. (2007) also reported that the 
both liposomes and cell membranes dissociate nCRP into mCRP. Later, 
Eisenhardt et al. (2009b) stated that the nCRP-mCRP dissociation occurs 
when nCRP binds to the derivates of phosphatidylcholine (PC) exposed on the 
cell membranes and this dissociation is followed by the accumulation of the 
mCRP in tissue. Indeed, the presence of mCRP has been confirmed in kidney 
biopsies of diabetic patients with CKD (Schwedler et al., 2003), in 
atherosclerosis tissue (Eisenhardt et al., 2009b) and in post- ischemic brain 
tissue (Slevin et al., 2015).  
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Fig 1.4. nCRP can be dissociated into sub-units or monomeric CRPs (mCRPs). A schematic 
showing how nCRP is dissociated into mCRP. Phospholipase (PLA2) cause de exposure of 
phosphatidylcholine (PC). The circulating nCRP binds to the PC exposed on cell membranes. 
Activated complement system binding with the nCRP dissociates the nCRP into mCRP. This 
dissociation increases the pro-inflammatory events when the mCRP binds to monocytes, 
neuthophilis and platelets. Adapted from: Caprio, V., L. Badimon, M. Di Napoli, W.-H. Fang, G. R. 
Ferris, B. Guo, R. S. Iemma, D. Liu, Y. Zeinolabediny and M. Slevin (2018). "pCRP-mCRP 
Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-
Inflammatory Chemotherapeutics." Frontiers in immunology 9: 1089. 
 
1.1.7.9 The pro-inflammatory effects of nCRP are triggered by 
mCRP. 
 
For several years the nCRP was reported to have a strong pro-inflammatory 
activity. However, this concept has changed substantially after it was reported 
that the nCRP pro-apoptotic and pro-inflammatory effect may be due to the 
presence of both sodium azide and/or LPS in the commercial nCRP sample 
(van den Berg et al., 2004; Albert et al., 2005; Pepys et al., 2005). These 
publications were followed by other studies which observed that nCRP is 
characterised by both pro and anti-inflammatory activities while mCRP mainly 
featured pro-inflammatory proprieties on different cell types, such as 
neutrophils, platelets and ECs. Khreiss et al. (2002) reported that, contrary to 
nCRP, the binding of mCRP to FcγRIII (CD16) activates the MAPK/ERK and 
PI3-Kinase/Akt signalling pathways, inhibiting the apoptotic process and 
decreasing Deoxyribose Nucleic Acid (DNA) fragmentation in neutrophils. 
Later, Tarek et al. (2004) showed that, differently to nCRP, mCRP is capable 
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of increasing neutrophil adhesion to human coronary ECs (HCAECs) when it 
binds to the FcγRIII (CD16) receptors. This process activates the MAPK-
MAPKp38 intrinsic pathway, which triggers the synthesis and release of pro-
inflammatory mediators, such as IL-8, MCP-1, E-selectin, ICAM-1 and VCAM-
1 (Khreiss et al., 2004a). Furthermore, Tarek et al. (2006) reported that mCRP 
increases IL-8 secretion through the activation of both NF-KB and activator 
protein-1 (AP-1) in human neutrophil cells.  
 
In platelets, Molins et al. (2008) stated that, differently to nCRP, mCRP is 
capable of: (I) increasing the activation marker P-selectin; (II) increasing their 
deposition; (III) and also increasing thrombus frequency. 
 
mCRP has been shown to have pro-angiogenic effects in ECs, through the 
activation of both extracellular signal regulated kinase (ERK) (Turu et al., 2008) 
and the PI3K/Akt survival intrinsic pathway (Boras et al., 2014). Peña et al. 
(2017) reported that human microvascular ECs (HMECs) mCRP can: (I) 
encourage angiogenesis in vivo; (II) promote endothelia tube formation; (III) 
promote mEC motility; (IV) and increase MCP-1 synthesis and release through 
the activation of the AKT intrinsic pathway and the ETS1 transcription factor. 
In another study by Molins et al. (2017) it was reported that mCRP (I) affects 
the ARPE-19 cell viability, (II) facilitates paracellular permeability, (III) 
decreases transepithelial electrical resistance, (IV) and perturbs the 
expression of both ZO-1 and occluding in retinal pigment epithelium cells.  
 
1.1.7.10 Mitogen-activated protein kinase (MAPK) and Nuclear factor 
K chain transcription in B cells (NF-KB). 
 
As previously reported in paragraph 1.1.7.9, several studies reported that the 
mCRP pro-inflammatory activity is triggered when MAPKs or NF-KB are 
activated (Khreiss et al., 2002; Tarek et al., 2002; Tarek et al., 2004; Tarek et 
al., 2006; Turu et al., 2008).  
 
MAPKs are proteins able to control essential cellular procedures, such as 
stress responses, apoptosis and immune defence (Dong et al., 2002; Wada 
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and Penninger, 2004; Ai et al., 2016). Literature has reported that MAPKs are 
one of the most important cascade signals in all eukaryotic animals, fungi and 
plants (Bardwell, 2006). This evolutionary conserved, intracellular signal 
transduction pathway has the pivotal role of controlling numerous fundamental 
cellular processes, such as stress response and inflammation (Kaminska, 
2005; Cargnello and Roux, 2011).  
 
As shown in (Fig 1.5), when Cytokines, PAMPs, DAMPs, TGF-β1, hormones 
or growth factors stimulate MAP kinase kinase kinases (MAPKKKs) (Liu et al., 
2007; Kyriakis and Avruch, 2012; Johnson and Lapadat, 2002). In turn, 
MAPKKKs activate MAP kinase kinase (MAPKK) (Morrison, 2012). MAPKK 
then phosphorylates and activates the last MAP kinases (MAPKs) (Zhou et al., 
2010). MAPKs can be dived into three different MAPK pathways, known as the 
extracellular signal regulated kinase (ERK), c-JUN N-terminal kinase (JNK) 
and the Mitogen-activated protein kinase p38 (MAPKp38) (Lu and Xu, 2006; 
Zarubin and Han, 2005).  
 
The first MAPK to have been elucidated was the extracellular signal regulated 
kinase (ERK1/2) (Seger and Krebs, 1995). According to literature, this intrinsic 
pathway is usually (but not only) triggered by the activation of small G proteins 
(e.g., Ras), Ca2+activation and/or PKC-mediated activation (Lawrence et al., 
2008). When this occurs, the signal is propagated by the activation of the 
protein kinases Raf-1, B-Raf and A-Raf (Rafs), which are all serine/threonine-
specific protein kinases belonging to the MAPKKKs level of this intrinsic 
pathway (Kyriakis et al., 1993; Wellbrock et al., 2004). After this initial 
activation, the signalling is diffused through the activation of MAPKKs (MEKs) 
(Ahn et al., 1991; Gómez and Cohen, 1991; Kyriakis et al., 1992), which are 
two proteins with molecular weight of 45 kDa and 46 kDa (MEK1 and MEK2 
respectively) (Wortzel and Seger, 2011). When MEKs, i.e., MEK1 and MEK2 
(Caunt et al., 2015) are activated after phosphorylation	of Ser298 and Ser386 
(Nadeau et al., 2009), in turn, these protein kinases phosphorylate the Tyr and 
Thr of ERKs (Seger et al., 1992; Seger et al., 1995). ERKs are two evolutionary 
conserved MAPKs (ERK1 and ERK 2) synthesised by two different genes 
(Mapk3 and Mapk1 respectively) (Upadhya et al., 2013) which often has 
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similar regulation and function (Buscà et al., 2016). After being stimulated, 
ERK1 and ERK2 phosphorylate other substrates present in the cytoplasm 
(Lenormand et al., 1993). Literature has reported that ERK1/2 are responsible 
for the induction and regulation a massive quantity of substrate (Yoon and 
Seger, 2006; Daub et al., 2008), most of them are localized in the Golgi 
apparatus, cytoplasm, mitochondria, endosomes/lysosomes and various other 
membranes (Plotnikov et al., 2011). This substrate may enter into the nucleus 
and stimulate gene expression in reaction to the previous extracellular stimuli 
regulating the cell proliferation, differentiation, apoptosis and inflammation 
response (Deming et al., 2008; Papa et al., 2019; Guo et al., 2020). When the 
activation of ERKs is associated with inflammation, this intrinsic pathway 
increases NF-KB and activator protein-1 (AP-1) activity (Mandrekar and 
Szabo, 2009).  
 
The c-JUN N-terminal kinase (JNK) cascade is also referred to as stress-
activated protein kinases (SAPKs) (Dunand-Sauthier et al., 2005). This 
intrinsic pathway was originally recognized as a regulator of the transcription 
factor c-Jun (R. J. Davis, 1994; Xia et al., 1995). Several stimuli can lead to 
the activation of JNK, such as bacteria, growth factors, heat shock 
inflammatory cytokines and UV radiation (Hamdi et al., 2005; Bogoyevitch and 
Kobe, 2006; Seki et al., 2012). When this stimulus binds to cells, they activate 
several MAPKKKs, such as apoptosis signal-regulating kinase 1 (ASK-1), 
mixed lineage kinase (MLK) 2/3, and transforming growth factor !-activated 
kinase (TAK) 1 (Davis, 2000). Upon activation, MAPKKKs transmit the signals 
by phosphorylating Thr and Ser residue, which, in turn, leads to MAPKK 
(MKK4 and/or MKK7) activation (Wang et al., 2007). When MKK7 (also known 
as MEK7) is activated, this protein kinase phosphorylates the JNK intrinsic 
pathway (Park et al., 2019). When MKK4 (also known as MEK4) is 
phosphorylated, this protein kinase is not only able to phosphorylate and 
activate all three JNK isoforms (JNK 1/2/3) but can also stimulate the 
MAPKp38 signalling pathway (Brancho et al., 2003), another stress-activated 
MAPK cascade (Whitmarsh and Davis, 2007). After phosphorylation, JNK can 
stimulate several transcription factors, such as AP1, activating transcription  
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Fig 1.5. The Mitogen-Activated Protein Kinase (MAPK) Pathway. A pathway showing extra-cellular stimuli activate MAPKKKs, this serine/threonine-specific protein 
kinase activates MAPKK. MAPKKs in turn activate, the MAPKs (ERK1/2, JNK1/2 and MAPKp38). The phosphorylated MAPK signalling pathways induces the activation 
and the translocation of the NF-KB transcription factors. Adapted from: Dong, C., R. J. Davis and R. A. Flavell (2002). "MAP KINASES IN THE IMMUNE RESPONSE." 
Annual review of immunology 20(1): 55-72. 
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factors (ATF) and the ETS Like-1 protein (Elk1) (Chadee and Kyriakis, 2010) 
and NF-KB (Maeda, 2010).  
 
MAPKp38 is another MAPK divided into MAPKp38! (MAPK14), MAPKp38" 
(MAPK11), MAPKp38# (MAPK12/ER- K6) and MAPKp38$ (MAPK13/SAPK4) 
pathways (Zarubin and Han, 2005; Lu and Xu, 2006). MAPKp38 are activated 
by environmental and cellular stress conditions induced by pathogens (virus 
and bacteria), growth factors, heat shock and/or cytokines (Obata et al., 2000). 
Taking in consideration that this MAPK is activated by the same stimuli present 
in MAPK/JNK, it is not surprising that this intrinsic pathway is stimulated by the 
same MAPKKKs, i.e., MLK 2/3, ASK1 and TAK1 (Harada et al., 2006; Handley 
et al., 2007; Sakurai, 2012). Similar to other MAPKs, when MAPKKKs i.e MLK 
2/3, ASK 1 and TAK1 are stimulated they induce phosphorylation and the 
activation of MAPKKs i.e., MEKK3, MEKK4 and MEKK6 (Tanaka et al., 2002; 
Craig et al., 2008; Park et al., 2019). Literature reports that MEKK3 is a protein 
kinase, belonging to the MEKK/STE11 family (Blank et al., 1996; Su et al., 
2001) and is capable of stimulating the MAPKp38!, MAPKp38" and 
MAPKp38$ signalling pathways (Y. Jiang et al., 1997), while MKK6 is a 
MAPKK that stimulates all MAPKp38 isoforms i.e., MAPKp38!, MAPKp38", 
MAPKp38#, and MAPKp38$ pathways (Eyers et al., 2005). Once MAPKp38 is 
stimulated, this protein kinase activates several substrates or transcription 
factors. Amongst these, literature reported that the MAP kinase-activated 
protein kinase 2 (MAPKAPK2) (Mahtani et al., 2001) and MAP kinase-
activated protein kinase 3 (MAPKAPK3) (McLaughlin et al., 1996) are 
specifically activated by MAPKp38. When one of these two substrates is 
phosphorylated, these MAPKAPKs induce the cAMP response element-
binding protein (CREB) (Maizels et al., 2001) and/or small heat shock protein 
27 (HSP27) activation (Vidyasagar et al., 2012). Furthermore, Moens et al. 
(2013) reported that MAPKAPKs also stimulate the transcription factor ATF-1, 
the MAPK-interacting kinases (MNK1 and 2), the mitogen- and stress-
activated kinase (MSK) 1 and 2, and p38-regulated/activated kinase (PRAK). 
Moreover, there are several transcription factors MAPKp38 stimulates, 
including myocyte enhancer factor 2 (MEF2) (Han and Molkentin, 2000), the 
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ATF-1 and ATF-2 (LaJevic et al., 2011), the E26 transformation-specific 
sequence-1 (ETS-1) (Liu et al., 2017b) and NF-KB (Xiao et al., 2020).  
 
The phosphorylation of the MAPK intrinsic pathway is a fundamental step for 
the stimulation of numerous protein kinases and TFs (Liu et al., 2007; Wei et 
al., 2020). Amongst the different TFs, several studies have reported that 
MAPKs are able to stimulate NF-KB (Tak and Firestein, 2001; Sun et al., 
2013b; Martinez et al., 2016). NF-KBs are transcription factors (Fig 1.6) protein  
 
Fig 1.6. The transcription factor Nuclear factor K chain transcription in B cells (NF-KB). Cells are 
activated by TNF-α, IL-1 and/or LPS. This induces IκBα phosphorylation (P) mediated by the signal 
(NEMO-IKK1-IKK2 macromolecular complex). IKK2 promotes IκBα phosphorylation, adding 
ubiquitin molecules (ubiquitylation) and disintegrating the cytoplasmic inhibitor (IκBα) by the 26S 
proteasome. Degradation of the IκBα cytoplasmic inhibitor allows the NF-КB to translocate into 
the nucleus. Adapted from: Chen L-F, Greene WC. Shaping the nuclear action of NF-КB. Nature 
Reviews Molecular Cell Biology. 2004;5(5):392-401. 
complexes identified in seven different proteins, i.e., p105, p100, p50, p52, 
RELA/p65, c-REL RELB originated from five different NF-KB/REL genes, i.e., 
NFKB1, NFKB2, RELA, c-REL, and RELB (Chen and Greene, 2004). Under 
physiological conditions, (Fig 1.6) the NF-KB complex is located in the 
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cytoplasm attached to its inhibitory IκBα kinase cytoplasmic inhibitor (Hayden 
et al., 2006b). The IκBα kinase cytoplasmic inhibitor allows the NF-KB to enter 
into the nucleus and to regulate the gene expression only when an external 
stimulus degrades the IkB protein, by triggering a sequence of specific steps 
(Oeckinghaus and Ghosh, 2009). Once in the nucleus, NF-KB up-regulates 
the gene expression of several pro-inflammatory cytokines, such as TNF-α, IL-
1 and IL-6 (Hayden et al., 2006b; Hayden and Ghosh, 2008; Lawrence, 2009; 
Tanaka et al., 2014; Pires et al., 2018). Several studies demonstrated that both 
MAPK and NF-KB pathways are triggered when monocytes and macrophages 
carry out their fundamental role during the inflammatory phase, due to their 
capacity to secrete several pro-inflammatory cytokines (Liu et al., 2003; Liu et 
al., 2017a). 
  
43 | P a g .  
  




One of the first studies on monocytes evidenced that mature monocytes 
differentiated into tissue macrophages when they migrated from the circulation 
to the organs (van Furth and Cohn, 1968). Much has been done since that first 
study to better clarify the origin and differentiation of monocytes (Fig 1.7). 
Nowadays, it is known that a human monocyte (I) originates from a 
haematopoietic stem cell (HSC), (II) becomes a common myeloid progenitor 
(CMP), (III) further develops into a granulocyte-macrophage progenitor (GMP), 
(IV) then progress to a macrophage and DC progenitor (MDP) and (V) then 
develops into a monocyte (Chow et al., 2011). 
 
Fig. 1.7. The origin of monocytes. When a haematopoietic stem cell (HSC) becomes a common 
myeloid progenitor (CMP), it then develops into a GMP, matures into a macrophage and DC 
progenitor (MDP) and, in the end, it further evolves to become a monocyte. The monocytes 
subsequently differentiate when they are recruited from the peripheral bloodstream. Adapted 
from: Chow A, Merad M, Brown BD. Studying the mononuclear phagocyte system in the 
molecular age. Nature Reviews Immunology. 2011;11(11):788-98. 
 
1.2.1.1 Monocyte Subsets. 
 
The Nomenclature Committee of the International Union of Immunological 
Societies subdivided human monocytes into three major populations (Ziegler-
Heitbrock et al., 2010), “CD14++ CD16- monocytes” (also known as classical 
monocytes), “CD14+ CD16+ monocytes” (also known as intermediate 
monocytes) and CD14+ CD16++ monocytes (also known as non-classical 
monocytes) (Sampath et al., 2018; Kapellos et al., 2019). This classification 
was based on distinct phenotypical and anatomical characteristics. For 
44 | P a g .  
  
example Boyette et al. (2017) reported that: (I) the classical and intermediate 
monocytes mainly expressed the CD11b surface marker, whilst the non-
classical monocytes expressed the CD11c and CX3CR1 surface markers; (II) 
classical monocyte subtypes were described as being bigger than the non-
classical ones; (III) only classical and intermediate subtypes can express pro-
inflammatory cytokines, such us IL-1β, IL-6 and TNF-α; (IV) the classical 
monocyte subtype was found to be the only subset that could differentiate itself 
into monocyte-derived dendritic cells (DCs), whilst all the other three groups 
could only differentiate themselves into monocyte-derived macrophages. Ogle 
et al. (2016) reported that the classical monocyte subtype is a subgroup that 
(I) arises from both bone marrow and spleen, (II) expresses the CC-chemokine 
receptor (CCR2), (III) are recruited from the blood to the injured site when the 
CC-chemokine ligand 2 (CCL2 also know MCP-1) in the blood binds to 
classical monocytes via CCR2 receptors. Furthermore, it was reported that the 
classical monocyte subtype is recruited during CCR2 activation in the 
presence of the CCL7 protein (also known as MCP-3), which was highly 
expressed during infections and inflammation conditions, induced by bacterial, 
protozoal, fungal, viral infections and damage tissue (Shi and Pamer, 2011). 
Another paper stated that once recruited and activated, this cell subtype 
eliminates the bacteria by boosting the concentration of both inducible nitric 
oxide synthase (iNOS) and NO, which induces DNA damage and affects their 
metabolism (Xiong and Pamer, 2014). Ogle et al. (2016) reported that once 
the pro-inflammatory cell phenotypes conclude their activity they leave their 
place to the non-classic monocytes, which are able to assist and repair the 
damaged tissue during the last phase of wound healing process (WHP) (Ogle 
et al., 2016).  
 
1.2.1.2 Human Monocyte Subsets in Major Chronic Inflammatory 
Diseases. 
 
Over the last few years, several studies have reported that life-style habits a 
have a significant effect on the number of circulating monocytes (Kapellos et 
al., 2019). Indeed, numerous studies have evidenced that there is a notable 
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increase of circulating monocytes in several NCDs (Ozanska et al., 2020). A 
high monocyte count (MC) was observed in several chronic inflammatory 
conditions, e.g., obesity, CKD, arteriosclerosis and stroke (Rogacev et al., 
2014; Chistiakov et al., 2018), where the presence both  nCRP/mCRP was 
also confirmed (Schwedler et al., 2003; Eisenhardt et al., 2009b; Thiele et al., 
2014a; Thiele et al., 2015; Slevin et al., 2017).  
 
For example, as aforementioned in chapter 1 paragraph 1.1.7.1. in obesity, the 
AT cells release pro-inflammatory mediators, such as PAI-1, HMGB-1 and 
MCP-1 (Makki et al., 2013; Guzmán-Ruiz et al., 2014). Indeed, MCP-1 is a 
constantly present chemoattractant protein in the systemic circulation of the 
obese population (Panee, 2012). An increase in MCP-1 is often associated 
with an increase in MC count (Yoshimura et al., 2015). A study carried out in 
2002 on 300 obese subjects reported a higher average MC (13–18%) in the 
obese group than in the healthy control group (54 subjects) (Kullo et al., 2002). 
Schipper et al. (2012) reported that 60 obese children, aged 6 to 16, with a 
BMI of >30 kg/m2, had a (I) low insulin sensitivity and low HDL-cholesterol 
levels; (II) but an elevated systolic blood pressure; (III) an elevated presence 
of several pro-inflammatory mediators; (IV) a high nCRP concentration of 
>1.70 mg/L; (VI) and an increase in their MC, especially the classical pro-
inflammatory (CD14++CD16−) monocyte subtype. Pecht et al. (2014) reported 
that the MC is directly associated with obesity and its complications. Devevre 
et al. (2015) evidenced that their obese population had a higher MC than 
normal-weight nondiabetic volunteers. The same study also reported that the 
monocytes collected from the obese population released more pro-
inflammatory mediators when stimulated by LPS or viral ssRNA, than healthy 
subjects (Devevre et al., 2015). Similar results were also reported in a study 
by Leite et al. (2017) who evidenced that obese patients, aged 20 to 63 years 
with a BMI of >30 kg/m2 had higher: (I) leptin plasma levels (1.17 ng/ml); (II) 
systolic blood pressure (129 ± 16 mm Hg, F) and diastolic blood pressure (89 
± 9 mm Hg, F); (III) nCRP concentration (3.020 mg/L); (IV) and the non-
classical monocyte subtypes (CD14+ CD16++) also had a higher inflammatory 
pattern than that of the healthy non-obese control group. Choi et al. (2017) 
studied 439 men and 561 women over 65-years of age and observed a high 
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BMI and white blood cell count, serum nCRP levels of 0.25 mg/dL and a high 
MC, all of which were associated with a high risk of death. Wouters et al. (2017) 
used flow cytometry to compare 29 obese male patients, aged 45.0 to 54.0 
years, with a BMI of >30 kg/m2, to a healthy control group. They confirmed 
that the percentage of both classical and nonclassical monocytes was higher 
in the obese group than in the healthy controls (Wouters et al., 2017). In a 
recent study, Friedrich et al. (2019) reported the presence of the three 
monocyte phenotypes in their obese study group, which included 60 obese 
patients with a BMI of ≥ 30 kg/m2 aged 45.0 to 47. They evidenced an elevated 
HbA1c-IFCC, nCRP (10.4 ± 0.9 mg/mL) and leukocyte and monocyte 
concentration. Furthermore, Friedrich et al. (2019) reported that there was a 
statistically significant association between the absolute number of 
CD14++CD16- pro-inflammatory classical monocytes and fat mass.  
 
The increase in monocyte counts due observed in obesity also explains why a 
rise in these white blood cells could be considered a prognostic marker of 
several obesity-related diseases, such as CKD, arteriosclerosis and stroke 
(Gkrania-Klotsas et al., 2010; Zhang et al., 2017b; Kovesdy et al., 2017; 
Authier et al., 2020). For example, Wallquist et al. (2013) studied 12 patients 
with CKD and observed an increase in CD16+ monocytes in the circulation. 
Similar results were also reported by Bowe et al. (2017) who confirmed that 
elevated MCs had a statistically significant correlation with CKD. Rogacev et 
al. (2014) reported on 438 CKD patients with elevated CD14++CD16+ 
monocyte counts, which were predictive of cardiovascular events. It is known 
that patients with CKD run a higher risk of developing some cardiovascular 
diseases, such as atherosclerosis (Kon et al., 2011), another chronic disease 
where the MC count is alternated. Indeed, it has also been suggested that MC 
is a useful predictor of subclinical carotid arteriosclerosis in both genders with 
an average age of 53.3 ± 13 years (Chapman et al., 2004). Johnsen et al. 
(2005) reported on 2,610 healthy subjects aged 25 to 82 years without 
arteriosclerotic plaques, their 7-year follow-up evidenced that age, gender, 
total cholesterol, especially MC, were all predictors of future arteriosclerotic 
plaque formation. Later, Rogacev et al. (2010) reported on the relationship the 
three monocyte phenotypes have with obesity and arteriosclerosis. They 
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studied total of 569 subjects and observed that their BMI had a positive 
association with CD16+ (intermediate and non-classical) monocytes but not 
with CD16- monocytes. Furthermore, they also confirmed that in those in the 
obese group with a BMI of ≥ 35 kg/m2, the CD16+ monocytes were two-fold 
that of the healthy control group (Rogacev et al., 2010). Similar results were 
also confirmed by Poitou et al. (2011) who reported that 144 obese patients 
with a BMI range of 25.3 to 68.6 kg/m2 and elevated nCRP (> 4.4 mg/mL) also 
had an elevated concentration of intermediate and non-classical monocyte 
phenotype, which, in turn, were also associated with a higher risk of developing 
arteriosclerosis. Berg et al. (2012) reported there was a linear association 
between an elevated classic monocyte (CD14++CD16-) concentration and a 
higher incidence of coronary events, IS and CVD. The same study also 
evidenced that this association was particularly strong even when these 
diseases were not associated with gender, age, smoking, HDL cholesterol, 
diabetes and/or hypertension (Berg et al., 2012). Yang et al. (2014a) reported 
that there was also an increase in MC in other pathologies, such as coronary 
arterial disease (CAD), left ventricular dysfunction and left ventricular 
aneurysm. More recently, Kim et al. (2017) reported that in people with an BMI 
>24.5 kg/m2, there was a linear association with total WBC count, age, BMI 
and nCRP levels. Furthermore, the same study confirmed that the WBC count 
was specifically associated to a higher risk of coronary artery atherosclerosis 
and cardiovascular disease, due to an increase in MC (Kim et al., 2017). 
Therefore, it is not surprising that several studies have also reported an 
increase in MC in some cardiovascular disease, such as IS. Indeed, a 
statistically significant increase in MC was observed by Urra et al. (2009) in 45 
stroke patients evaluated 180 minutes after the of stroke onset, compared with 
the healthy controls. Kaito et al. (2013) reported that IS increases MC 
(especially the classical monocyte subset CD14++CD16−) in the circulation. 
Moreover, an elevated MC has been also associated with an elevated nCRP 
concentration in IS (Chiba and Umegaki, 2013; Liberale et al., 2017). Similar 
results were also reported by Dong et al. (2020) who reported that an elevate 
MC after an IS event is associated to a poor outcome.  
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An MC increase has also been associated to an increase in recruitment 
infiltration and monocyte accumulation from the circulation to the tissue 
affected by disease itself respectively, in all these medical conditions (Woollard 
and Geissmann, 2010; Chiba and Umegaki, 2013; Malissen et al., 2014; 
Naicker et al., 2018). This accumulation is immediately followed by a 
differentiation from monocytes to monocyte-derived macrophages (BMdM) 




Macrophages can be classified into two different groups: Tissue 
resident macrophages (TRM) and blood monocyte-derived macrophages 
(BMdM). For the sake of simplification, the term macrophage will be used to 
indicate blood monocyte-derived-macrophages in this paragraph.  
 
1.2.2.1 Monocytes differentiation into macrophages. 
 
Monocytes are recruited around the injury site when TRM, fibroblasts and 
endothelial cells (ECs) release CCL2 and CX3CL1 and the CCR2/CCL2 and 
CX3CR1/CX3CL1 pathways are activated (Deshmane et al., 2009; Sindrilaru 
and Scharffetter-Kochanek, 2013). This recruitment is also facilitated by the 
presence of cell adhesion molecules (CAMs) expressed on ECs which enable 
the monocytes to bind and roll on the endothelium, which helps them reach 
the injured site (Chi and Melendez, 2007; Hansson and Hermansson, 2011; 
Jin et al., 2013). Once at the injury site, monocytes extravasate into the 
surrounding area and express specific surface makers, such as F4/80, CD11b, 
CD18, CD68, colony stimulating factor 1 receptor (CSF1R), pathogen 
recognition receptors (PRRs) and FC receptors (Geissmann et al., 2010; 
Murray and Wynn, 2011; Malissen et al., 2014), they then differentiate into a 
naïve M0 resting macrophage phenotype (Orekhov et al., 2019). This 
macrophage accumulation has been confirmed in several tissues specifically 
affected by several NCDs where the presence of both nCRP and mCRP has 
also been observed. Indeed, it has been reported that the presence of 
macrophages in the kidney is a common finding in chronic kidney disease 
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(CKD) and the amount of macrophage accumulation is associated with the 
severity of renal injury (Wang and Harris, 2011). Macrophage accumulation in 
CKD was also confirmed in a study which reported that these immune system 
cells also play a pivotal role in CKD progression (Ohara et al., 2019). This 
fundamental role was also reconfirmed in a recent review by Engel and Chade 
(2019) where the authors also add that the manipulation of these immune 
system cells may provide a potential therapy against CKD. 
 
CKD, is a chronic disease often associated to atherosclerosis, another chronic 
medical condition where the local accumulation of monocyte-derivate 
macrophages in arteriosclerotic inflamed tissue has been also confirmed (Kon 
et al., 2011; Olechnowicz-Tietz et al., 2013; Balla et al., 2013). Indeed, Zeller 
and Srivastava (2014) reported that, after monocyte recruitment, these cells 
differentiate into monocyte-derived macrophages in the sub-endothelial space 
artery. Flynn et al. (2019) stated that the majority of macrophages present in 
arteriosclerotic plaques originate from the infiltration of circulating monocytes 
into arteriosclerotic plaque tissue (Flynn et al., 2019). Moreover, Barrett (2020) 
stated that the accumulation of monocyte-derived macrophages is so elevated 
the macrophage count increases by up to 20-fold in the aorta during the 
atherogenesis process. This exponential increase is probably associated to 
the pivotal role monocyte-derived macrophages play during atherosclerosis 
progression (Flynn et al., 2019).  
 
It is known that atherosclerosis increases the risk of IS events (Banerjee and 
Chimowitz, 2017) and, not surprisingly, an accumulation of monocyte-derived 
macrophages has been also confirmed in this condition (Chiba and Umegaki, 
2013). Indeed, Kim and Cho (2016) observed an accumulation of both 
monocytes and monocyte-derived macrophages after acute IS injury. Khan et 
al. (2016) reported that a provoked IS event, in an adult male mouse (10-12 
weeks), through a distal middle cerebral artery led to an accumulation of 
monocyte-derived macrophages in its ischemic brain tissue (IBT). Similar 
results were also confirmed by Pedragosa et al. (2018) in IBT. They reported 
that an IS event provoked in an adult male mouse, through a right middle 
cerebral artery occlusion, confirmed an increase in monocyte-derived 
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macrophage accumulation in IBT (Pedragosa et al., 2018). A recent review 
also evidenced an accumulation of monocyte-derived macrophages in IBT 
(Jian et al., 2019).  
 
1.2.2.2 Two macrophages subtypes. 
 
Macrophages polarize from the M0 phenotype into pro or anti-inflammatory 
(M1 or M2 respectively) phenotypes depending on the stimuli they receive from 
in the injury site (Chistiakov et al., 2015; Ley, 2017). Pro-inflammatory 
cytokines, LPS, DAMPs and PAMPs enable the resting M0 phenotype to 
evolve into the M1 classically activated phenotype, which secretes pro-
inflammatory cytokines (IL-1, IL-6, IL-12, TNF-α) and iNOS (Koh and DiPietro, 
2011; Liu et al., 2017a). An in vivo investigation by Mirza and Koh (2011) 
reported an increase in the pro-inflammatory macrophage M1 (which 
expressed a high concentration of IL-1β, MMP-9 and NOS) on day 5, in an 8-
millimetre excisional wound. However, the same authors observed that there 
was a substantial decrease in the pro-inflammatory mediators after a rise in 
anti-inflammatory markers (CD206 and CD36), insulin growth factor 1 (IGF-1), 
transforming growth factor-β (TGF-β) and vascular endothelial growth factors 
(VEGF) on day 10 (Mirza and Koh, 2011). The polarisation from M1 
macrophages to M2 macrophages appears to be promoted by basophils when 
these cells release interleukin-4 (IL-4) and interleukin-13 (IL-13) near the injury 
site (Egawa et al., 2013; Kang and Biswas, 2013; Van Dyken and Locksley, 
2013).  
 
These two interleukins activate the arginase pathway (Fig 1.8) and boost the 
arginine metabolism, triggering L-ornithine, polyamine and proline activity 
(Mills et al., 2000; Mills, 2001; Gordon, 2003). The polyamine and proline 
activity increases the secretion of IL-10, arginase-1, collagen and the fibroblast 
stimulating factor typically release by the M2 macrophages (Ogle et al., 2016; 
Ley, 2017). However, recent studies have demonstrated that both nCRP and 
mCRP affect macrophages by facilitating or interfering with this polarization 
process (Moore et al., 2001; Trial et al., 2016; Pilling et al., 2017).  
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Fig 1.8. Macrophages polarisation: from M1 to M2. When IL-4 and IL-13 boost the arginine metabolism to L-ornithine, the polyminase and proline activity is 
intensified. The activation of these two pathways allow the cell to polarize into an anti-inflammatory phenotype. These cells then release collagen and facilitate cell 
proliferation. Adapted from: Gordon, S. (2003). "Alternative activation of macrophages." Nature Reviews Immunology 3(1): 23-35. 




Fig 1.9. Two macrophages subtypes. As previously described, the macrophage subclassification is not only theoretical but also practical. As shown in figure the two 
different macrophage subtypes perform separate functions and activities during the wound healing process. Adapted from: Sindrilaru A, Scharffetter-Kochanek K. 
Disclosure of the Culprits: Macrophages—Versatile Regulators of Wound Healing. Advances in Wound Care. 2013;2:357-68. 
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1.2.3 The contradictory effects of nCRP and mCRP on monocytes and 
macrophages. 
 
As aforementioned, an accumulation of monocytes/macrophages, nCRP and 
mCRP has been confirmed in several inflamed tissues. As aforementioned in 
paragraph 1.1.7.9, several studies have demonstrated that nCRP exert both 
anti and pro-inflammatory activities in a context dependant manner, whilst 
mCRP primarily encourages pro-inflammatory actions on different cell types, 
such as neutrophils, platelets and ECs. Similar results were also confirmed in 
both monocytes and macrophages. Eisenhardt et al. (2009b) reported that in 
monocytes, contrary to nCRP, mCRP binding through the lipid rafts and FCγRs 
can (I) activate the phosphatidylinositol 3-kinase (PI3K) intrinsic pathway; (II) 
increase monocyte adhesion and (III) enhance pro-inflammatory activity. In 
2011, Eisenhardt et al. (2011), showed that mCRP prompts an exclusive 
release of pro-inflammatory markers in THP-1 monocytes. Similar results were 
also reported in others studies which confirmed that if M0 resting macrophages 
are stimulated with mCRP, they polarize into an M1 pro-inflammatory 
phenotype (Trial et al., 2016), whilst if stimulated by nCRP they polarize into 
an M2 anti-inflammatory phenotype, which induces the release of the IL-10 
anti-inflammatory cytokine (Moore et al., 2001; Pilling et al., 2017). More 
recently, Sproston et al. (2018) confirmed that although mCRP is able to raise 
the inducible NOS (iNOS) and Nitric Oxide (NO) concentration in 
monocytes/macrophages, the same study also reported that nCRP reduces 
this release in the same type of cells. Therefore, observing the contrasting 
results, it seems that nCRP-mCRP dissociation is the culprit responsible for 
the pro-inflammatory activity even when the mCRP form binds to monocytes 
and/or macrophages (Wu et al., 2015). Furthermore, knowing that 
accumulation of both monocytes, macrophages and mCRP have been 
observed in several inflamed tissues and have been associated to some 
NCDs, such an IS (Slevin et al., 2010; Chiba and Umegaki, 2013), Alzheimer 
(Feng et al., 2011; Slevin et al., 2017; Mammana et al., 2018), CKD (Schwedler 
et al., 2003; Guiteras et al., 2016; Ohara et al., 2019) and infarcted myocardial 
tissue (Nahrendorf et al., 2010; Thiele et al., 2014b; O'Rourke et al., 2019), it 
has been postulated that the use of a small molecular inhibitor (SMI) may well 
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provide a useful strategy to block the potential mCRP pro-inflammatory (Thiele 
et al., 2015; Caprio et al., 2018).  
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1.3 Pharmacological treatment to reduce nCRP-mCRP 
dissociation and pro-inflammatory activity. 
 
1.3.1 The use of nCRP-mCRP dissociation inhibitor may be a valid 
therapeutic strategy to block the mCRP pro-inflammatory 
activity. 
 
Over the years, several studies have reported that the two CRPs (nCRP and 
mCRP) proteins exert opposing actions in several cell types (Sproston et al., 
2018; Molins et al., 2008; Khreiss et al., 2004b). These contradictory results 
suggest that nCRP-mCRP dissociation is the underlying cause of pro-
inflammatory activity (Thiele et al., 2015) and it has been postulated that the 
use of a small molecule inhibitor (SMI) may inhibit this process, making it a 
promising anti-inflammatory strategy (Thiele et al., 2015; Caprio et al., 2018). 
Pepys et al. (2006) documented that 1,6-bis(phosphocholine)-hexane (1,6-bis-
PC) block the nCRP negative-activity by binding together two nCRP 
molecules. Later Thiele et al. (2014a) reported that the use of 1,6-bis-PC 
prevents dissociation from nCRP to mCRP, reducing the leukocyte recruitment 
and the TNF-α and IL-6 pro-inflammatory cytokine expression. However, 
although 1,6-bis-PC could be considered a potential nCRP-mCRP inhibitor 
(Pepys et al., 2006), literature also suggests that there are some limitations in 
the use of this SMI due to its short half-life and low affinity binding to the nCRP 
form (Kd= 150 nM) (Thiele et al., 2015). This limitation leaves open the 
opportunity to study other small molecules. Amongst which, the 
neurotransmitter Acetylcholine (ACh) appears to have a similar chemical 
structure to 1,6-bis-PC, which could be useful to block the mCRP pro-
inflammatory activity more efficiently (Slevin et al., 2018). This hypothesis is 
further supported by the fact that, during the inflammation stage, the nCRP is 
known to reduce the serum-ACh levels (Nazarov et al., 2007) released through 
the cholinergic anti-inflammatory pathway (CAIP) (Murray and Reardon, 
2018). This CAIP is an unusual anti-inflammatory mechanism activated by the 
tenth cranial nerve (Borovikova et al., 2000; Tracey, 2009).  
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1.3.2 The 10 cranial nerve. 
 
The tenth cranial vagus nerve (VN) belongs to the autonomic nervous system 
(ANS) (Dantzer et al., 2000). This “wandering” nerve, connects to multiple 
organs and stimulates parasympathetic activity that is able to contrast the 
sympathetic activity induced by splanchnic nerves (Breit et al., 2018). Indeed, 
this cranial nerve innervates organs belonging to the cardiovascular and 
respiratory apparatus (Berthoud and Neuhuber, 2000), also regulate the heart 
and respiratory rate (Babic and Browning, 2014). Furthermore, this nerve is 
the main component of the neuroendocrine–immune axis and plays a pivotal 
anti-inflammatory role in infection and/or other inflammatory events (Tracey, 
2007; Johnston and Webster, 2009). This anti-inflammatory activity is 
recognized as the inflammatory reflex (IR) (Andersson, 2005). 
 
1.3.3 The inflammatory reflex. 
 
The IR starts when PAMPs or DAMPs bind to the TLRs expressed on several 
immune systems (Kawasaki and Kawai, 2014; Hug et al., 2018) favouring the 
release of several pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α 
(Dantzer et al., 2000). Once these pro-inflammatory cytokines bind to their 
respective receptor present on VN-afferents fibres (Goehler et al., 1999; 
Tracey, 2002; Tracey, 2007; Oke and Tracey, 2008; Pavlov and Tracey, 2012), 
the VN-afferent fibers send an action potential to the nucleus tractus solitarius 
(NTS) localized in the medulla oblongata (Tracey, 2002). The NTS that 
connects to the corticotrophin-releasing-factor (CRF)-producing neurons 
present in the hypothalamus (Aguilera and Liu, 2012), stimulates the 
Hypothalamic–pituitary–adrenal (HPA) axis (Yan et al., 1998; Eskandari and 
Sternberg, 2002). The HPA send an action potential to both the nucleus 
ambiguus (NA) and the dorsal motor nucleus (DMN) (Bernik et al., 2002). The 
VN-effert fibres rise from the NA and DMN (Fig 1.10) and innervate various 
organs, such as the heart, lung, liver, intestine and celiac ganglion (Tracey, 
2009; Howland, 2014; Yuan and Silberstein, 2016).  
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Fig 1.10. The inflammatory reflex. Immune cells release a large amount of cytokines when they 
detect LPS, pathogen fragments and/or tissue injury molecules. These cytokines activate the 
nucleus tractus solitaries (NTS) when binding with the VN sensitive afferent fibers (activated red 
line). The NTS connecting to the nucleus ambiguous (NA), the dorsal motor nucleus (DMN) and 
the area postrema (AP) is able to, activate the vagus nerves efferents (blue line). The VN 
cholinergic efferents then reduce the pro-inflammatory cytokine release through spleen, liver and 
gastrointestinal activity. Adapted Source: Pavlov VA, Tracey KJ. The vagus nerve and the 
inflammatory reflex - Linking immunity and metabolism. Nature Reviews Endocrinology. 
2012;8(12):743-54. 
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1.3.4 The cholinergic anti-inflammatory pathway (CAIP), ACh and 
the α7 nicotinic acetylcholine receptor (α7nAChR). 
 
As show in Fig 1.11, CAIP is activated when the VN-efferent fibre promotes 
the secretion of ACh into the celiac ganglion, which, in turn provokes the 
release of norepinephrine (NE) (also known as noradrenaline -NA-) into the 
spleen (Tracey, 2009). There the NE binds through β2A receptors (β2AR) 
expressed on CD4+ CD44highCD62Llow T-cells stimulate the release of ACh 
(Pavlov and Tracey, 2005; Tracey, 2009; Wu et al., 2014). The ACh binds to 
the α7 nicotinic acetylcholine receptor (α7nAChR) on the macrophages (Orr-
Urtreger et al., 1997; Wang et al., 2003; Gallowitsch-Puerta and Pavlov, 2007). 
The α7nAChR acts on JAK2, STAT3 and NF-KB transciptor factors (Fig 1.11) 
and blocks the pro-inflammatory cytokine release (Nathan, 2002; Tracey, 
2002; de Jonge et al., 2005; Metz and Tracey, 2005; Tracey, 2007; Hoover, 
2017; Li et al., 2018; Liu et al., 2018b; Yamada and Ichinose, 2018).  
 
The α7nAChR sub-unit can also be activated by Nicotine which, a natural plant 
element with surprising anti-inflammatory activity (Kalra et al., 2004; Benowitz, 
2009). It has been reported that when this compound binds to the α7nAChR, 
it blocks the NF-KB transcriptional activity also reducing the TNF-α pro-
inflammatory cytokine release in U937 monocytes (Yoshikawa et al., 2006a). 
Tsoyi et al. (2011) reported that when Nicotine binds to α7nAChR it stimulates 
the PI3K/AkT/Nrf-2 intrisic pathway, which exerts an anti-inflammatory activity 
through the Heme Oxygenase-1 (HO-1) anti-inflammatory gene. More 
recently, St-Pierre et al. (2016) stated that when Nicotine binds to α7 and α9 
nAChRs, it is able to reduce the ratio of pro-inflammatory versus anti-
inflammatory monocytes with a consequent decrease in the liberation of pro-
inflammatory cytokines.  
 
1.2.1 The Anti-inflammatory activity of both ACh and Nicotine. 
 
Due to their potential bond with the α7nAChR, both ACh and Nicotine have 
been protagonists of a series of studies that discussed their promising roles  
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Fig 1.11. The protective effect of α7nAChR subunit. As aforementioned, the efferent VN increases the spleen, liver and gastrointestinal activity. These three organs 
increase the secretion of ACh. The anti-inflammatory activity is triggered when ACh binds to the α7 nicotinic acetylcholine receptor (α7nAChR) (expressed on 
macrophages or other immune cells) and is able to regulate the NF-КB and STAT3 activity reducing the pro-inflammatory cytokine release. Adapted from: Pavlov VA, 
Tracey KJ. The vagus nerve and the inflammatory reflex - Linking immunity and metabolism. Nature Reviews Endocrinology. 2012;8(12):743-54 
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as an anti-inflammatory therapeutic approach against several NCDs. Indeed, 
Caravaca et al. (2020) reported that the activation of CAIP could be a useful anti-
inflammatory strategy against atherosclerosis and two other recent publications 
evidenced that both ACh and Nicotine have a potential anti-inflammatory activity 
against stroke and AD (Han et al., 2017; Katsuki and Matsumoto, 2018).  
 
The mCRP presence and pro-inflammatory activity has been confirmed in these 
three NCDs. For example, Eisenhardt et al. (2009b) reported that the 
development of atherosclerosis is favoured when mCRP binds to monocytes 
through lipid rafts and FCγRs inside atherosclerotic plaques. Thiele et al. (2014b) 
reported the presence of mCRP in post-ischemic myocardium tissue and that it 
was associated to: (I) the increased expression of CD68+; (II) to the enhanced 
adhesion of monocytes and ROS generation; and (III) triggered its pro-
inflammatory activity when it bound to both CD64 (FCγI) and CD16 (FCγIII) 
receptors. Slevin et al. (2010) reported observing mCRP near newly formed blood 
vessels (angiogenesis) in IS tissue. Later, other studies demonstrated a clear link 
between mCRP accumulation in post-ischemic brain tissue and the development 
of AD dementia (Strang et al., 2012; Slevin et al., 2015; Slevin et al., 2017), even 
if the underlying mechanisms are still a question of debate.  
 
Noteworthy is the fact that the observation of mCRP in all these NCDs has always 
been co-associated with the presence, recruitment and/or activation of both 
monocytes and macrophages (Eisenhardt et al., 2009b; Chiba and Umegaki, 
2013; Thiele et al., 2014b; Thiele et al., 2015; Guiteras et al., 2016; Mammana et 
al., 2018), which are the same immune system cells that trigger a strong anti-
inflammatory activity when stimulated by ACh and/or Nicotine through α7nAChR 
(Orr-Urtreger et al., 1997; Borovikova et al., 2000; Wang et al., 2003; Gallowitsch-
Puerta and Pavlov, 2007; Benowitz, 2009; Han et al., 2017). 
 
1.3 Aims  
The aim of this project was to determine the effects of the mCRP form specifically 
expressed in several NCDs and chronic inflamed tissue. Therefore, the study 
carried out during this PhD project were focused on the mCRP-induced pro-
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inflammatory cytokine production in human-derived U937 
monocytes/macrophages, as an in-vitro model of inflammation.  
1.4 Objectives  
The specific objectives of the project were:  
• To highlight whether the nCRP/mCRP dissociation could effectively be 
carried out experimentally. 
• To evaluate whether the SMIs (ACh o Nicotine) are able to bind to nCRP 
and to inhibits its dissociation. 
• To investigate the effects of exogenous exposure of mCRP isoforms on 
U937monocyte-derived macrophages.  
• To evaluated whether the MAPK and NF-KB intrinsic pathways could be 
activated in U937monocyte-derived macrophages by mCRP stimulation. 
• To evaluate the activity of the two cholinergic small molecular compounds, 
i.e., ACh and Nicotine, in order to assess their anti-inflammatory capacity. 
• To investigate the α7nAChR role in reducing the human-derived U937 
macrophage pro-inflammatory cytokine release.  
  






CHAPTER 2 GENERAL 
MATERIALS AND METHODS. 
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2.1 Ethics. 
Ethical approval for the in vitro study was granted by Manchester Metropolitan 
University (MMU) in strict agreement with the MMU Academic Ethics committee. 
 
2.2 Materials. 
Table 2.1 List of cell culture materials 
Cell Culture Supplier Cat. Number 
Human haematopoietic cell line 
U937 
ATTC® CRL-1593.2™ 
RPMI (RPMI 1640 with L-glutamine 
Lonza) 
Lonza BE12-702F 
Fetal Bovine Serum - Sigma® FBS- F9665 
Nunc EasYFlask 25cm2 T-25 Thermo-Fiscer scientific 156340 
Nunc EasYFlask 75cm T-75 Thermo-Fisher scientific 156499 · 
6 well plate Nunclon™ Delta 
Surface 
Thermo-Fisher scientific 140675 LOT158007 
Tipone® 1000 µL StarLab S1122-1730 
Tipone® 200 µL 1120-8710 StarLab S1120-8710 
Tipone®20/10 µL StarLab S1120-3710 
Dulbecco's Phosphate Buffered 
Saline DPBS -1X-,9,5mM PO4 
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Table 2.2 List of Antibodies and Primers 
Antibodies and Primers Supplier Cat. Number 
Anti–Hu CD11c Thermo-Fisher scientific LOT2008210 
CD16 antibody Abcam [MEM-154] – Azide Free ab46679) 
CD32 antibody Abcam [OTI9C6] ab124408) 
CD64 antibody Abcam 
[10.1]–Low Endotoxin Azide Free 
ab185738) 




(Thr180/Tyr182) (28B10) Mouse 
mAb #9216 
Secondary antibody Goat Anti-
rabbit IgG (H+L) (human IgG-
adsorbed) horseradish peroxidase 
conjugate 
BioRad 170-6515 
18S TaqMan® Gene Expression 
Assays 
Thermo-Fisher scientific 
Hs03003631_g1 4453320 Dye 
FAM-MGB 
TNF TaqMan® Gene Expression 
Assays 
Thermo-Fisher scientific 
Hs00174128_m1 n˚: 4331182 Dye 
FAM-MGB 
IL-6 TaqMan® Gene Expression Thermo-Fisher scientific 
Hs00174131_m1 n˚: 4331182 Dye 
FAM-MGB 
IL-10 TaqMan® Gene Expression 
Assays 
Thermo-Fisher scientific 
Hs00961622_m1 Cat n˚: 4331182 
Dye FAM-MGB 
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Table 2. 3 List of Manufactures’ kits and reagents 
Manufactures’ kits and 
reagents 
Supplier Cat. Number 
High Capacity Endotoxin Removal 
Spin Columns 
Thermo Scientific™ 88274 
FITC Annexin V Apoptosis Detection 
Kit 1 
BD Bioscience 556547 Lot 8072965 
Alamar Blu Cell Titer-Blue® Promega G8080 
BCA assay method (Pierce™ BCA 
Protein Assay Kit). 
Thermo Scientific™ 23227 
TGX Stain-Free™ FastCast™ 
Acrylamide Kit, 12% from BioRad. 
BioRad. 1610185 
DuoSet ELISA Ancillary Reagent Kit 2 R&D Systems, bio-techbrand®. DY008 
Human TNF-α DuoSet ELISA R&D Systems, bio-techbrand®. DY210 
Human IL-1β/IL-1F2 DuoSet ELISA R&D Systems, bio-techbrand®. DY201-05 
Human IL-6 DuoSet ELISA R&D Systems, bio-techbrand®. DY206-05 
Human CCL2/MCP-1 R&D Systems, bio-techbrand®. DY27905 
Human IFN-γ DuoSet ELISA R&D Systems, bio-techbrand®. DY285-05 
Human IL-10 DuoSet ELISA R&D Systems, bio-techbrand®. DY217B-05 
ECL Western Blotting Substrate 
Chemiluminescent Western ECL HRP 
Thermo Scientific™Pierce™ 32106 
Kit Purification RNA (RNeasy plus) Qiagen 74134 
TaqMan Reverse Transcription 
reagents Applied Biosystems ® By 
Life Technologies ™ 
Thermo Scientific™Pierce™ 1877894 REF N8080234 
TaqMan™ Fast Advanced Master Mix Applied Biosystems™ 4444557 
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Table 2.4 List of Chemicals 
Chemicals Supplier Cat. Number 
Dimethyl sulfoxide Sigma® (DMSO 276855) 
Trypan Blu solution Corning® 17416001 
Phorbol-12-myristate 13-acetate (PMA) Sigma® 793461 
Trypsin-EDTA solution Trypsin-EDTA 







Paraformaldehyde Sigma® P6148 LOT#041M1792V 
Radioimmunoprecipitation (RIPA) buffer Sigma® R0278 
Protease Inhibitor Cocktail (P8340 Sigma®) Sigma® P8340 
Phosphatase Inhibitor Cocktail 2 (Sigma®). Sigma® P5726 
N.N.N’,N’ Tetramethyyl-Ethylenediamine 
(TEMED) 100 ml Sigma® 
Sigma® LOT71K1515 T8133 
Ammonium Persulfate (APS) A3678-25 
LOT# MKBX2380V Sigma® 
Sigma® A3678-25 LOT# MKBX2380V 
β-mercaptoethanol  
(2-Mercaptoethanol M3148-25ml Sigma®) 
Sigma® LOT#BCBH6010V 
Tris-Base (TBS) LOT168464 BNP152-1 
BP152-1 
Fisher Bioreagents® LOT168464 BNP152-1 
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Table 2.5 List of Chemicals 
Chemicals Supplier Cat. Number 
Tris-Base (TBS) LOT168464 BNP152-1 
BP152-1 
Fisher Bioreagents® LOT168464 BNP152-1 
Tween® 93773-250G Sigma® LOT#BCBF5959V 
(Ethylenedinitrilo)tetraacetic acid (Edetic 
acid REF1233508-200MG Sigma®) 
Sigma® REF1233508-200MG 
Triton-X 100 (Triton™ X-100 Sigma ®) Sigma® 2315025 
Invitrogen™ UltraPure™ Urea Invitrogen™ 15505027 
Methylated Spirit (IDA 99), 99% (v/v), Pure, 
(Industrial Methylated Spirit, 74 0.P.)–
Fischer Chemical 
Fischer Chemical 10552904 
Ethanolo (Ethanol 99%+, Absolute, Extra 
Pure, SLR, Fisher Chemical) 
Fischer Chemical 10680993 
Acetylcholine chloride (-ACh- 2-
acetyloxyethyl(trimethyl)azanium; chloride 
Sigma Aldrich® A2661 
Nicotine 3-[(2S)-1-methylpyrrolidin-2-
yl]pyridine ((−)-Nicotine); Sigma Aldrich® 
Product Number N3876. 





Sigma Aldrich A79922 
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Table 2.6 List of other general materials 
Other general materials Supplier Cat. Number 
Lipopolysaccharides (LPS) Sigma Aldrich L2637 
Nitrocellulose membranes 
(Amersham Protran 




Slide-A-Lyzer™ Dialysis Cassettes Thermo Fisher 66212 
Amicon® Ultra centrifuge filter Merck Millipore LtD C7719 
96 well black plate 









Tipone®1.5 mL natural flat cap micro-
centrifuge tubes 
StarLab Cat No S1615-5500 
Tipone®2 mL 
Natural flat cap micro-
centrifuge tubes CP 
material 
N°E1420-2000 LOT NOI 
30717003 
PCR Eppendorf (0.2 ml PCR Tube, Flat 
Cap –natural-) 
StarLab 
Cat. No. I1402-8100 LOT 
18034) 
Slide dual chamber for cell count BioRad Cat #145-0011 
Centrifuge tube 15 ml  
(15ml, 120x17mm, PP) 
Sarstedt Tube NC9531248 
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Table 2.7. List of other general materials 
Other general materials Supplier Cat. Number 
Centrifuge tube 50 ml (Screw Cap Tube 
50ml, 28X114mm, PP, conical base with 
skirted bottom) 
Sarstedt Tube NC9874179 
Oxoid™ Phosphate Buffered Saline Tablets Thermo Scientific™ Cat Num BR0014G 
Pierce™ High Capacity Endotoxin Removal 
Spin Columns, 0.5 mL 
Thermo Scientific™ 2162373.3 
Detoxi-Gel™ Endotoxin Removing Columns, 
1 mL 
Thermo Scientific™ Cat num 20344 
Depc-Treatted Water, DNase/RNase free Bioline Cat No. BIO-38031 
96-Well PCR Plate, Semi-Skirted, Raised 
Rim, Low Profile (for FAST® Systems), 
natural 
Starlab Cat. No. E1403-7700 
C-reactive protein–Human- 5 mg- Yo Protein Cat Number 226 
Eppendorf tube 
(Greiner Bio-One 
Cryos™ 1 mL) 
123278 
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Table 2.8 List of equipment 
Equipment Supplier Cat. Number 
Eppendorf centrifuge  
(Eppendorf Centrifuge 5415 D) 
Sigma® Z604062 
Odyssey® Fc Imaging System Licor Not reported 
Centrifuge Sigma 3-16K DJB Lab care 10280 
Spectrafuge™ 24D Digital Lab 
Microcentrifuge 
Labnet international C2400 
-80 freezer (-86°C UltraFlow Freezer) Nuaire Not reported 
Mr. Frosty  
(Mr. Frosty™ Freezing Container) 
Thermo Scientific™ 5100-0001 
Water bath (Grant JB Nova) Grant JB Nova JBN12 
Incubator (Nuaire ISO class 5 HEPA) Nuaire Not reported 
Count cell (BioRad TC10™ automatic cell 
count) 
BioRad #1450010 
Ice (Ice machine KF85 ) Porkka Not reported 
Live cell imaging microscope Leica CTR 6000 
FACS machine (BD FACSVerse™) BD Bioscience Not reported 
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Table 2.9 List of equipment 
Equipment Supplier Cat. Number 
Sonic machine  
(Grant Ultra sonic bath XUBA1) 
The Laboratory Store Not reported 
Microplate Reader  
(Synergy™ HT Microplate Reader) 
BioTek® Not reported 
Inc Accublock™ Digital Dry Bath Labnet international Not reported 
PowerPac™ Basic BioRad #1645050 
Electrophoresis unit ATTO, Japan AE-6500 
Trans-blot SD Semydry Transfer Cell BioRad 1703940 
NanoDrop™ One/OneC Microvolume UV-Vis 
Spectrophotometer 
Thermo Scientific™ ND-ONE-W 
Thermal cycler (Q-Cycler 96) Hain Lifescience 7024007 
Thermal cycler StepOnePlus™ Real-Time 
PCR System 
Thermo Scientific™ 4376600 
dH2O Elix® Progard TS2 Merck Millipore LtD No PR0G0T0S2 
Primo Vert Tissue Culture Microscope ZEISS Not reported 
Mini Vortex Mixer Fisher Scientific Fischer Scientifc 14-955-151 
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Table 2.10 List of Software 
Zeiss ZEN Lite Software 
Imagine Studio™ Lite (LI-COR®) 
BDFacs suit V1.0.6 
Microsoft Excel 2013 for Windows 
Leica Application Suite X (LAS X) 3.4.2.18368 
StepOne™ and StepOnePlus™ Software v2.3 
GraphPad Prism version 7 for Windows  
GraphPad Software, La Jolla California USA (www.graphpad.com) 
 
2.3 Monomeric C-reactive Protein (mCRP) preparation.  
The pentameric or native (nCRP) commercial form was purchased from Yo 
protein laboratories (C-reactive protein –Human- 5 mg Cat Number 226 Yo 
Protein).  
2.3.1 Dissociation from nCRP to mCRP. 
 
The nCRP was inserted into a buffer containing 10 mM EDTA (Edetic acid 
REF1233508-200MG Sigma®) and 8 M urea (Invitrogen™ UltraPure™ Urea 
15505027), to induce dissociation from nCRP into mCRP. The solution was 
incubated in a water bath (Grant JB Nova) at +37°C for two hours. This method 
was adopted in line with the Potempa protocol (Potempa et al., 1983; Potempa 




After incubation, the nCRP was dialysed using Thermo Fisher Slide-A-Lyzer™ 
Dialysis Cassettes (Thermo Fisher Scientific). The mCRP was dialysed with a 
dH2O buffer containing PBS (Thermo Scientific™ Oxoid™ Phosphate Buffered 
Saline Tablets Cat num BR0014G). Ten mL of mCRP was put into a 10 mL Fisher 
Slide-A-Lyzer™ G2 Dialysis Cassette. On day one the whole buffer (PBS + dH2O 
+ mCRP) was changed every two hours, for a total of three changes, using 
aseptic techniques. The mCRP was then maintained at a temperature of +4°C in 
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a dark room. After the third change, the mCRP was left to rest overnight at +4°C. 
The buffer was changed twice every four hours on day 2. After eight hours, the 
mCRP was recollected from the dialysis Cassette.  
 
2.3.3  Protein Concentration 
 
An Amicon® Ultra centrifuge filter (Amicon® Ultra centrifuge filter Merck Millipore 
LtD) was used to concentrate the dialysed protein, according to the 
manufacturer’s instructions. The sample was loaded and the Amicon® Ultra 
centrifuge filter Merck Millipore LtD column was centrifuged (DJB Lab care Sigma 
3-16K 10280) at 4500 x g for 25 minutes at +4°C. 
 
2.3.4 mCRP Endotoxin Purification  
 
A 0.5 mL Pierce™ High-Capacity Endotoxin Removal Spin Column was used to 
remove any endotoxin in the protein sample. The Endotoxin purification protocol 
was carried out according to the manufacturer’s guidelines. Briefly, the column 
was put into a collection tube and spun at 500 × g for 1 minute so as to eliminate 
the storage solution. The column was then regenerated by 0.2N NaOH and 
inverted several times to ensure the resin was completely re-suspended in the 
solution and then incubated overnight at room temperature. The following day, 
the column was spun at 500 × g for 1 minute and the solution was discarded. A 
total of 2M NaCl was added to the column and inverted several times to ensure 
the resin was completely re-suspended in the mixture. The column was spun at 
500 × g for 1 minute and the solution was discarded. Endotoxin-free ultrapure 
water was added to the column and the column was inverted several times to 
ensure the resin was suspended. The column was spun at 500 × g for 1 minute 
and the solution was discarded. The sample was added to the column and 
inverted several times to suspend the sample in the resin. The sample was 
incubated in the column at +4 °C overnight. The following day, the column was 
spun again (500 × g for 1 minute) and the sample was collected.  
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2.3.5 Anti-nCRP and anti-mCRP3H12 antibodies Endotoxin purification  
 
Thermo Scientific™ Detoxi-Gel™ Endotoxin Removing Columns kit 1 mL (Cat 
num 20344) was used according to the manufacturer’s instructions. Briefly, 
Detoxi-Gel Resin was degassed by suction for 15 minutes and the resin was left 
to precipitate for 30 minutes. The resin was washed it with sodium deoxycholate 
followed by pyrogen-free buffer. The sample was applied to the column in 
pyrogen-free buffer or water. The column flow was stopped for an hour once the 
sample had entered the resin bed, to optimise the yield. When the sample 
emerged from the column, it was collected. 
 
2.4 Molecular Docking 
All the SMIs were constructed and modelled, and energy minimized in neutral 
form by standard molecular mechanics methods. For the protein preparation, 
discovery studio Biovia 2020 (Dassault Systèmes, Vélizy-Villacoublay, France)  
which was use to visualize and modify receptor and ligand structures. Interaction 
analysis was carried out using the Accelrys Discovery Studio Visualizer. Atomic 
charges were assigned using the Gasteiger-Marsili procedure. For SMIs (docking 
with CRP subunit) the crystal structure of CRP was retrieved from the RCSB 
Protein Data Bank (PDB ID: 3PVO; resolution: 3.0 Å 
https://www.rcsb.org/structure/3PVO). The protein targets were refined using 
AutoDock 4.25 (Morris et al., 2009) using a well-established cross docking 
protocol to identify the conformations that have significant binding affinity with 
mCRP (Boraei et al., 2019). Briefly, water molecules were removed while 
hydrogen atoms were added using the ADT module implemented in AutoDock. 
The charges were adjusted using Gasteiger charge module for proteins 
implemented in AutoDock. Docking was performed for both complexes using the 
empirical free energy function and the Lamarckian protocol (Morris et al., 1998). 
The atomic charges for the protein were assigned using the same Gasteiger-
Marsili method. Mass-centred grid maps were generated with 40 grid points for 
every direction and with 0.375 Å spacing by the AutoGrid program for the catalytic 
domains of CRP subunit. Starting position was randomly chosen on the entire 
protein surface as well as the orientations, and torsions were used for the ligands. 
The results were analysed for the presence of hydrogen bonding, hydrophobic 
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and p-p interactions between hits and the active site of the protein. The common 
interactions in both complexes were scrutinized. All the figures were rendered 
with the software Pymol and Jsmol.  
 
2.5 Bicinchoninic Acid assay (BCA Assay). 
Briefly, a 25 µL standard and sample was plated on 96-well microplate in 
duplicate (96-Well PCR Plate, Semi-Skirted, Raised Rim, Low Profile, for FAST® 
Systems, natural Cat. No. E1403-7700 Starlab). The BCA working solution was 
prepared by mixing 50 parts of reagent A and one part of reagent B (ratio 1:50).  
Afterwards, 200 μL of the final solution was added to each protein standard and 
sample. The plate was placed onto on a plate shaker delicately shaken for 30 
seconds and incubated for 30 minutes at +37 °C. The optical densities were 
measured by a microplate reader (Synergy™ HT Microplate Reader BioTek®) at 
an absorbance of 562 nm after cooling the plate at room temperature for 5 
minutes. The protein concentration was then calculated by standard curves. The 
results were calculated by the GraphPad Prism version 7 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com) and expressed in pg/mL.  
 
Table 2.11 BCA Standards 
Standards Albumin concentration (μg/ml) 
A 2000 μg/ml 
B 1500 μg/ml 
C 1000 μg/ml 
D 750 μg/ml 
E 500 μg/ml 
F 250 μg/ml 
G 125 μg/ml 
H 25 μg/ml 
I 0 μg/ml 
 
2.6 Dot Blot Protein analysis.  
Dot Blot was carried out using a total of 3 μL of media with 100 μg/mL of protein 
blotted onto nitrocellulose membranes (Amersham Protran 0.45 NC nitrocellulose 
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Western blotting membranes). The membranes were then blocked with 1% 
Bovine Serum Albumine (BSA - A2153-100G LOT#SLBZ1221 Sigma®) in TBS 
Tween PH 7.4 (Tris-Base –TBS- BNP152-1 BP152-1 Fisher Bioreagents® and 
Tween® 93773-250G Sigma®) for one hour, with gentle shaking, at room 
temperature. They were then incubated with anti-nCRP and anti-mCRP (anti-
mCRP3H12) primary antibodies at +4°C overnight. After incubation, they were 
washed three times in TBS-Tween for ten minutes at room temperature. 
Afterwards, the membranes were incubated with the secondary antibody which 
was diluted 1:2000 with 5% milk (Marvel Dried Skimmed Milk Powder) and TBS-
Tween for one hour, at room temperature. After a further washing cycle (three 
times, ten minutes each time, in TBS-Tween at room temperature), the 
chemiluminescent reagent was added to the membrane for one minute before 
developing the image. The membrane images were developed by the Odyssey® 
Fc Imaging System and analysed by the software Imagine Studio™ Lite (LI-
COR). 
 
2.7 General aseptic procedure. 
All experiments and procedures were carried out in an aseptic environment under 
a class II biological safety cabinet (BSC) (WALKER safety cabinet limited), to 
avoid contamination by outside air. Before starting, the BSC was exposed to UV 
rays for at least 15 minutes followed by another 15 minutes of ongoing airflow 
and ethanol [70% volume/volume (v/v)] to sanitize the BSC surfaces. For good 
practice, only previously autoclaved (Dixon surgical LTD autoclave machine) 
sterile tips and other sterile materials were used. Before the experiments were 
set-up, the cells were controlled for any contamination under a microscope at x40 
magnification (Primo Vert Tissue Culture Microscope ZEISS). Once these 
procedures had been completed, the BSC surface was cleaned again with 70% 
Industrial Methylated Spirit [-IMS Methylated Spirit IDA 99), 99% (v/v), Pure, 
(Industrial Methylated Spirit, 74 0.P.)–Fischer Chemical].  
 
2.8 The human haematopoietic cell line U937. 
The U937 monocyte cell line i.e. an oncogenic human monocyte cell line, 
differentiated into macrophage-like cells was used as an in vitro model of 
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inflammation. These cells had been harvested from a subject with generalised 
histiocytic lymphoma as reported by Sundström et al. (1976). In response to 
stimuli, they appeared to form into cells with the characteristics of macrophages 
(Passmore et al., 2001). These cells have also been used in other studies 
focused on the inflammation stage (Power et al., 2003; Yamagata et al., 2010; C. 
F. Vogel et al., 2012; Yamadera et al., 2018). They were also used to investigate 
mCRP production under conditions pertinent to the atherogenic process 
(Ciubotaru et al., 2005; Sproston et al., 2018).  
 
General technique: As aforementioned, for safety reasons, all the experiments 
and procedures were carried out in an aseptic environment under a class II BSC 
according to the local bio-security and safety procedures. Firstly, the safety 
cabinet was sterilised with Ethanol [70% volume/volume (v/v)]. So as to reduce 
the possibility of contamination, only previously autoclaved sterile tips and other 
sterile materials were used. Furthermore, the growth medium (RPMI 1640 with 
L-glutamine Lonza, supplemented with 10% FBS -F9665 Sigma®-) was pre-
warmed by placing a 50 mL centrifuge tube (Sarstedt Inc Screw Cap Tube 50 
mL, 28X114mm, PP, conical base with skirted bottom) into a +37 °C water bath 
(Grant JB Nova) for at least 10 ten minutes, before starting treatment procedures.  
 
2.9 Cryopreservation.  
Fetal Bovine Serum (FBS F9665 Sigma®), was prepared with 10% Dimethyl 
sulfoxide (DMSO 276855 Sigma®) to complete the storage solution. Briefly, 1 mL 
of DMSO was mixed in 9 mL of cold FBS and stored at -20 °C until use. The 
growth medium was removed from the flask (T-25 Nunc™ Easyflask Thermo 
Scientific) and transferred to a 15 mL centrifuge tube (Sarstedt Tube 15ml, 
120x17mm, PP). The tube was centrifuged at a speed of 1500 rpm (430 x g) for 
7 minutes, then the growth medium was discarded. The storage solution was 
immediately added to the cell and aliquoted into 1 mL Eppendorf tubes (Greiner 
Bio-One Cryo.s™ 1 mL). After which, the Eppendorf tubes were put into a 
freezing container (Thermo Scientific™ Mr. Frosty™ Freezing Container), stored 
at -80°C (Nuaire -86°C UltraFlow Freezer) for 120 minutes, then removed from 
the freezer and stored in liquid nitrogen until use. 
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2.10 Cell recovery. 
The Eppendorf tube was removed from the liquid nitrogen and immediately 
placed into a water bath at +37 °C for 2 minutes. The storage solution was then 
removed from the Eppendorf tube under the BSC and transferred to a 15 mL 
centrifuge tube. The tube was then centrifuged for 3 minutes at 2000 rpm (765 x 
g). The storage solution was then discarded and replaced with 2 mL of growth 
medium After pipetting, the growth medium was transferred into a T-25 flask and 
then incubated (ISO class 5 HEPA Nuaire) at + 37°C, 5% CO2 95% air, humidified 
cell culture incubator. 
 
2.11 Cell culture.  
Monocyte U937 cells were grown in a growth medium (RPMI 1640 with L-
glutamine Lonza) supplemented with 10% FBS (FBS F9665 Sigma®) in 95% 
humidified air with 5% CO2 at +37°C in a T-75 flask (T-75 Nunc™ Easyflask 
Thermo Scientific) from passage 10 to 14. 
 
2.11.1 Cell counting.  
 
BioRad’s TC10™ automated cell counter was used for cell count. A 20 μL cell 
suspension was extracted from the sub-cultured U937 monocyte cells and put 
into an Eppendorf tube containing 20 μL of trypan blue dye (Trypan Blu solution-
Lot 17416001 Corning®). Ratio 1:1. After pipetting, 10 μL of the sample solution 
was loaded onto a dual-chamber slide (BioRad’s Cell Counting Slide for TC10™ 
dual chamber Cat #145-0011). The slide was successively inserted into the 
TC10™ automated cell counter, which prompted the automatic cell count. Once 
this procedure was concluded, the machine showed the total cell count, the 




The media was removed from the flask (T-75 Nunc™ Easyflask Thermo 
Scientific) and transferred to a 50 mL centrifuge tube (Sarstedt Inc Screw Cap 
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Tube 50 mL, 28X114mm, PP, conical base with skirted bottom). The tube was 
centrifuged for 7 minutes at 1500 rpm (430 x g). After centrifuging, the spent 
growth medium was discarded and a new growth medium added in an amount 
that allowed for a cell concentration equal to 1 x 106 cell/mL. The growth medium 
was changed every three to four days. 
 
2.12 Differentiation. 
Literature reports that the monocyte U937 cell line has the potential to 
differentiate when treated with Phorbol-12-myristate 13-acetate (PMA) for 72 
hours (Sproston et al., 2018). The following procedure was adopted in the present 
research. The spent growth medium was removed from the flask and put into a 
50 mL centrifuge tube. The tube was centrifuged (DJB Lab care Sigma 3-16K 
10280) for 7 minutes at 1,500 rpm (430 x g). After centrifuging, the spent growth 
medium was discarded and 3 mL of fresh growth medium was added. Cell 
viability and count were estimated by both the Trypan Blu solution and BioRad’s 
TC10™ automated cell counter, as previously described. The initial cell viability 
was maintained above 90% for all experiments. The cells were then diluted at a 
1 x 106 cell/mL concentration. The U937 cells were seeded at an initial density of 
2 × 106 cell/well to induce to differentiation from floating monocytes into adherent 
macrophages. The differential medium contained RPMI 1640 with L-glutamine 
(1640 medium Lonza) supplemented with 10% FBS (F9665 Sigma®) and 
phorbol-12-myristate 13-acetate (PMA793461 Sigma®) at 50 ng/mL. The cells 
were grown on a 6-well plate (Nunclon™ Delta Surface Thermo-Scientific Cat. 
n°140675 LOT158007) for 72 hours. Following differentiation, the Dulbecco's 
Phosphate Buffered Saline (DPBS) was pre-warmed at +37°C in a water bath 
and then the cells were washed twice with the saline solution.  
 
2.13 Enzyme-linked immunosorbent assays (ELISA). 
Enzyme-Linked Immunosorbent Assay (ELISA) is a meticulous, rigorous, 
quantitative immunoassays method, which allows for the quantification of the 
antigen-antibody interaction through a catalytic action (Watanabe et al., 2013). 
As this technique has been widely used, it is not surprising to notice that multi-
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analyses screening ELISAs have also been developed to detect simultaneous 
multiple antigen-antibody interactions (Zhang et al., 2011).  
 
All the manufactures’ kits and reagents were purchased by the R&D Systems bio-
techbrand® and the tests were performed according to the manufacturer's 
instructions. To reduce the possibility of contamination, only previously 
autoclaved (Dixon surgical LTD autoclave machine) sterile tips and materials 
were used. 
 
The medium was collected from a 6-well plate and inserted into an eppendorf 
tube and centrifuged at 1000 rpm (Eppendorf Centrifuge 5415 D) for 5 minutes. 
A total of 1800 μL of media was then transferred to another 2 mL eppendorf tube 
and stored at −80 °C (Nuaire -86°C UltraFlow Freezer) overnight. The captured 
antibody was diluted at working concentration in PBS (both capture antibody and 
PBS were included in the DuoSet ELISA Ancillary Reagent Kit 2 Catalog #DY008 
R&D Systems bio-techbrand®). Following this step, the 96-well plate was coated 
with 100 μL of diluted capture antibody and incubated in a dark environment, at 
room temperature overnight. The day after the plate was washed 3 times with 
400 μL wash buffer (washing buffer included in the same kit, i.e., the DuoSet 
ELISA Ancillary Reagent Kit 2). Once the washing cycle had been completed, the 
plate was blocked by adding 300 μL of reagent diluent (reagent diluent included 
in DuoSet ELISA Ancillary Reagent Kit 2) to each well. The plate was then 
incubated in a dark environment, at room temperature for a further 2 hours. Once 
these procedures had been completed, the plate was washed again 3 times with 
the washing buffer. After the last wash, 100 μL of the sample and standard curve 
(standard curve diluted in reagent diluent) was added to each well and incubated 
for 2 hours in a dark environment, at room temperature. All samples were added 
in duplicate. The plate was washed three more times with the washing buffer. A 
total of 100 μL of detection antibody (detection antibody included in the DuoSet 
ELISA Ancillary Reagent Kit 2) was added to the reagent diluent, then to each 
well and incubated in a dark environment, at room temperature for 2 hours. The 
plate was washed 3 more times with the same washing buffer and procedure. 
After the last wash, 100 μL of reagent diluents, containing Streptavidin-HRP (HRP 
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included in the DuoSet ELISA Ancillary Reagent Kit 2), was added to each well. 
The plate was covered and incubated for 20 minutes in a dark environment, at 
room temperature. After which, the plate was washed three more times and 100 
μL of substrate solution (Solution A + Solution B in a ratio 1:1 included DuoSet 
ELISA Ancillary Reagent Kit 2) was added to each well and incubated for 20 
minutes in a dark environment at room temperature. After 20 minutes 50 μL of 
stop solution (included in the DuoSet ELISA Ancillary Reagent Kit 2) was added 
to each well. The optical densities on the plates were read by a microplate reader 
at an absorbance of 450 nm. The protein concentration was then calculated by 
standard curves. The result was calculated by the GraphPad Prism version 7 for 
Windows (GraphPad Software, La Jolla California USA, www.graphpad.com) and 
expressed in pg/mL.  
  
2.14 Cytotoxic testing. 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
and Resazurin (element of Alamar Blue reagents) are two extremely useful 
compounds to determine if, organic extracts, nano-drugs, peptides, inhibitory 
RNA sequences and SMI exert a cytotoxic and/or anti-proliferative effect on cells 
(Ediriweera et al., 2018). However, there is a substantial difference between 
these two compounds. Differently to MTT, Alamar Blue is nontoxic to cells and 
provides results without killing them. Rampersad (2012) reported that Alamar 
Blue allows for a highly sensitive, user-friendly, non-toxic and non-radioactive 
assay that can potentially be used with both fluorescence and/or absorbance-
based instrumentation readers.  
 
In the experiments herein described, this cell assay was used to evaluate the 
level of the cytotoxic effect small molecule inhibitors (SMIs) have on U937-
derived macrophages. Following differentiation (as aforementioned) the cells 
were treated for 24 hours by SMIs at different concentrations. Ethanol (Ethanol 
99%+, Absolute, Extra Pure, SLR, Fisher Chemical) at 20% was used as a 
positive control. After 24 hours, Cell Titer-Blue® (Promega) was added and the 
medium was incubated (Nuaire ISO class 5 HEPA, 95% humidified air, with 5% 
CO2, at +37°C) for 4 hours. Optical densities on plates were read by a microplate 
reader (Synergy™ HT Microplate Reader BioTek®) in the florescence mode 
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(530/25 excitation and 590/35 emission). The percentage of cell viability was 
calculated from the original raw data by Microsoft Excel 2013 for Windows. 
GraphPad Prism version 7 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com) was used for the graphs. 
 
2.15 Apoptosis detection methods.  
Macrophage apoptosis was estimated by the Annexin-V Fluorescein 
isothiocyanate (FITC) apoptosis detection kit (FITC Annexin V Apoptosis 
Detection Kit 1 Cat 556547 LOT8072965 BD Bioscience), according to the 
manufacturer’s instructions. The cell samples were analysed by a BD 
FACSVerse™ (BD Bioscience) flow cytometry apparatus, with the aid of the 
BDFacs suit V1.0.6 software. This kit works as follows. Firstly, FITC Annexin V 
binding with phosphatidylserine (translocated during apoptosis) can be used to 
determine which percentage of cells are undergoing apoptosis. Secondly, 
Propidium Iodide (PI) is used to detect viable cells with undamaged membranes. 
This is possible because the membranes of dead and damaged cells are 
permeable to PI. 
 
Following differentiation (as aforementioned), the compounds were added at a 
specific moment in time and at a specific concentration (the time-point and the 
specific concentration that had been previously identified by cytotoxic testing 
(2.15). After 24 hours in the incubator, the growth medium containing the 
compounds was removed from the 6 well plate. The cells were then washed with 
DPBS, which had been pre-warmed at +37°C in a water bath. After washing, the 
cells were trypsinized with Trypsin-EDTA solution and then incubated for 5 
minutes. After this procedure, the cells were checked (Primo Vert Tissue Culture 
Microscope ZEISS), to confirm if the cells had completely detached. A total of 4.5 
mL of RPMI 1640 with L-glutamine (1640 medium Lonza), supplemented with 
10% of FBS (F9665 Sigma®) was added to the cells to block the Trypsin activity. 
The cells were then transferred to a centrifuge tube and centrifuged for 7 minutes 
at a speed equal to 1500 rpm (430 x g). After which, the solution (containing RPMI 
1640 with L-glutamine, 10% FBS and Trypsin-EDTA solution) was removed. The 
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cells were washed twice with DPBS and resuspended in 1X binding buffer 
(containing FITC Annexin V Apoptosis Detection Kit 1 Cat 556547 LOT8072965 
BD Bioscience) at a concentration of 1 x 106 cells/mL. 100 μL of the solution (1 x 
105 cells) was then transferred to the falcon tube for flow cytometry (Falcon™ 
Round-Bottom Polystyrene Tubes Falcon 352058). Five μL of FITC Annexin V 
and 5 μL PI was then added to the tube which was then vortexed (Fisher Scientific 
Mini Vortex Mixer) for 30 seconds and incubated for 15 minutes, at room 
temperature, in a dark environment. Fifteen minutes later, 400 μL of 1X Binding 
Buffer was added to each tube and both BD FACSVerse™ (BD Bioscience) and 
BDFacs suit V1.0.6 software were used to analyze the apoptotic effect of each 
compound.  
 
2.16 Flow cytometry.  
Flow cytometry (FCM) is a technique used in the immunological field (Cossarizza 
et al., 2017) as it is able to identify several cellular features (including size and 
internal complexity) through the analysis of intermittent laser light (Henel and 
Schmitz, 2007).  
 
Following differentiation (as previously described), the cells were washed three 
times with DPBS pre-warmed at +37°C in a water bath. A total of 1.5 mL of 
Trypsin-EDTA solution was added to the cell and the solution was incubated for 
5 minutes. After this procedure an inverted phase contrast cell culture 
microscope, was used to confirm if the cells had completely detached (Primo Vert 
Tissue Culture Microscope ZEISS). A total of 4.5 mL of RPMI 1640 with L-
glutamine (1640 medium Lonza), supplemented with 10% of FBS (F9665 
Sigma®), were added to the cells to block the Trypsin activity. Following this 
procedure, the cells were transferred to a centrifuge tube and centrifuged for 7 
minutes, at a speed of 1500 rpm (430 x g). Seven minutes later, the solution 
(containing RPMI 1640 with L-glutamine, 10% FBS and Trypsin-EDTA solution) 
was removed. The cells were then transferred from the 15 mL Sarstedt tube to a 
previously autoclaved eppendorf tube through DPBS. Following the transfer 
procedure, the cells were washed twice in DPBS and centrifuged (Eppendorf 
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Centrifuge 5415 D) at 500 x g for 5 minutes, at room temperature. After the 
second washing, the cells were suspend in a 200 µL solution of 4% 
paraformaldehyde (P6148-500G LOT#041M1792V Sigma®), dissolved in dH2O 
and incubated in a dark environment, at room temperature for 15 minutes. After 
which, they were washed thoroughly with 1 mL DPBS and immediately 
centrifuged, at 500 x g for 5 minutes. Following the last washing procedure, 0.125 
μg/mL of anti-human CD11c antibody (Thermo-fisher Anti–Hu CD11c 
LOT2008210) was diluted in a washing buffer containing 10% FBS (F9665 
Sigma®) and DPBS (BE17-512F Lonza). The antibody was then added and 
incubated at +4°C in a dark chamber (fridge) for 30 minutes. A total of 200 µL of 
washing buffer was then added to the cells and centrifuged at 500 x g for 5 
minutes. Once the last washing phase had been completed, the supernatant was 
removed and 500 µL of DPBS (BE17-512F Lonza) was added to transfer the cells 
into the flow cytometry tube (Falcon™ Round-Bottom Polystyrene Tubes Falcon 
352058). The final data were obtained by the BD FACSVerse™ (BD Bioscience) 
and the analyses were carried out by the BDFacs suit V1.0.6 software. 
 
2.17 Western Blots. 
The first technique used to transfer the proteins from a polyacrylamide gel to a 
nitrocellulose sheet was described in 1979 (Towbin et al., 1979). Western blotting 
(WB), is a biological molecular technique (Mahmood and Yang, 2012) able to 
identify specific proteins once they have been separated using a vertical gel 
electrophoresis system, blotted onto nitrocellulose membranes and incubated 
with a selected antibody. WB is one of the most preferred quantification protein 
methods adopted in molecular biology laboratories.  
 
So as to reduce the possibility of contamination, only previously autoclaved 
(Dixon surgical LTD autoclave machine) sterile tips and materials were used. The 
medium was collected from the 6-well plate and put into a 15 mL centrifuge tube. 
The cells were lysed by adding 200 μL/well of ice-cold buffer 
Radioimmunoprecipitation (RIPA) (R0278 Sigma®) containing a protease 
inhibitor cocktail (P8340 Sigma®) and a phosphatase inhibitor cocktail 2 (P5726 
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Sigma®) on ice (Ice machine Porkka KF85). The lysed cells were then put in an 
Eppendorf tube (Greiner Bio-One Cryos™ 1 mL), sonicated for 30 seconds 
(Grant Ultra sonic bath XUBA1) and centrifuged (Eppendorf Centrifuge 5415 D) 
at 0.1 rfc for one minute. After centrifugation, 180 µL of protein lysates was 
transferred into another eppendorf tube. The protein concentration of the lysed 
cells was determined by the BCA assay method (Pierce™ BCA Protein Assay 
Kit), as previously described. At the end of the BCA assay procedure, the sample 
was stored in a -80 °C in a freezer overnight. So as to reduce and denature the 
sample, the following day the sample was diluted onto a loading buffer (traditional 
laemmli buffer) containing β-mercaptoethanol (2-Mercaptoethanol M3148-25ml 
LOT#BCBH6010V Sigma®) and bromophenol blue. The samples were warmed 
for 5 minutes at a +95 °C (Inc Accublock ™ Digital Dry Bath Labnet international). 
Equal amounts of protein extracts were electrophoresed on 12% SDS 
polyacrylamide gels (TGX Stain-Free™ FastCast™ Acrylamide Kit 12% from Bio-
Rad, TEMED Sigma® LOT71K1515 T8133 100 mL, Ammonium Persulfate –
APS- A3678-25 Sigma® LOT# MKBX2380V). Once the electrophoresed had 
been completed, the phase proteins were electroblotted, using a semi-dry 
apparatus (Trans-blot SD Semydry Transfer Cell BioRad), onto a nitrocellulose 
membrane (Amersham Protran 0.45 NC nitrocellulose Western blotting 
membranes). The membranes were then blocked by adding 1% Bovine Serum 
Albine (BSA A2153-100G LOT#SLBZ1221 Sigma®), diluted in TBS Tween (Tris-
Base –TBS- Fisher Bioreagents® LOT168464 BNP152-1 BP152-1; Tween® 
93773-250G LOT#BCBF5959V Sigma® and dH20 at pH 7.4). The membranes 
were shaken gently in a dark environment, at room temperature, for 1 hour. They 
were then stained with a primary antibody (Anti-NF-КBp65-phospho S529- 
antibody AB194758 Abcam; Phospho-p38 MAPK-Thr180/Tyr182-28B10- Mouse 
mAb#9216 Cell Signaling Tecnology®), which had been diluted in a blocking 
buffer containing 1% BSA in TBS-Tween (Ph 7.4). The membranes and the 
antibodies were then shaken gently in a dark environment, at +4 °C overnight. 
On the second day, the membranes were washed three times (10 minutes each 
time), with TBS-Tween in a dark environment, at room temperature. Once the last 
washing phase had been completed, the membranes were incubated again with 
86 | P a g .  
  
a horse-radish peroxidase-conjugated antibody (Secondary antibody Goat Anti-
rabbit IgG -H+L-human IgG-adsorbed horseradish peroxidase conjugate -HRP- 
Cat n° 170-6515 BioRad) diluted in (1:3000) in TBS-Tween containing 5% of de-
fatted milk (Marvel Dried Skimmed Milk Powder) in a dark environment, at room 
temperature, with continuous mixing for 1 hour. After which, they were washed 
three times (as described) in TBS Tween PH 7.4. The membrane was visualized 
using the ECL chemiluminescence detection method. Membrane images were 
obtained with the Odyssey® Fc Imaging System and were analysed by the 
software Imagine Studio™ Lite (LI-COR).  
 
2.18 Reverse transcription-polymerase chain reaction (RT-
PCR). 
Polymerase chain reaction (PCR) is a technique able to amplify a few DNA 
segments into thousands of millions of copies, using a DNA-polymerase enzyme 
and a primer (Valones et al., 2009). As this is an extremely rapid, cost-effective 
and user-friendly technique, there is an increase in publications reporting its use 
(VanGuilder et al., 2008). In this investigation a specific type of qRT-PCR, the 
Reverse transcriptases-qPCR (RT-qPCR), was used.  
 
2.18.1 RNA purification.  
 
The RNA purification procedure in this study was carried out on ice. Moreover, 
only previously autoclaved sterile material was used.  
 
The medium was collected from a 6-well plate and discharged a 15 mL centrifuge 
tube. Cell lysing was done by adding 350 µL of Buffer RLT Plus (the lysis buffer 
included the RNeasy plus mini kit 50 Cat No./ID:74134 Qiagen) containing β-
mercaptoethanol. The lysed cells were collected and stored overnight at −80°C 
before starting the RNA purification procedure, which was carried out using a 
dedicated kit (RNeasy plus mini kit 50 Cat No./ID:74134 Qiagen).  
 
After removal from storage the day after, the sample was transferred from the 
Eppendorf tube to the gDNA eliminator column (included in the RNeasy plus mini 
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kit). It was then centrifuged at more than ≥11,000 rpm for 30 seconds. The column 
was then disposed of and the flow-through was saved. A total of 350 µL of 70% 
ethanol was added and mixed to the column. Seven-hundred µL (350 µL of cell 
lyse + 350 µL of 70% ethanol) of the sample was then transferred to the RNeasy 
spin column and transferred to a 2 mL collection tube (both the RNeasy spin 
column and the collection tube were supplied in the kit) and centrifuged for 15 
seconds at more than 11,000 rpm. The flow-through was once again disposed of. 
A further 500 µL of Buffer RW1 (buffer included in the RNeasy plus mini kit) was 
added to the RNeasy spin column and centrifuged for 15 seconds, at more than 
11,000 rpm to wash the spin column. The flow-through was disposed of again. 
Five-hundred µL buffer RPE (buffer included in the RNeasy plus mini kit) was 
added to the RNeasy spin column and centrifuged for 15 seconds at ≥11,000 rpm 
to rinse the RNeasy spin column membrane. The RNeasy spin column was then 
relocated to a new 2 mL collection tube and both the old collection tube and the 
flow-through were disposed of. The new collection tube was centrifuged for 1 
minute. The RNeasy spin column was transferred to a new 1.5 mL collection tube 
(supplied) and 30 µL of RNase-free water (RNase-free water included in the 
RNeasy plus mini kit) was directly added to the spin column membrane. Lastly, 
the RNeasy spin column was centrifuged for one minute at more than 11,000 rpm 
to clear the spin column membrane. The last two steps were repeated one more 
time.  
 
2.18.2 RNA concentration phase. 
 
In summary, 1 µL of each sample was loaded onto the Thermo Scientific™ 
NanoDrop™ One/OneC Microvolume UV-Vis Spectrophotometer used to 
quantify the RNA concentration. Once this procedure had been concluded, the 
machine provided an automatic quantification of the total RNA concentration.  
 
2.18.3  The reverse transcription phase. 
 
The cDNA was obtained through the reverse transcription phase TaqMan 
Reverse Transcription reagents (LOT 1877894 REF N8080234 Applied 
Biosystems® By Life Technologies™). Briefly, an equal volume of 500 ng/mL of 
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RNA was transferred into a 0.2 mL PCR tube with2 µL of X10 RT Buffer, .4 µL of 
Magnesium chloride (MgCl₂), 1 µL of dNTP Mixture , 1 µL of RNase Inhibitor, 1 
µL MultiScribe™ Reverse Transcriptase, 1 µL of Random Hexamers. The 
remaining super pure dH2O (Depc-Treated Water, DNase/RNase free Cat n°. 
BIO-38031 Bioline) so as to arrive at a total volume of 20 µL. The mixed 
components were vortexed (Mini Vortex Mixer Fisher Scientific) and centrifuged 
(Spectrafuge™ 24D Digital Lab Microcentrifuge Labnet international) briefly to 
collect solutions at the bottom of the reaction tubes. The reaction mix was then 
incubated inside a Thermal cycler (Q-Cycler 96 Hain Lifescience) according to 
the protocol described in Table 2.12. Once the incubation phase had been 
completed, the mixed contents were vortexed again. 
 
Table 2.12 The protocol for reverse transcription phase. 
 






2.18.4  Real time PCR  
 
This phase was performed using both the Applied Biosystems™ TaqMan™ Fast 
Advanced Master Mix and the TaqMan® Gene Expression Assays (18S; IL-1β; 
IL-6; IL-10). All the reagents were plated in 96-well PCR Plate in the appropriate 
quantity, as reported in Table 2.13.  
 
Table 2.13 Quantity of reagent volume necessary for the PCR phase. 
 
TaqMan™ Fast Advanced Master Mix 10 µL 
TaqMan® Gene Expression Assays 1 µL 
Depc-Treated Water, DNase/RNase 
free Cat No. BIO-38031 BIOLINE 
7 µL 
RT 2 µL 
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The plate was then centrifuged briefly to collect solutions at the bottom of the 
reaction tubes. StepOnePlus™ The Real-Time PCR System was used as a 
Thermal Cycler. The amplification protocol was performed according to the 
manufacturer's instructions and is summarised in Table 2.14. 
Table 2.14 The PCR phase protocol  










2 minutes 2 minutes 1 second 20 seconds 
 
StepOne™ and StepOnePlus™ Software v2.3 extrapolated the results, while 
Microsoft Excel 2013 for Windows and GraphPad Prism version 7 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad.com) provided the 
data analysis.  
 
2.19 Statistical Analyses. 
GraphPad Prism version 7 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com) was used for all the statistical analyses. Statistical 
significance was set at a p-value of <0.05 and a 95% Confidence Interval (CI) 
was fixed, while errors were fixed at 5 %. The same software was also used to 
produce graphical outputs. Where appropriate, experiments were validated by 
the One-way analysis of variance (ANOVA) test, followed by Tukey's post-test or 
Student’s t-test.  
 
  







CHAPTER 3 RESULTS:  
How Acetylcholine affects 
the dissociation of native C- 
Reactive Protein to 
monomeric CRP. 
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CHAPTER 3: How ACh affects the dissociation of nCRP to mCRP. 
A persistently acute phase response (APR) can promote atherogenesis, 
atherosclerosis incidents (Rader, 2000; Lowenstein and Matsushita, 2004; 
Ambrose and Barua, 2004; Libby, 2012; Siasos et al., 2014; Poulsen et al., 2015; 
Katakami, 2018) and increase nCRP concentration (Ceron et al., 2005).  
 
A study, carried out in 2009, reported that activated platelets were able to 
dissociate nCRP into monomeric C-reactive protein (mCRP) when these cells 
were found near the human aorta and carotid artery atherosclerotic plaques 
(Eisenhardt et al., 2009b). Once dissociated, mCRP acquires different functional 
properties to the original nCRP. Indeed, T. Khreiss et al. (2004) reported that 
mCRP was able to up-regulate P-selection and increase the formation of 
neutrophil-platelets and neutrophil aggregation when the monomer bounded with 
the FCγIIIb (CD16) receptors. Taylor and Van Den Berg (2007) reported that this 
new monomeric conformational form (mCRP), differently to nCRP, was also able 
to bind to human umbilical vein endothelial cells (HUVECs). Eisenhardt et al. 
(2009b) study described how this in vivo dissociation was followed by an increase 
in monocyte adhesion and Reactive Oxygen Species (ROS) but this process was 
abolished when CD64 (FCγI), CD32 (FCγIIa), CD16 (FCγIII) receptors were 
blocked. It has been observed that mCRP is able to increase paracellular 
permeability, lower the transepithelial electrical resistance and reduce ZO-1 
expression, as well as occluding proteins, when mCRP binds with retinal pigment 
epithelial cells (Molins et al., 2017). A recent review has evidenced that, while 
nCRP is characterised by both pro and anti-inflammatory activities, mCRP mainly 
features pro-inflammatory proprieties on different cell types, such as endothelial 
cells leukocytes and platelets (Wu et al., 2015).  
 
The contradictory literature data as to the role nCRP plays in inflammation posed 
a challenge for the estimation of exactly how much weight nCRP carries in the 
inflammatory response (Sproston and Ashworth, 2018). Thiele et al. (2015) 
stated that these pro-inflammatory features can now be imputed to the 
monomeric isoform and the prevention of the dissociation from nCRP to mCRP 
may well be a way to block pro-inflammatory activity. Consequently, some 
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authors have attempted to impair nCRP to mCRP dissociation with different 
approaches (Thiele et al., 2014a; Thiele et al., 2015).  
 
A small molecular dissociate-inhibitor was used to block the nCRP and mCRP 
pro-inflammatory activity. Based on fact that Pepys et al. (2006) confirmed that 
1,6-bis(phosphocholine)-hexane acts as a specific small-molecule inhibitor of 
nCRP activity, Thiele et al. (2014a), reported that mCRP triggered its pro-
inflammatory activity when it bound to both CD64 (FCγI) and CD16 (FCγIII) 
receptors and the use of 1,6-bis-PC (inhibiting the dissociation from nCRP to 
mCRP) reduced leukocyte recruitment and TNF-α expression, as well as IL-6 
pro-inflammatory cytokines release (Thiele et al., 2014a).  
 
Several studies have recently reported that an increase in pro-inflammatory 
cytokines has been associated with an inflammatory reflex activation (Tracey, 
2002; Tracey, 2007; Oke and Tracey, 2008; Pavlov and Tracey, 2012). 
Inflammatory reflex activation is associated with an increase in Acetylcholine 
(ACh) through the cholinergic anti-inflammatory pathway (CAIP) (Pavlov and 
Tracey, 2005; Tracey, 2009). Considering the close structural homology between 
1,6-bis(phosphocholine)-hexane and the ACh neurotransmitter (Slevin et al., 
2018), it is reasonable to hypothesize that ACh neurotransmitter might also bind 
to nCRP, inhibiting its dissociation. This hypothesis is further supported by the 
fact that nCRP is known to lead to lower ACh levels in plasma via a capture 
process (Nazarov et al., 2007). Therefore, there is the possibility that when the 
ACh neurotransmitter binds to nCRP, it acquires the capacity to prevent 
dissociation from nCRP into mCRP. 
 
Furthermore, two other small cholinergic molecules, i.e., Nicotine and Tacrine, 
were also tested during this research to assess whether these compounds were 
able to bind to nCRP, thus inhibiting dissociation into mCRP.  
 
Aim and objectives: To obtain further information on whether SMIs such as ACh, 
Tacrine and Nicotine can be used to block, or at least reduce, nCRP-mCRP dissociation. 
 
This was addressed by the following objectives: 
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• The literature reports that preventing the dissociation from nCRP to mCRP 
may well be a way to block pro-inflammatory activity. However, the fact 
that there are two different CRP (nCRP and mCRP) forms makes it difficult 
to ensure a selective strategy. The use of anti-mCRP antibody could be 
potential strategy to address this issue. On the basis of this reasoning, a 
first experiment was designed to make a selective identification of the two 
different forms of CRP, by the use of antibodies. Several studies have 
used dissociation methods against nCRP, e.g., Potempa et al. (1983) and 
Taylor and Van Den Berg (2007). Both methods, i.e., Potempa’s and 
heating method, were assessed to evaluate how the nCRP/mCRP ratio is 
affected during the dissociation phase. 
 
• The 1,6-bis(phosphocholine)-hexane has a very similar chemical 
strucuture to that exerted by ACh (Slevin et al., 2018). Should other 
molecules be proven able to inhibit nCRP-mCRP dissociation, a new class 
of compounds that can be used against nCRP to mitigate its pro-
inflammatory effect could be proposed. Therefore, the primary aim of this 
research was to determine whether selected Small Molecular Inhibitors 
(SMIs), i.e., ACh, Tacrine and Nicotine, have the capacity to block or 
impair nCRP-mCRP dissociation.  
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3.1 Antibody evaluation. 
 
Therapeutic antibodies have been used to treat several diseases. The possibility 
to adopt this strategy against nCRP prompted the evaluation of the efficacy of 
Anti-nCRP in binding to the nCRP. The anti-mCRP3H12 mouse monoclonal 
antibody was developed by Dr L.A. Potempa and fully characterized as previously 
described (Diehl et al., 2000). The experiment was designed to assess the 
antibody binding selectivity against both the native CRP (nCRP) and the 
monomeric CRP (mCRP) forms, respectively (Fig. 3.1). Anti-nCRP and anti- 




Fig. 3.1. Antibody efficiency evaluation. Anti-nCRP and anti-mCRP3H12 were characterized. Both 
showed a strong capacity to bind with both nCRP and mCRP respectively. In this dot-blot binding 
assay, 100 µg/mL nCRP and mCRP were loaded onto the membrane. The unpaired One-tailed t-test, 
with a 95% Confidence Interval (CI) and an α error fixed at 5% showed that, at the same 
concentration (100 µg/mL), the anti-nCRP antibody selectively bound with the nCRP obtained from 
Yo protein laboratories (p-value* <0.0086). At the same concentration (100 µg/mL) and using the 
same statistical parameters, the anti-mCRP3H12 antibody showed the same selectivity to bind with 
the appropriate conformational mCRP form (p-value ***<0.0005). (n=3) 
 
95 | P a g .  
  
3.2 The Dissociation method against native-CRP. 
 
So as to determine the best way to dissociate nCRP from a pentameric to a 
monomeric, nCRP was incubated in high concentrations of urea (Potempa et al., 
1983; Williams et al., 2020). Potempa et al. (1983) demonstrated that the 
pentameric nCRP form was dissociated into the monomeric form (mCRP) by 10 
mM EDTA and 8 M urea incubated at +37°C for two hours.  
 
As shown in Fig. 3.2, a strong dissociation from the nCRP form to the monomeric 
form (mCRP) was observed. Dialysis was then performed. However, it was not 
clear how this procedure is able to attenuate the capacity of anti-mCRP3H12 in 
binding with the mCRP form (Fig. 3.2). It was observed that the two antibodies 
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Fig. 3.2. nCRP dissociation into mCRPs. Dissociation of nCRP into its pro-inflammatory isoform mCRP was validated. A-C) After incubation and in high urea concentrations 
(8M) and EDTA (10mm), the anti-nCRP antibody confirmed that nCRP (100 µg/mL) showed a high dissociation from nCRP into the mCRP forms (100 µg/mL). In this dot-
blot binding assay, 100 µg/mL nCRP (commercial or control) and mCRP (generated or control) were loaded on the membrane. The One-way ANOVA, together with 
Tukey's post-hoc, a 95% CI and a 5% α error, confirmed a statically significant difference before and after the Potempa method (p-value***<0.0005). The dialysis process 
reduced the mCRP concentration, partially affecting the statically significant difference obtained previously (p-value**<0.0047). B-D) After incubation and in high urea 
concentrations (8M) and EDTA (10mm), the anti-mCRP3H12 antibody confirmed that nCRP (100 µg/mL) had a high percentage of dissociation from the native into the 
monomeric forms (100 µg/mL). The One-way ANOVA, along with Tukey's post-hoc, a 95% CI and a 5% α error, confirmed a statistically significant difference before and 
after the Potempa method (p-value***<0.0005). The dialysis process reduced the mCRP concentration, affecting partially the statical difference obtain previously 
(p**<0.0091). (n=3) 
.
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Taylor and Van Den Berg (2007) reported on the possibility to dissociate nCRP 
into mCRP by heating the nCRP at a temperature of +70 °C for one hour. 
According to Taylor and Van Den Berg (2007) the protein obtained by this new 
method was structurally and functionally the same as that of Potempa’s 
(Potempa et al., 1983; Potempa et al., 2015). As shown in Fig.3.3 A, the anti-
nCRP antibody selectively bound only with the nCRP form, showing no 
difference between the commercial nCRP and the nCRP control. 
 
nCRP was exposed to Potempa’s dissociation method or heating Fig. 3.3B. 
Both methods dissociated the nCRP into mCRP, as confirmed by the anti-
mCRP3H12 antibody Fig. 3.3B. This dissociation led to a difference between 
the original nCRP protein and the final product (mCRP). However, the heating 
process seemed to affect to mCRP yield (Fig. 3.3B.), which may be due to it 
having a higher protein degradation than the Potempa method Fig. 3.3B. 
 
Fig. 3.3. Dissociation methods for nCRP into mCRP. Figure A showed no difference between the 
commercial nCRP and the one received from Potempa’s laboratories (nCRP control). In this dot-
blot binding assay, both the dissociated method (nCRP heat at a temperature of +70 °C for one 
hour and Potempa’s procedure) were able to dissociate the nCRP into the mCRP. Antibody 
selectivity for the mCRP and nCRP was also assessed. The results showed that the anti-mCRP3H12 
antibody was only able to bind the mCRP. This experiment was repeated once (n=1; 2 technical 
replicates).  
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3.3 SMIs binding with nCRP during and after dissociation into 
mCRP. 
 
As aforementioned, both Potempa’s method and heating dissociated the 
nCRP into the mCRP conformational form. Furthermore, the results of this 
study also evidenced that, when the nCRP was dissociated using Potempa’s 
method, the anti-mCRP3H12 antibody acquired a higher binding capacity to 
the new conformational form than it did through heating Fig. 3.3B.  
 
Whether or not the aforementioned SMIs were able to block the dissociation 
from nCRP into mCRP, was also evaluated. As the ACh neurotransmitter has 
a similar structural homology to that of the 1,6-bis (phosphocholine)-hexane 
(Slevin et al., 2018), a specific nCRP small-molecule inhibitor (Pepys et al., 
2006), it was reasonable to target nCRP with SMIs (Fig. 3.4). A further two 
SMIs were tested for their ability to inhibit nCRP, i.e., Tacrine and Nicotine as 
ligands and protein-ligand computational docking was carried out to evaluate 
the target binding site (Fig. 3.4). The SMIs concentration (ACh 100 µM, Tac 
10 µM, or Nicotine a 150 ng/mL), were the same reported in the experiment 
5.2 the SMIs were incubated in a buffer for two to four hours (the same time-
point used in experiment 5.4). 
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Fig 3.4. Small Molecule inhibitors (SMIs) binding site evaluation with nCRP during and after 
dissociation into mCRP. A) nCRP structural analysis showed two crucial sites: A) Highlighted in 
orange: the subunit binding site; in blue (B): the ligand binding site. Computational modelling of 
mCRP in combination with SMIs was carried out. The nCRP subunit docking was evaluated with 
C) Ach, D) Nicotine and E) Tacrine. All three SMIs bound partially with the protein but very weakly 
and did not bind covalently to the protein active site (Kcal/mol A:-7.29, B:-7.50, C:-7.06). 
Furthermore, none of the 3 SMIs occupied the aforementioned binding sites, A and B. 
Furthermore, none of the three SMIs did not occupy the two binding sites mentioned in A and B. 
There was a difference in the binding trend for anti-mCRP3H12 antibody 
between the mCRP generated by the commercial nCRP+SMIs (ACh or 
Tacrine or Nicotine) and the control mCRP (Fig. 3.5). Moreover, this 
preliminary result also evidenced that there was no difference amongst the 
groups where the mCRP had been generated by the commercial nCRP, with 
or without the SMI pre-treatment.
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Fig. 3.5. nCRP-mCRP dissociation was not affected by SMIs. In this dot-blot binding assay, commercial nCRP (Yo protein) was used in all groups. In this dot-blot 
binding assays, 100 µg/mL nCRP and mCRP were loaded onto the membrane with ACh (100 µM), Tac (10 µM), or Nicotine a (150 ng/mL). The nCRP control and the 
mCRP received from Potempa’s laboratories (mCRP control) were used as a control. The preliminary result here reported show evidenced a difference before and 
after Potempa’s method. This provisional data also confirms that there were no differences amongst the groups where the mCRP had been generated from the nCRP 
from Yo protein laboratories (with or without SMI pre-treatment). (n=1-3 technical replicates).  
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This experiment demonstrated that SMIs are not able to block nCRP 
dissociation into mCRP. Furthermore, despite a similar structural homology 
between ACh and the 1,6-bis(phosphocholine)-hexane, this SMI was not able 
to prevent nCRP dissociation. The possibility of there being a potential direct 
bond between the pure mCRP and SMIs was investigated. To do so, the 
mCRP (100 µg/mL) and the SMIs were incubated in a buffer for two to four 
hours (the same time-point and concentration used in experiment 5.4) and no 
potential binding was observed between the SMIs and CRP in its monomeric 
form (Fig. 3.6).  
 
The experiments described hereafter showed that dissociation could 
effectively be carried out experimentally. However, these preliminary results 
confirmed that the presence of SMIs did not affect the dissociation. The results 
herein reported suggested that SMIs do not have the capacity to block the 
dissociation from nCRP into mCRP nor do they directly bind with the mCRP. 
These preliminary results were later confirmed through surface plasmon 
resonance (SPR), in data published by the authors of this study (Slevin et al., 
2018). 
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Fig.3.6. SMIs don’t bind with mCRP. A dot-blot binding assay showing the anti-mCRP3H12 
antibody binding affinity with the mCRP form. A total of 100 µg/mL mCRP was loaded onto the 
membrane with ACh (100 µM), Tacrine (10 µM) or Nicotine (150 ng/mL). The antibody maintained 
a high binding activity even in the presence of ACh (100 µM), Tacrine (10 µM) and Nicotine (150 
ng/mL) and an equal amount of mCRP protein concentration (100 µg/mL). These preliminary 
results showed that SMIs do not bind with the pure mCRP form. (n=1-2 technical replicates). 
 
   




A perpetual low-chronic inflammatory (LCI) state is correlated with an increase 
in nCRP levels (Dinh et al., 2019) and the probability that atherosclerosis will 
be promoted (Ambrose and Barua, 2004; Libby, 2012; Siasos et al., 2014; 
Poulsen et al., 2015; Katakami, 2018). LCI leads to endothelial cell (EC) 
damage (Parnell et al., 2012), increases the presence of signs of injury and 
impairs tight junctions (Pant et al., 2014). Activated platelets are involved in 
atherogenesis progression (Gawaz et al., 2005; Nording et al., 2015) 
dissociating the nCRP into mCRP and its accumulation in the atherosclerotic 
necrotic core, further increasing the local pro-inflammatory activity (Eisenhardt 
et al., 2009b). For this reason, this research was to establish whether SMIs, 
i.e., ACh, Tacrine and Nicotine, have the ability to block or at least impair 
nCRP-mCRP dissociation in order to moderate the level of inflammation 
caused by the mCRP.  
 
The first step was to determine the ability antibodies have (anti-nCRP and anti-
mCRP3H12) to selectively bind with their respective protein target. A second 
experiment was carried out to confirm the dissociation of nCRP into the mCRP 
form. This was followed by a comparison between the two types of dissociation 
methods. The last experiments assessed whether the previously selected 
SMIs were able to block, or at least reduce, this dissociation.  
 
The antibodies were able to specifically bind with their respective proteins. As 
previously described by Potempa et al. (1983) and Potempa et al. (2015), urea 
(8 M) and EDTA (10 mM) led to the dissociation of nCRP into mCRP (Fig. 3.2). 
It was also observed (Fig. 3.3) that the nCRP dissociation occurred when the 
nCRP was heated at +70 °C for one hour (Taylor and Van Den Berg, 2007). 
However, this method also influenced the capacity the anti-mCRP3H12 
antibody had to bind with the insoluble pro-inflammatory form (mCRP) and had 
a lower efficacy.  
 
Next, the SMIs were used to prevent nCRP dissociation. However, although 
ACh has some structural similarity to1,6-bisPC, it was unable to block 
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dissociation (Fig. 3.5) nor did it interact with the mCRP alone (Fig. 3.6), in line 
with the surface plasmon resonance (SPR) reported in a recent publication 
from this work (Slevin et al., 2018). This was also observed when the two other 
SMIs were tested, i.e. neither Nicotine nor Tacrine were able to prevent 
dissociation.  
 
The fact that the SMIs did not prevent nCRP dissociation might be due to the 
different binding site locations between the SMIs and the ruptured nCRP sites. 
The computational docking analysis showed that all SMIs bound on the edge 
of the nCRP subunit, which might not suffice to avoid its dissociation. 
Furthermore, maybe the fact that the SMI ACh, despite their similarity to 1,6-
bisPC, do not bind to nCRP or bind very weakly, could explain the feeble 
charge. However, an interesting finding came to light i.e. the observation of 
antibody selectivity, which could be used as a strategy target mCRP and 
mitigate its inflammatory effect downstream. 
 
3.5 Key findings: 
 
The key findings of the experiments described in this chapter are: 
• The selective identification of the two different forms of CRP (nCRP and 
mCRP), via antibody strategy, was investigated by dot-blot binding 
assays this evidenced: (I) that there are two different conformational 
forms; (II) that the antibodies used were able to bind separately both 
with the native and the monomeric CRP forms. Both the anti-nCRP and 
anti-mCRP3H12 antibodies had the same binding selectivity capacity 
with the appropriate conformational form. 
 
• The second step confirmed that both dissociative methods tested, i.e., 
Potempa’s and heating, were able to dissociate the nCRP into mCRP 
and to evaluate how the ratio nCRP/mCRP is affected during the 
dissociation step. Moreover, dot-blot binding assay confirmed 
dissociation from nCRP into the mCRP by both methods (Potempa’s 
and heating), however, both methods affected how the anti-mCRP 
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antibody (anti-mCRP3H12) bound to monomeric CRP. 
 
• One of the goals was to determine whether selected SMIs had the ability 
to block the dissociation of nCRP-mCRP. Even in the presence of ACh, 
Tacrine and Nicotine and an equal amount of protein concentration (see 
paragraph 3.3 for concentrations) the antibody maintained a high 
binding activity. This result, along with those obtained by the SPR 
evidenced that SMIs did not affect dissociation, nor did they have any 




A high nCRP (>2.2 mg/L) blood level has been associated with increased 
inflammation. Moreover, nCRP has been associated with a wide variety of 
conditions mostly related to inflammation pathways, these range from infection 
to cancer and a high risk of heart attack (Sproston and Ashworth, 2018). 
Despite this, the correlation between these pathologies and nCRP/mCRP 
remains elusive. In an effort to shed some light on the underlying mechanisms 
that lead to the dissociation of the nCRP into mCRP, the selectivity and 
specificity the antibody has, as well as the role SMIs play in reducing the 
dissociation from nCRP to mCRP, was evaluated.  
 
The aforementioned experiments demonstrated that dissociation could be 
successfully carried out experimentally. Even if this data showed that the SMIs 
were unable to block the dissociation from nCRP into mCRP, the antibody 
selectivity between the two forms nCRP and mCRP provided promising results 
as to the possibility of using therapeutic antibody strategies to mitigate the level 
of inflammation triggered by the effect of mCRP. However, future studies are 
necessary to validate the use of antibody therapy against mCRP in humans. 
  






CHAPTER 4 RESULTS: 
Assessment of whether 
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CHAPTER 4: Assessment of whether mCRP stimulation induces 
monocyte-derived macrophage pro-inflammatory activity. 
 
Atherosclerotic disease (ADs) is a pathological physiological condition 
affecting the cardiovascular system which increases the concentration of 
lipoprotein(a), plasminogen activator inhibitor-141, nCRP and monocytes count 
(Arenillas et al., 2008; Flynn et al., 2019). It has been observed that ADs 
platelet activation dissociates nCRP into mCRP, which accumulates in the 
aorta, promoting the development of carotid artery atherosclerotic plaques 
(Eisenhardt et al., 2009b) which are a known risk factor for Myocardial 
Infarction and (MI) ischemic stroke (IS) (Swirski and Nahrendorf, 2013; Yaghi 
et al., 2019).  
 
The first medical intervention for both MI and IS should be targeted to restoring 
the blood flow (Pisters and Lip, 2013; Howard, 2016). However, once this goal 
has been accomplished, the ischemia/reperfusion injury (IRI) facilitates the 
accumulation of both native C-reactive protein (nCRP) and monomeric CRP 
(mCRP) in re-perfused tissue (McFadyen et al., 2018). Indeed, two studies 
have already demonstrated the accumulation of nCRP and mCRP in post-
ischemic cerebrals tissues (Slevin et al., 2010; Napoli et al., 2018). When 
mCRP is accumulated in the brain it increases the pro-angiogenic effects 
induced by the activation of the extracellular signal-regulated kinase (ERK) 
(Turu et al., 2008) and the PI3K/Akt survival intrinsic pathway (Boras et al., 
2014) in endothelial cells (ECs). Eisenhardt et al. (2009b) reported that the 
mCRP pro-angiogenic and pro-inflammatory effects in ECs are mediated by 
FC-γ receptors (FCγRs). Thiele et al. (2014a) confirm that these pro-
angiogenic and pro-inflammatory effects are associated with an increased 
expression of CD68+ monocytes and reactive oxygen species (ROS) 
production in proximity to post-ischemic tissue. This provides a possible 
explanation as to why monocyte accumulation in post-ischemic tissue has 
been observed in both IS and MI (Chiba and Umegaki, 2013; Swirski and 
Nahrendorf, 2013).  
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As aforementioned in chapter 1, paragraph 1.2.2.1 after recruitment from the 
systemic circulation, monocytes differentiate into naïve M0 resting 
macrophages at the site of injury (Malissen et al., 2014; Orekhov et al., 2019). 
After this initial resting state, macrophages polarize into pro (M1) or anti (M2) 
inflammatory phenotypes depending on the stimuli that they have received at 
the injury site (Chistiakov et al., 2015). That is, this polarization seems to 
depend on the presence of both Pathogen Associated Molecular Patterns 
(PAMP) and Damage-associated molecular patterns (DAMPs) released due to 
cellular stress or tissue injury (Liu et al., 2017a). When polarization takes place, 
these cells express new surface makers, e.g., F4/80, CD11b, CD18, CD68, 
colony stimulating factor 1 receptor (CSF1R) and increase the human FCγRs  
(van de Winkel and Anderson, 1991; Rothe et al., 1996; Murray and Wynn, 
2011).  
 
FCγRs are expressed on cells of the immune system, such us monocytes and 
macrophages, (van de Winkel and Anderson, 1991; Rothe et al., 1996) and 
are also considered the principal nCRP-binding receptors (Tron et al., 2008). 
Literature reports that when nCRP binds with these receptors, the immune 
system releases both pro and anti-inflammatory cytokines (Ferrarese et al., 
1999; Lu et al., 2018). However, whilst some authors suggested that this 
binding is a fundamental step involved in inflammatory activity (Lu et al., 2012), 
others researcher evidenced that identifying which form of CRP (nCRP or 
mCRP) has a pro or anti-inflammatory effect is challenging (Tanigaki et al., 
2015). Later, these doubts were clarified by other studies which reported that 
while mCRP is able to increase the release of Nitric Oxide (NO) in monocytes, 
they also confirmed that nCRP reduces the quantity of NO released in the 
same type of cells (Sproston et al., 2018). Furthermore, other studies reported 
that if macrophages are stimulated with mCRP they polarize into an M1 pro-
inflammatory phenotype (Trial et al., 2016), whilst if they are stimulated with 
nCRP, macrophages release a high amount of M2 IL-10 anti-inflammatory 
cytokine (Pilling et al., 2017; Moore et al., 2001). However, at the best of our 
knowledge currently there no data available that clarify whether mCRP is 
capable of promoting the release of pro-inflammatory cytokines in U937 
monocyte-derived macrophages.  
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Therefore, knowing that monocyte infiltration and mCRP accumulation in 
ischemic tissue is a typical consequence of ischemic events (Slevin et al., 
2010; Gronberg et al., 2013; Swirski and Nahrendorf, 2013; McFadyen et al., 
2018), raises the hypothesis that the mCRP may also bind with the newly 
recruited monocyte-derived macrophages through the FCγRs, triggering the 
downstream inflammation cascade. So as to enhance the know-how as to the 
role mCRP plays in inflammation, the possibility that mCRP binds with 
monocyte-U937 derived macrophages was investigated. Furthermore, it was 
also tested whether mCRP pro-inflammatory features could potentially be 
mediated by FCγRs. 
 
Aim and objectives: To establish whether and how mCRP has a pro-inflammatory 
effect in monocyte- derived macrophages. 
 
This was addressed by the following objectives: 
 
• Literature reports that both monocytes and macrophages play a pivotal 
role during and after an inflammatory response (Atri et al., 2018). This 
fundamental role has been associated with their capacity to release 
both pro and anti-inflammatory cytokines (W. Xu et al., 2013). This has 
led to a series of experiments, carried out to clarify whether the U937 
monocytes and macrophages were able to release pro or anti-
inflammatory cytokines.  
 
• Literature confirms that mCRP is capable of polarizing macrophages 
into a specific M1 pro-inflammatory phenotype (Trial et al., 2016). 
Subsequently, it has been reported that, when mCRP binds monocytes 
chemotaxis activity is enhanced as is the concentration of NO and iNOS 
(Fujita et al., 2014; Sproston et al., 2018). However, none of these 
studies reported whether mCRP is able to control the pro and anti-
inflammatory cytokine release following monocyte/macrophage cell 
interaction. Thus, the mCRP interaction with monocyte and 
macrophage cells and its effect on the cytokine cascade was evaluated. 
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• FCγRs are specific markers able to discriminate the monocyte-derived 
macrophages from dendritic cells (DCs) (Satpathy et al., 2012; Bain and 
Mowat, 2014). Thiele et al. (2014a) reported that mCRP triggered 
monocyte pro-inflammatory activity when bond to FCγRI (also known 
as CD64) and/or as FcγRIII (also known as CD16) receptors. However, 
similar study on macrophages has not been covered yet, and its 
inflammatory role has to be examined. It was also evaluated whether 
mCRP was capable of inducing inflammation via binding to FCγRs and 
whether anti-FCγRs antibodies inhibit the binding of mCRP and 
macrophages, reducing the mCRP pro-inflammatory activity. 
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4.1 Human haematopoietic U937 cell duplication. 
 
Preliminary data on U937 replication time frame evaluation was carried out to 
optimize the experiments performed during this study. As shown in Fig. 4.1 
they duplicated each day. As shown in the graph Fig. 4.1 and Table 4.1, 
enough cells to perform the experiments were obtained (1.24 x107 cells) in one 
week.  
 
Fig 4.1 and Table 4.1. Human haematopoietic U937 cell duplication. Cell replication of the U937 
monocyte cell line in a growing media (RPMI 1640 with L-glutamine Lonza with 10% FBS F9665 
Sigma®) was tested from passage 10 to 14 in a T-75 cell culture flask. Cell counting was done by 
the BioRad TC10™ automated cell counter. The U937monocyte cell sub-culturing was loaded onto 
a dual-chamber slide (BioRad Cell Counting Slides for TC10™ dual chamber), with 10 μL of sample 
solution (containing 5 μL of cell suspension and 5 μL of trypan blue dye). The slide was then put 
into the TC10™ automated cell counter to obtain the total cell count, the percentage of cell 
viability and the number of live cells (n=3).  
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4.2 U937 monocyte stimulation with Lipopolysaccharides (LPS) 
and mCRP assessment of pro-inflammatory effects. 
 
After evaluating the U937monocyte duplication rate, this cell line was used to 
assess their potential role in triggering the inflammation process. As the LPS 
found in the outer membrane of Gram-negative bacteria are capable of 
inducing an acute inflammatory response on mononuclear cells (PBMCs) and 
monocytes (Ngkelo et al., 2012) it was used as a positive control. TNF-α was 
selected as a reference, as previously reported (van der Bruggen et al., 1999) 
to assess whether monocytes are able to release pro-inflammatory cytokines. 
mCRP concentration (100 μg/mL) and time-point (24 hours) were the same as 
those used in experiment 4.5, where the mCRP biological activity on 
monocyte-derived macrophages was tested. 
 
Although the monocytes were exposed to LPS (100 ng/mL) they did not 
release TNF-α pro-inflammatory cytokines. This datum is in line with previously 
published experiments which confirmed that a pro-inflammatory response 
could be initiated only after differentiation from monocytes to macrophages 
(Hida et al., 2000).  
 
As shown in Fig. 4.2, enzyme-linked immunosorbent assay (ELISA) was 
carried out on the monocyte media that had been stimulated by LPS (100 
ng/mL) or mCRP (at 100 µg/mL). There was no statistical significance in any 
of the conditions.  
 




Fig.4.2. Monocytes did not release TNF-α pro-inflammatory cytokines. The U937 monocytes were exposed to LPS (100 ng/mL used as the positive control) or to 
mCRP (100 µg/mL) for 24 hours in a growing media (RPMI 1640 with L-glutamine Lonza with 10% FBS F9665 Sigma®). TNF-α production in the supernatant was 
measured by ELISA kits (R&D System). The results are shown as the mean ± SD. The One-way analysis of variance (ANOVA) and Tukey's post-hoc test with a CI 95% 
and a fixed 5% α error confirmed that there were no significant differences amongst the groups. The U937 monocytes did not release any significant TNF-α (<20 
pg/mL), even in the presence of LPS at a concentration of 100 ng/mL). (n=3) 
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4.3 Phorbol-12-myristate 13-acetate (PMA) as a treatment: for cell 
differentiation and viability. 
 
After ascertaining that U937 monocyte cell lines were unable to release 
significant concentrations of TNF-α, in line with a previous study (Hida et al., 
2000), the development of an inflammation in vitro model was the next step.  
 
Firstly, monocyte differentiation in macrophages was assessed. As 
aforementioned in chapter 1, paragraph 1.2.2.2, macrophages are principally 
divided into the M1 (pro-inflammatory) and M2 (anti-inflammatory) subtype and 
have different biological and functional proprieties (Ley, 2017). However, 
before reaching these final states, monocytes differentiate into the 
macrophage resting subtype (M0) (Zhao et al., 2017). Previous studies have 
reported that PMA is able to differentiate the U937 monocytes into 
macrophages (Passmore et al., 2001) in the resting M0 subtype without 
affecting their polarization (Song et al., 2015). The macrophages were then 
differentiated using the U937 differentiation method (PMA at concentration of 
50 ng/mL for 72 hours), according to the Sproston et al. (2018) study. This 
experiment was carried to observe how what effect PMA had on U937 cell 
viability (Table 4.2 and Fig 4.3) and differentiation (Fig 4.4 and Fig.4.5).  
 
As shown in Fig. 4.3, after PMA treatment for 72-hours (50 ng/mL), it was 
observed that cell viability had been significantly affected. Only 10% of the 
initial concentration (2 x 106 cell/mL) attached to the 6-well plate (2 x 105 
cell/mL).  
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Table 4.2. and Fig. 4.3. Phorbol-12-myristate 13-acetate (PMA) as a treatment: for cell 
differentiation. Differentiation from floating monocytes into adherent macrophages was induced 
by exposing the U937 cells to a differentiated media containing RPMI 1640 with L-glutamine 
(1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and phorbol-12-myristate 
13-acetate (PMA793461 Sigma®) at 50 ng/mL for 72 hours. After PMA treatment, 20 μL of 
unattached or attached cells were placed into an eppendorf tube containing 20 μL of trypan blue 
solution. This was then loaded onto a dual-chamber slide. The slide was then put into the TC10™ 
automated cell counter to obtain the total cell count, the percentage of cell viability and the 
number of live cells. The results are shown as the mean ± SD. ****P < 0.0001. As can be observed 
in the figure, the U937 cell viability was significantly reduced by PMA. The one-tailed unpaired t-
test with a 99% CI and a 1% α error confirmed the substantial reduction of cell viability before 
(2x106 cells/well) and after (2x105 cells/well) PMA use (p-value<0.0001). Table 4.2 shows how 
only 9.05 % of U937 cells were viable after exposure to PMA. (n=3)   
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After having ascertained whether cell viability was affected by PMA treatment, 
the differentiation of monocytes into macrophages after PMA treatment was 
evaluated. At this stage, the unattached cells were removed and only 
untreated and treated (macrophages) were tested by the FACS analysis.  
 
Fig. 4.4 and Fig 4.5 depict the differentiation from monocytes into 
macrophages. Fig. 4.4A shows monocytes as suspension cells that are clearly 
separated one from the other. This fundamental characteristic is lost after PMA 
treatment. Following differentiation Fig. 4.4B, where macrophages are also 
able to form clusters, they go through morphological and phenotypic changes, 
allowing them to attach to the plastic flask.  
 
The next step, after 72 hours of PMA stimulation, was FACS analysis using 
the anti-huCD11c antibody (Wentworth et al., 2010; Yu et al., 2016; Sproston 
et al., 2018). As shown in Fig.4.5, PMA-differentiated cells substantially 
increased the CD11c macrophage marker (40.8% CD11c+), whilst monocytes 
lacked the CD11c macrophage marker (0.0% CD11c+). Fig. 4.5 shows a 
significant difference (p-value<0.0001) in Human-CD11c expression before 
and after PMA treatment and between the groups (undifferentiated U937 
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Fig. 4.4. Monocytes and macrophages. Fig (A) U937monocyte cells were grown in a growth medium (RPMI 1640 with L-glutamine Lonza) with 10% FBS (FBS F9665 
Sigma®) in humidified air at 95% with 5% CO2 at 37°C in a T-75 flask from passage 10 to 14. Following PMA treatment (50 ng/mL for 72-hours), suspension cells 
(monocytes) became monocyte-derived macrophages and attached to the well (B). Following PMA treatment, macrophages formed clusters (B).  
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Fig 4.5. Macrophages PMA-differentiated significantly increase CD11c macrophage marker. After 72 hours of PMA stimulation U937monocyte cells cultured into 
RPMI 1640 with L-glutamine (1640 medium Lonza) with 10% of FBS (F9665 Sigma®) and PMA at 50 ng/mL for 72 hours, were examined by FACS analysis by using anti-
huCD11c (Thermo-fisher Anti–Hu CD11c LOT2008210) in order to confirm monocytes vs macrophages differentiation. Results showed a significant difference as the 
mean ± SD. ****p-value < 0.0001. Fig.4.5A. Two divergent populations of cells were identified. One-tailed unpaired t-test with a 99% CI and a 1% α confirm a significant 
difference (p-value< 0.0001) before and after PMA treatment. CD11c macrophages markers (40.8% CD11c+) is not present monocyte (0.0% CD11c+). (n=3). 
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4.4 U937 macrophages model to study inflammation. 
 
The ELISA test was performed after FACS to assess the functional differentiation 
for U937 monocytes into U937 macrophages. On the basis of findings published 
in literature, it was presumed that PMA stimulation differentiates monocytes into 
macrophages (Sproston et al., 2018). When this differentiation happen, 
macrophages are then able to increase the cytokine production (Hida et al., 
2000). This assay evaluated the ability the U937 monocyte-derived macrophages 
had to release the TNF-α, IL-6 and IL-10 cytokine. The macrophages were 
stimulated with LPS, as it has the capacity to stimulate macrophages to release 
both pro and anti-inflammatory cytokines, such us TNF-α, IL-6 and IL-10 
(Tucureanu et al., 2018). TNF-α was tested as it is has been reported that this 
pro-inflammatory cytokine plays an essential role in numerous inflammatory 
diseases and is predominantly released by macrophages (Parameswaran and 
Patial, 2010). IL-6 was selected for its relevant role in several situations relating 
chronic inflammation (Barnes et al., 2011). IL-10, which has anti-inflammatory 
effects, was assessed as it as it is released by M2 (Shi et al., 2019). 
 
The capacity macrophages have to release high amounts of pro-inflammatory 
cytokines, as shown in Fig 4.6, was confirmed through the TNF-α and it was 
observed that only the PMA treated cells (monocyte-derived macrophages) had 
the ability to release the TNF-α cytokine (p-value<0.0001). 
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Fig. 4.6. TNF-α pro-inflammatory cytokine is released from macrophages. After a 72-hour PMA 
treatment (50 ng/mL), the monocyte-derived macrophages were stimulated with LPS at a 
concentration of 100, 10 and 1 ng/mL for 24 hours. The TNF-α production was quantified by ELISA 
kits (R&D System). The results are shown as the mean ± SD. ****p-value < 0.0001. As shown in figure, 
after PMA differentiation the macrophages were capable of releasing the TNF-α pro-inflammatory 
cytokine when stimulated by LPS. The One-way ANOVA test, followed by the Tukey Post-doc test 
with a 99.9% CI and a α error fixed at 0.01%, confirmed a statistical difference (p-value <0.0001) 
between monocyte groups and macrophage groups. (n=3).  
The results also evidenced that the release of TNF-α pro-inflammatory cytokine 
was consistent and independent from the LPS concentration. Moreover, they 
indicated that macrophages can provide a useful pathobiological model to study 
inflammation.  
 
Further experiments were set-up to optimise LPS as a positive control to evaluate 
other cytokine levels. Based on the confirmation that TNF-α pro-inflammatory 
cytokine was consistent and independent from LPS concentration (Fig 4.6), LPS 
at 10 ng/mL was selected as a positive control to assess whether macrophages 
are capable of increasing the IL-6 and IL-10 cytokine concentrations. 
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As reported in Fig. 4.7, the ELISA test showed that LPS stimulation (10 ng/mL) 
led to the production of macrophage-derived IL-6 and IL-10. A statistical 
difference (p-value<0.0001) in the IL-6 concentration in the presence or absence 
of LPS (10 ng/mL) was assessed at three set time points, i.e., 6, 12 and 24 hours.  
 
A similar result was reported for IL-10 (Fig. 4.7). There was a statistically 
significant increase in macrophage IL-10 production after LPS stimulation at 10 
ng/mL. However, differently to IL-6, the lL-10 release did not remain constant over 
the three time points, reaching its maximum level at 12 hours.  
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Fig 4.7. Macrophages are responsible for releasing IL-6 and IL-10 protein cytokines. After 72-hour PMA exposure (50 ng/mL), the macrophages were stimulated 
with LPS at a concentration of 10 ng/mL for 6, 12 and 24 hours. The IL-6 (A) and IL-10 cytokine release was quantified by ELISA kits (R&D System). The results are 
shown as the mean ± SD. ****P-value < 0.0001. As shown in figure, after PMA stimulation, the macrophages were able to release both the IL-6 and the IL-10 cytokine 
when stimulated with LPS. The One-way ANOVA test, with a 99% CI and a 1% α error, showed a statistical difference (p-value<0.0001) between the unstimulated 
and the LPS stimulated macrophages groups (A). A statistical difference (p-value<0.0031) was observed in the IL-10 concentration between the unstimulated 
macrophage group and the group where the macrophages were stimulated by LPS for 6 hours (IL-10 release: 111.5 vs 284.5 pg/mL, respectively). This difference was 
also confirmed in the group stimulated for 12 (111.5 vs 475.9 pg/mL, respectively) and 24 hours (111.5 vs 416.7 pg/mL respectively) (p-value<0.0003). A statistical 
difference (p-value=0.0021) in IL-10 concentration between the 6 and 12 hours LPS groups (284.5 vs 475.9 pg/mL respectively) and the 6 and 24 hours LPS groups 
(284.5 vs 416.7 pg/mL respectively) was confirmed (p-value=0.0085). No significant difference was observed between the group that had been stimulated for 12 
hours and the one stimulated for 24 hours (475.9 vs 416.7 pg/mL respectively). (n=3). 
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4.5 Monomeric-CRP increased the IL-1β gene expression. 
 
After evaluating the macrophage response, in terms of cytokines after LPS 
stimulation, the effect of the monomeric C-reactive protein and its contribution 
on pro-inflammatory effects were observed. mCRP is mainly characterized as 
a pro-inflammatory protein in different cell types, such as ECs, leukocytes and 
platelets (Thiele et al., 2014a; Wu et al., 2015). The effect of mCRP at a 
transcriptomic level was evaluated by RT-PCR. The protein level was then 
evaluated, as reported in paragraph 4.6 and Fig.4.9 The IL-1β gene 
expression was taken as a reference, bearing in mind that a previous study 
reported that the TNF-α mRNA life span is short, even in the presence of a 
high TNF-α cytokine release (Mijatovic et al., 2000).  
 
After 24 hours of macrophage LPS (10 ng/mL) or mCRP (100 μg/mL) 
stimulation, the IL-1β gene expression level was assessed as shown in 
Fig.4.8. The result here reported confirm that a concentration of 100 μg/mL 
the mCRP increased the IL-1β gene expression at 24 hours. 
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Fig. 4.8. Monomeric-CRP increases the IL-1β mRNA expression. After differentiation, the 
monocyte-derived macrophages were stimulated by LPS (10 ng/mL) or mCRP (100 µg/mL) for 24 
hours. The IL-1β gene expression was quantified by both the TaqMan™ Fast Advanced Master 
Mix and TaqMan® Gene Expression Assays. The results are shown as the mean ± SD. ****p-value< 
0.0001, ***p-value < 0.005. The One-way ANOVA test, followed by the Tukey Post-doc test with 
a 99.9% CI and a α error 0.01%, evidenced a statistically significant difference (p-value<0.002) 
between the unstimulated macrophage and the mCRP group when both groups were tested at 
24 hours. The ANOVA test also indicated a higher statistical difference (p-value<0.0001) between 
the positive control and the mCRP group after 24 hours. (n=3). 
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4.6 mCRP promotes a pro-inflammatory in U937-derived 
macrophages. 
 
After observing that mCRP exposure increases IL-1β at a transcriptomic level, 
the protein expression was also assessed. Four different cytokines (TNF-α; IL-
6; IL-10; and IFN-γ) were examined and compared with the unstimulated 
macrophages. TNF-α was tested as it is has been reported that this pro-
inflammatory cytokine plays a pivotal role in several inflammatory diseases 
and is principally released by macrophages (Parameswaran and Patial, 2010). 
Whilst IL-6 was selected for its relevant role in several situations relating 
chronic inflammation and conditions with endothelial cell dysfunction (Barnes 
et al., 2011). IL-10, which has anti-inflammatory effects, was evaluated as it as 
it is released by M2 macrophages that bind to the IL-10R present in M1 
macrophages (Shi et al., 2019) . This is able to reduce the release of both TNF-
α and IL-6 pro-inflammatory cytokines (Moore et al., 2001). In addition to the 
other cytokines, IFN-γ was also assessed to evaluate its inflammatory effect 
in the model studied, even if it has been reported that IFN-γ is not released by 
macrophages (Schoenborn and Wilson, 2007; Kulkarni et al., 2016).  
 
The results showed that macrophages had a very strong pro-inflammatory 
activity when stimulated with 100 µg/mL of mCRP for 24 hours Fig. 4.9.  
 
As shown in Fig. 4.9A. TNF-α protein concentrations among the unstimulated 
macrophage group, the positive control group (LPS 10 ng/mL) and the group 
stimulated with mCRP (100 µg/mL) were evaluated after 24 hours. There was 
a statistically significant difference between: the unstimulated macrophage 
group and the positive control; the unstimulated macrophage group and the 
mCRP group; the positive control and the mCRP group. 
 
Fig. 4.9B shows the IL-6 protein concentrations in the unstimulated 
macrophage group, the positive control group (LPS 10 ng/mL) and the group 
stimulated with mCRP (100 µg/mL), evaluated after 24 hours. There was a 
statistically significant difference between: the unstimulated macrophage 
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group and the positive control group; the unstimulated macrophage group and 
the mCRP group; the positive control and the mCRP group. 
 
mCRP stimulation did not increase the IL-10 concentration. No statistical 
differences (p-value = 0.1519) were observed between the unstimulated 
macrophage group and the mCRP group (1523 vs 132.6 pg/mL respectively) 
(Fig. 4.10A.). Fig. 4.10A shows the statistically significant difference (p-
value<0.0001) between the positive control group and the mCRP group (3872 
vs 132.6 pg/mL, respectively).  
 
The role macrophages play in IFN-γ cytokine production was also evaluated. 
In agreement with literature (Schoenborn and Wilson, 2007; Kulkarni et al., 
2016), the macrophages were unable to release any IFN-γ cytokines (Fig. 
4.10B). This is most likely due to the fact that macrophages can only release 
IFN-γ in response to both IL-12 and IL-18 stimulation, as suggested by Darwich 
et al. (2009). 
 
The results shown in Fig. 4.9 and Fig. 4.10 showed that stimulation with 
mCRP, at a concentration of 100 µg/mL, was able to increase the TNF-α 
production and the IL-6 protein concentration. However, the results also 
indicated that mCRP may also partially reduce the IL-10 concentration, without 
increasing the IFN-γ protein concentration (Fig.4.10B). 
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Fig. 4.9. mCRP increases both TNF-α and IL-6. After differentiation, the macrophages were treated with positive control (LPS 10 ng/mL) or mCRP (100 µg/mL) for 24 
hours. The TNF-α (A) and IL-6 (B) production was quantified by ELISA kits (R&D System). The results are shown as the mean ± SD. ****p-value <0.0001, **p-value 
≤0.05. Monomeric-CRP increased the concentration of TNF-α (A) and IL-6 (B) pro-inflammatory cytokines. Fig (A) The One-way ANOVA test, with a 95% CI and a 5%α 
error, confirmed a statistically significant difference (p-value<0.0044) between the unstimulated macrophage group and the mCRP group (113.8 vs 1110 pg/mL 
respectively). The ANOVA also demonstrated a statistical difference (p-value<0.042) between the positive control group and the mCRP group (1540 vs 1110 pg/mL 
respectively). Fig (B) The One-way ANOVA test, with a 95.% CI and a 5%α error confirmed the statistical difference (p-value<0.0001) between the unstimulated 
macrophage group and mCRP group (27.86 vs 266 pg/mL, respectively) as well as a statistically significant difference (p-value<0.0001) between the positive control 
group and the mCRP group (798.4 vs 266.1 pg/mL, respectively) (n=3). 
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Fig. 4.10. IL-10 and IFN-γ levels are not susceptible to mCRP. After 72 hours of PMA (50 ng/mL) treatment, the macrophages were stimulated with positive control 
(LPS 10 ng/mL) or mCRP (100 µg/mL) for 24 hours. The IL-10 (A)-and IFN-γ (B) production was quantified by ELISA kits (R&D System). The results are shown as the 
mean ± SD. ****p-value <0.0001, *p-value <0.10. Fig (A) The One-way ANOVA test, with a 95 % CI and a 5%α error confirmed a statistically significant difference (p-
value <0.0001) between the positive control group and the mCRP group (3872 vs 132.6 pg/mL, respectively). Fig (B) shows that the macrophages were unable to 
release any IFN-γ cytokines (<20 pg/mL). (n=3). 
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4.7 FCγR antibodies did not induce pro-inflammatory effects on 
U937 macrophages. 
 
After confirming that mCRP had both biological and pro-inflammatory effects, 
the next step was that of clarifying whether blocking the FCγRs would have led 
to a reduced mCRP biological and pro-inflammatory activity. As 
aforementioned in the introduction paragraph, mCRP pro-inflammatory 
proprieties were abolished when FCγI (CD64), FCγIIa (CD32) and FCγIII 
(CD16) were blocked (T. Khreiss et al., 2004; Eisenhardt et al., 2009b; Thiele 
et al., 2014a). This prompted the assessment of the correlation between 
mCRP pro-inflammatory activity and the FCγRs. However, to address the 
hypothesis that mCRP pro-inflammatory proprieties were FCγR mediated, it 
was necessary to evaluate whether the FCγR antibodies had pro-inflammatory 
effects on U937 macrophages (ELISA test).  
 
As detailed in paragraph 4.6, TNF-α, IL-6 and IL-10 were tested in this 
experiment. The antibody concentration (100 µg/mL) was the same as that 
used for mCRP (previously reported in paragraph 4.6). The macrophages were 
stimulated by the anti-FCγRs antibodies for 24 hours, which was the best pre-
incubation time-point for all (SMIs) to inhibit mCRP pro-inflammatory activity 
(see chapter 5, paragraph 5.4).  
 
As shown in Fig. 4.11A, the TNF-α protein concentrations in the unstimulated 
macrophage group, the positive control group and the groups stimulated with 
anti-FCγRs antibodies (anti-CD16, anti-CD32, and anti-CD64) 24 hours after 
stimulation were evaluated. No statistically significant difference was observed 
among the unstimulated macrophage group and the FCγR antibody groups, 
with the exception of the unstimulated macrophage group and the anti-FCγRs 
(anti-CDs groups), were compared with the positive control group.  
 
As shown in Fig.4.11B, the IL-6 protein concentrations in the unstimulated 
macrophage group, the positive control group and the groups stimulated with  
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Fig. 4.11. FCγR antibodies did not induce pro-inflammatory effects on U937 macrophages. After differentiation (PMA 50 ng/mL for 72 hours), the macrophages were 
stimulated by LPS at 10 ng/mL (positive control) or anti-FCγRs antibodies (anti-CD16, anti-CD32, and anti-CD64) at a concentration of 100 μg/mL, for 24 hours. The 
TNF-α (A)-and IL-6 (B) production was quantified by ELISA kits (R&D System). Results are showed as the mean ± SD. ****p-value <0.0001. The positive control 
increased the TNF-α (A) and IL-6 (B) pro-inflammatory cytokine concentrations. Fig (A) The One-way ANOVA test, followed by the Tukey Post-doc test with a 99.9% 
CI and α error fixed at 0.001% revealed no statistical differences (p-value= 0.8779) between the unstimulated macrophage group (31.01 ± 14.33 pg/mL) and the group 
treated with all anti-FCγRs antibodies pooled together (157.8 ± 44.3 pg/mL) which presented with a higher value. The only statistically significant finding (p-value 
<0.0001) was observed when the unstimulated macrophage group and the positive control group (31.01 vs 1030 pg/mL respectively), along with the positive control 
group and the FCγRs groups, were compared (p-value<0.0001). Fig (B) The One-way ANOVA test, followed by the Tukey Post-doc test, with a 99.9% CI and α error 
fixed at 0.01% showed no statistically significant differences (p-value 0.9999) between the unstimulated macrophage group (0.2088 ± 0.2088 pg/mL) and the anti-
FCγRs antibodies pooled together (8.009 ± 5.119 pg/mL) which presented with a higher value. The only statistically significant difference (p-value <0.0001) was 
observed when the unstimulated macrophage group and the positive control group (0.2088 vs 465.1 pg/mL respectively) were compared, or when the positive control 
group was compared to the anti-FCγRs antibody groups (p-value <0.0001). (n=3)  
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anti-FCγRs antibodies (anti-CD16, anti-CD32, and anti-CD64) were compared 
24 hours after stimulation. The results showed no statistically significant 
difference among the unstimulated macrophage group and the FCγR antibody 
groups. The only statistically significant difference emerged when the 
unstimulated macrophage group and the anti-FCγRs groups (anti-CDs 
groups), were compared with the positive control group (LPS 10 ng/mL). 
 
As shown in Fig. 4.12, IL-10 protein concentrations in the unstimulated 
macrophage group, the positive control group and the group stimulated with 
anti-FCγRs antibodies (anti-CD16, anti-CD32, and anti-CD64) after 24 hours 
of stimulation, were evaluated. No statistically significant difference was 
observed among the unstimulated macrophage group and the anti-FCγR 
antibody groups. Furthermore, no statistical differences were reported for IL-
10 cytokines when the anti-FCγR antibody groups were compared to the 
positive control group. 
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Fig. 4.12. FCγR antibodies did not increase the release of IL-10 anti-inflammatory cytokine. After 
differentiation (PMA 50 ng/mL for 72 hours), the macrophages were stimulated by LPS at 10 
ng/mL (positive control) or anti-FCγRs antibodies (anti-CD16, anti-CD32, and anti-CD64) at a 
concentration of 100 μg/mL, for 24 hours. The production of IL-10 was quantified by ELISA kits 
(R&D System). LPS stimulation at 10 ng/mL increased the IL-10 anti-inflammatory cytokine 
concentration. The One-way ANOVA test, followed by the Tukey Post-doc test, with a 99.9% CI 
and an α error fixed at 0.01% showed no statistically significant differences (p> 0.9999) between 
the unstimulated macrophage group (647 ± 361.8, pg/mL) and the anti-FCγRI (anti-CD64) group 
(766.7 ± 425 pg/mL), the group with the highest value. The One-way ANOVA test also confirmed 
that there were no statistical differences (p-value= 0.1940) when the control groups were 
compared to the anti-CDs groups. (n=3).   
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4.8 The FCγRs antibodies did not activate any signalling pathways 
potentially associated to a pro-inflammatory response. 
 
After having confirmed that the anti-CD antibodies under study were not able 
to increase the cytokines release, it became essential to prove that the anti-
CD antibodies did not activate any signalling pathways that may be have been 
associated to a pro-inflammatory response. As detailed in chapter 1, 
paragraph 1.1.7.10 MAPK signalling pathways are triggered during 
inflammation, cancer and IS (Kaminska, 2005; Wang et al., 2006; Del Reino et 
al., 2014; Maik-Rachline et al., 2018). NF-КB is a transcription factor (Hayden 
and Ghosh, 2008) activated by viruses, bacterial toxins (including LPS), UV 
light, oxidative stresses, inflammatory stimuli and cytokines (Shih et al., 2015). 
It has been reported that when macrophages were exposed to LPS these cell 
up-regulated the MAPKp38/JNK/NF-KB intrinsic pathways and increased the 
production of pro-inflammatory cytokines, such as IL-1β and TNF-α (de 
Oliveira et al., 2017). The research data have shown that mCRP is able to 
raise the IL-6 concentration when both MAPKp38 and NF-КB signalling 
pathways are involved (Li et al., 2014). Confirming that activation of both 
MAPKp38 and NF-KB transcription factor increases the production of some 
pro-inflammatory cytokines (Yenari and Han, 2006; Jin et al., 2013; Li et al., 
2014). Bearing in mind that both these pathways are involved in inflammation, 
the next step to follow was that of evaluating whether the FCγR antibodies had 
the potential to activate a pro-inflammatory response.  
 
The following experiment used various treatment stimulation methods to 
evaluate the anti-FCγR pro-inflammatory antibody effect (anti-CD16, anti-
CD32 and anti-CD64). Cell lysate, obtained from unstimulated macrophages, 
was used as a negative control. The LPS stimulated U937 macrophages (10 
ng/mL), were used as a positive control (column 2). The activation effect on 
inflammatory pathways was evaluated by FCγRIII (anti-CD16), FCγRII (anti-
CD 32) and FCγRI (anti-CD64) antibody stimulation. Inflammatory pathway 
activation was evaluated without LPS (Fig 4.13). All the antibodies were used 
singularly and combined (Fig. 4.13). As reported in Fig. 4.13, none of the 
selected anti-FCγR antibodies were able to activate any signalling pathways 
that may have been associated to an inflammatory response. The results  
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Fig 4.13. The FCγRs antibodies did not activate MAPKp38 and NF-KB signalling pathways potentially associated to a pro-inflammatory response. Anti-FCγR (anti-
CD16, anti-CD32, and anti-CD64) antibody stimulation did not lead to an increase in the selected phosphoproteins MAPKp38 and NF-KBp65 which are known to be 
related to inflammation. After 3 days (72 hours) of PMA stimulation (50 ng/mL), the monocyte-derived macrophages were stimulated by LPS (10 ng/mL) anti-FCγRIII 
(CD16), anti-FCγRII (CD32) and the anti-FCγRI (CD64) antibody all at concentrations of 100 µg/mL. After discarding the medium, the macrophages were washed twice 
with PBS for 2 minutes followed by the addition of 250 μl of lysis buffer, containing a protease inhibitor cocktail, as well as a phosphatase inhibitor cocktail. Lane 1, 
unstimulated macrophage; Lane 2, LPS (10 ng/mL); Lane 3, anti-CD16 antibody (100 µg/mL), Lane, 4 anti-CD32 antibody (100 µg/mL), Lane5, anti-CD64 antibody (100 
µg/mL), Lane 6, anti-CD163264 antibodies (100 µg/mL). Fig (A) shows phospho-MAPKp38 expression and phospho-NF-KB expression. Fig (B) Graph shows the 
phospho-NF-KB expression. Fig (C) Graph shows the phospho- MAPKp38 expression (n=1). 
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showed that no antibodies were likely to increase either MAPKp38 
phosphorylation or NF-КBp65 phosphorylation.  
 
The ELISA assay also showed that when macrophages were incubated with 
antibodies, in combination with the LPS (10 ng/mL for 24 hours), there were 
no statistically significant differences (p-value=0.6858) in terms of TNF-α 
release.  
 
The TNF-α pro-inflammatory cytokines was selected based on the same hint 
expressed in chapter 4 paragraph 4.6. None of the anti-FCγR antibodies 
showed any anti-inflammatory properties. These results are summarised in 
Fig. 4.14. 
 
Fig. 4.14. Anti-FCγR antibodies are unable to inhibit LPS pro-inflammatory activity. After 72 
hours of PMA stimulation (50 ng/mL), the monocyte-derived macrophages were pre-treated with 
anti-FCγRIII (CD16), anti-FCγRII (CD32) and the anti-FCγRI (CD64) antibody at a concentration of 
100 µg/mL for 2 hours and then stimulated with LPS (10 ng/mL) for 24 hours. Only LPS (10 ng/mL) 
for 24 hours (i.e., without antibodies) was used as a positive control. The pro-inflammatory 
cytokine TNF-α was estimated by ELISA kits (R&D System). The results are shown as the mean ± 
SD. ****P-value <0.0001. There was a substantial increase in TNF-α in the macrophages after LPS 
stimulation at 10 ng/mL for 24 hours. The One-way ANOVA test with a 95 % CI and a 5%α error, 
confirmed the statistically significant difference (p-value <0.0001) among the unstimulated 
macrophage group and all the groups stimulated by LPS. There was no statistically significant 
difference when only the LPS stimulated groups were compared (p-value = 0.6858). (n=3)  
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4.9 The FCγRs antibodies did not block mCRP’s pro-inflammatory 
activity. 
 
After confirming that the FCγR antibodies did not contribute to triggering any 
pro or anti-inflammatory activity, a similar experiment was carried out by 
replacing LPS with the mCRP. TNF-α, and IL-6 protein levels were evaluated 
by the ELISA test, based on the same information in paragraph 4.6. 
Conversely, IL-10 and IFN-γ were not evaluated as there was no statistical 
difference in experiment 4.6. Therefore, this experiment aimed at assessing 
whether the mCRP pro-inflammatory activity could be mediated by FCγRs. 
The same antibody concentrations and time-points as in the experiment in 
paragraph 4.7. were adopted. Aimed at reducing the mCRP pro-inflammatory 
activity, it was assessed whether the FCγRs antibodies were capable of 
interfering with the binding site between mCRP and FCγRs.  
 
As shown in Fig. 4.15A, the TNF-α protein concentrations in the unstimulated 
macrophage group, the positive control group and the group stimulated with 
mCRP (pre-treated or not) with anti-FCγRs (anti-CD16, anti-CD32 and anti-
CD64) antibodies, were evaluated after 24 hours. No statistically significant 
difference was observed among the positive control group and the mCRP 
stimulated groups. Nor was there any statistical difference amongst the mCRP 
and anti-FCγR (anti-CD16, anti-CD32 and anti-CD64) antibody pre-stimulated 
groups. 
 
As shown in Fig.4.15B, the IL-6 protein concentrations in the unstimulated 
macrophage group, the positive control group and the group stimulated with 
mCRP (pre-treated or not) with anti-FCγRs (anti-CD16, anti-CD32, and anti-
CD64) antibodies for 24 hours, were evaluated and compared. There was no 
statistical significance when the positive control group was compared to the 
mCRP stimulated groups or when the mCRP group was compared to the anti-
FCγR (anti-CD16, anti-CD32, and anti-CD64) antibody pre-stimulated groups. 
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Fig 4.15. The FCγRs antibodies did not block mCRP’s pro-inflammatory activity. PMA exposure (50 ng/mL) monocyte-derived macrophages were pre-treated with 
anti-FCγRIII (CD16), anti-FCγRII (CD32) and the anti-FCγRI (CD64) antibody at a concentration of 100 µg/mL for 2 hours followed by 24 hours of mCRP (100 µg/mL) 
stimulation. LPS (10 ng/mL for 24 hours) stimulation was used as a positive control. The pro-inflammatory TNF-α and IL-6 cytokine estimation was made by ELISA kits 
(R&D System). The results are shown as the mean ± SD. ****p-value<0.0001 *p≤ 0.05. Fig (A) a statistically significant increased TNF-α production was observed in 
macrophages after mCRP stimulation at 100 µg/mL. The One-way ANOVA test, with Tukey's post-hoc test with a 99.9% CI and an α error fixed at 0.01%, confirmed 
the significant difference (p-value <0.0001) between the TNF-α expression level in the unstimulated macrophage group compared to the group with macrophages 
stimulated by mCRP (6.167 vs 1,068 pg/mL, respectively). However, none of the anti-FCγR antibodies under study were able to block mCRP pro-inflammatory activity 
(p-value =0.2708). Fig (B) The One-way ANOVA test, with Tukey's post-hoc test with a 99.9% CI and α error fixed at 0.01%, confirmed the significant difference (p-
value <0.0001) in the IL-6 expression level between the unstimulated macrophage group and the macrophage group stimulated by mCRP (1.531 vs 806.8 pg/mL, 
respectively). However, none of the anti-FCγR antibodies under study were able to block the mCRP pro-inflammatory activity (p-value=0.8816). (n=3) 




As aforementioned, in the event of an MI or IS, the priority is that of restoring 
the blood flow (Pisters and Lip, 2013; Howard, 2016). Several authors have 
reported an accumulation of nCRP, mCRP and macrophages during these 
pathophysiological events (Slevin et al., 2010; Chiba and Umegaki, 2013; 
Swirski and Nahrendorf, 2013; McFadyen et al., 2018), which might trigger 
macrophage pro-inflammatory activity. Therefore, it was assessed whether the 
macrophages were able to release pro-inflammatory cytokines when exposed 
to mCRP. Furthermore, it was determined whether the mCRP pro-
inflammatory activity was linked to mCRP bound to the FCγRs. 
 
The data obtained in this chapter suggest that monocytes are capable of a 
rapid duplication rate (Fig.4.1). However, these cells were unable to release 
the pro-inflammatory TNF-α cytokines after stimulation by LPS at 100 ng/mL 
(Fig. 4.6). Following a similar experimental design, LPS was replaced by 
mCRP. Previous studies have reported that mCRP could bind to αvβ3 and 
α4β1 integrins, as well as to FCγRI and FCγRIII receptors on monocytes 
(Fujita et al., 2014; Thiele et al., 2014a). Although some authors reported an 
increase (more than 1.5-fold) in NO and iNOS production (Sproston et al., 
2018), the data in this research showed that monocytes were not capable of 
increasing the TNF-α concentration. This datum is in agreement with other 
literature reports where it is stated that the increase in NO levels are 
associated to an increase in TNF-α and IL-6 only if the monocytes are 
differentiated into macrophages (Wang et al., 1997; Hur et al., 2004).  
 
As previously described in chapter 1 paragraph 1.2.2.1 and in the introduction 
chapter, monocytes are immune system cells able to differentiate into an initial 
resting macrophage (M0) phenotype (Zhao et al., 2017). In vitro differentiation 
can be obtained by PMA stimulation, which has been shown to differentiate 
the U937 monocytes into macrophages (Sproston et al., 2018) without 
influencing their polarization (Passmore et al., 2001; Song et al., 2015). In 
agreement with literature, the data herein reported confirm that PMA 
stimulation is able to lead to a significant increase in the Human-CD11c 
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macrophage markers (Sproston and Ashworth, 2018; Li et al., 2017). 
Furthermore, after macrophage differentiation, it was observed that these cells 
were also able to release both pro and anti-inflammatory cytokines (TNF-α, IL-
6, IL-10) after LPS stimulation (Fig. 4.6), in line with other authors (Wang et 
al., 1997; Hida et al., 2000; H. J. Hur et al., 2004; Tucureanu et al., 2018).  
 
After differentiating into a resting M0 macrophage phenotype state, 
macrophages are able to polarize into a pro (M1) or anti (M2) inflammatory 
phenotype (Orekhov et al., 2019). This polarization might be dependent on the 
presence of Pathogen Associated Molecular Patterns (PAMP) and/or 
Damage-associated molecular patterns (DAMPs) released upon cellular 
stress or tissue injury (Liu et al., 2017a). The past few years have witnessed 
publications reporting that nCRP could polarise macrophages from M2 to M1 
when they bind to FCγRII and FCγRI receptors (Devaraj and Jialal, 2011). 
However, more recent investigation has indicated that this maturation and 
polarisation are led by mCRP (Trial et al., 2016). If the maturation and 
polarisation towards a pro-inflammatory phenotype were led by mCRP, it might 
then also be suggested that mCRP may be the player responsible for the 
increase and release of the pro-inflammatory cytokines TNF-α and IL-6, 
without increasing the release of the anti-inflammatory cytokine IL-10 (which 
is synthesized specifically by the macrophage M2 phenotype) (Moore et al., 
2001).  
 
It was observed that mCRP had a direct biological activity on U937 monocyte-
derived macrophages. Indeed, the macrophages were able to up-regulate the 
IL-1β (Fig 4.8) gene expression level when stimulated by mCRP at a 
concentration of 100 µg/mL for 12 and 24 hours. This up-regulation was 
particularly high when the macrophages were stimulated by mCRP for 12 
hours (Fig 4.8). Furthermore, it was observed that these biological effects are 
directly related to an increase of both TNF-α and IL-6 (Fig. 4.9). However, 
differently to LPS, mCRP was unable to increase the IL-10 anti-inflammatory 
cytokine release (Fig. 4.10).  
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The possibility that the U937-derived macrophages were able to increase TNF-
α and IL-6 without increasing the release of IL-10 anti-inflammatory cytokines 
not only confirms the potential involvement of this protein in macrophages 
polarisation towards a pro-inflammatory phenotype (Trial et al., 2016), but also 
suggests that mCRP is capable of boosting inflammation, thus substantially 
altering the micro-environment (Singh et al., 2006), leading to serious 
detrimental clinical complications (Slevin et al., 2015; Krayem et al., 2017). An 
IS event is an example. The presence mCRP after an IS accident (Slevin et 
al., 2010) has been associated with the probability of developing future 
neurological clinical complications, such as dementia and Alzheimer 
(Desmond et al., 2002; Slevin et al., 2015; Slevin et al., 2017). Literature 
confirms that the macrophage M2 phenotype plays an important role after an 
IS event (Hu et al., 2012). Indeed, after an IS event the macrophage M2 
phenotype can originate through several mechanisms. For example, Gliem et 
al. (2012) confirmed that, following a transient middle cerebral artery occlusion 
(tMCAO), the recluted pro-inflammatory classical monocytes could be 
polarised into the non-classical monocyte phenotype M2. Other studies 
demonstrated that, when monocytes are recruited through the CC-chemokine 
receptor 2 (CCR2), they differentiated into macrophages leading to the 
polarisation of macrophages from the pro-inflammatory (M1) to the anti-
inflammatory phenotype (M2) (Gliem et al., 2016). This implies an increase in 
the transforming growth factor (TGF-β1), VCAM1, IL-10, brain-derived 
neurotrophic factors (BDNF), insulin-like growth factor (IGF-1) and vascular 
endothelial growth factor (VEGF) levels, all of which are associated with a 
better long-term spontaneous recovery (David and Kroner, 2011; Dobolyi et 
al., 2012; Wattananit et al., 2016; Chernykh et al., 2016). However, should this 
recruitment take place along with the concomitant mCRP-brain accumulation 
(Slevin et al., 2010), it maybe that the mCRP interferes with the maturation 
and/or polarisation from M0 or M1 to the M2 phenotype. This would induce a 
substantial reduction in anti-inflammatory cytokines and the release of the 
trophic factor, risking the facilitation of the appearance of serious clinic 
neurological consequences, as reported in two recent studies (Slevin et al., 
2015; Slevin et al., 2017). These hypotheses may well be of clinical value 
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considering that macrophage polarisation has recently been hypothesised as 
a novel therapy against stroke (Kanazawa et al., 2017). 
 
The possibility that mCRP facilitates and increases the release of both the 
TNF-α and IL-6 protein concentration, allows us to postulate which type of 
inflammatory pathway the mCRP is able to trigger. As aforementioned in 
paragraph 4.8, MAPKs and NF-KB are signalling pathways that activate during 
acute and chronic inflammation conditions (Wang et al., 2006; Hayden et al., 
2006a; Del Reino et al., 2014; Shih et al., 2015; Maik-Rachline et al., 2018). 
Once these pathways are activated, macrophages are able to increases the 
pro-inflammatory cytokine production, such as IL-1β and TNF-α (Jin et al., 
2013; Yang et al., 2014b). For example, some studies have reported that in 
LPS-activated RAW 264.7 macrophages and mice microglia cells, up-
regulation of MAPKp38/JNK/NF-KB pathways increase the production of pro-
inflammatory mediators, such as IL-1β and TNF-α (de Oliveira et al., 2017; Lim 
et al., 2018). Literature also confirms that there is an elevated increase in pro-
inflammatory cytokines when NF-KB nuclear translocation takes place in the 
M1 pro-inflammatory phenotype (Wang et al., 2014). When reflecting on the 
data and information obtained in this study, along with that of literature, it 
comes to mind that another interesting issue could be that of evaluating 
whether mCRP is capable of activating the ERK, JNK, MAPKp38 and NF-KB 
pathways. As mCRP is able to polarize macrophages towards to the pro-
inflammatory M1 phenotype (Trial et al., 2016), with the direct consequence of 
an increase in pro-inflammatory cytokines (result paragraph 4.6), it might also 
be possible that mCRP is able to increase the release of the pro-inflammatory 
mediator through the activation of MAPKp38/JNK/NF-KB pathway. 
 
This hypothesis could also be supported by the fact that mCRP is known to 
increase both NO and iNOS levels in monocytes (Sproston et al., 2018). This 
is associated with the activation of MAPKp38 as a fundamental step to produce 
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Fig 4.16. mCRP might increase the release of the pro-inflammatory mediator through the activation of MAPKp38/JNK/NF-KB pathway. Both MAPK and NF-КB are 
signalling pathways activated during acute and chronic inflammation. Studies have already reported that when both MAPKs and NF-KB are activated these signalling 
pathways are able to increase the pro-inflammatory mediator production, e.g., IL-1β, IL-6 and TNF-α. Knowing that mCRP is able to increase the production of these 
pro-inflammatory cytokines, it is feasible to hypothesize that this increase depends on an activation of these pathways.  
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NO and INOS in these immune-system cells (Ratajczak-Wrona et al., 2009). 
Moreover, a better understanding of the molecular mechanism involved in 
mCRP pro-inflammatory activity may pave the way for the identification a 
potential small molecular inhibitor capable of blocking, or at least reducing, this 
activity.  
 
In this project also assessed the ability mCRP has to stimulate macrophage 
IFN-γ release. IFN-γ is another pro-inflammatory cytokine present in acute and 
chronic inflammation and is mainly released by T-cells and natural killer (NK) 
cells (Muhl and Pfeilschifter, 2003; Gomez et al., 2015; Kulkarni et al., 2016). 
Although previous studies have already reported that macrophages could 
release IFN-γ only when they had previously been co-stimulated by both IL-12 
and IL-18 (Darwich et al., 2009), an ELISA assay was carried out to evaluate 
whether the mCRP pro-inflammatory proprieties could also be associated with 
an increase in this pro-inflammatory cytokine. However, as reported in the 
results section (Fig. 4.10) and confirmed in literature (Schoenborn and Wilson, 
2007; Kulkarni et al., 2016) the macrophages did not release IFN-γ after mCRP 
(100 µg/mL) or LPS stimulation (10 ng/mL).  
 
As aforementioned in the introduction paragraph of this chapter 4, a high FCγR 
expression was observed in oligodendrocytes, neurons, oligodendrocytes, 
astroglia, microglia, monocytes and macrophages (Okun et al., 2010). 
Macrophages have a high FCγRI (CD64), FCγRIIA (CD32a) and FCγRIII 
(CD16a) expression (Tanigaki et al., 2015). Bharadwaj et al. (1999) reported 
that nCRP was able to bind with the FCγRII receptors present in human U937 
monocyte cell lines, whilst Eisenhardt et al. (2009b) reported that the nCRP-
mCRP dissociation increased monocyte adhesion and ROS production, which 
was abolished when the FCγI (CD64), FCγII (CD32), FCγIII (CD16) receptors 
were blocked. This led to an assessment as to whether: (I) the FCγRs were 
able to mediate the mCRP pro-inflammatory activity; (II) whether this pro-
inflammatory action is suppressed after the FCγRs are blocked. 
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The data obtained during this research showed that stimulation with FCγR 
antibodies: (I) did not induce any pro-inflammatory effects on U937 
macrophages (4.11 and 4.12) (II); did not activate any signalling pathways 
potentially associated to a pro-inflammatory response (4.13); (III) did not 
reduce mCRP pro-inflammatory activity in U937monocyte-derived 
macrophages (Fig 4.15).  
 
Despite the lack of direct and specific evidence, a possible explanation as to 
why FCγR antibodies were unable to block the mCRP pro-inflammatory activity 
may be found in literature. Indeed, Ji et al. (2009) confirmed that mCRP can 
trigger pro-inflammatory activity in human ECs when it binds with the lipid raft 
microdomain rather than to the FCγRs. Recently, Jia et al. (2018) reported that 
mCRP was capable of binding directly with the cholesterol binding sequence 
(CBS) in bone marrow-derived macrophages (BMDMs) and in peripheral blood 
mononuclear cells (PBMCs). Therefore, it is most likely that mCRP triggers its 
pro-inflammatory activity when it binds with the lipid raft microdomains or CBS 
present in the U937monocyte-derived macrophage cell line (Fig 4.16).  
 
4.11 Key findings: 
 
The key findings of the experiments described in this chapter are: 
 
• U937 monocytes have a very high duplication capacity, despite their not 
being able to release pro-inflammatory TNF-α cytokines after LPS or 
mCRP stimulation. However, when U937 monocytes are PMA treated 
and successively stimulated with LPS they are able to differentiate and 
up-regulate the release of several cytokines, such as IL-1 β, TNF-α, IL-
6 and IL-10.  
 
• The results here reported confirm that mCRP interacts with 
macrophages and consequently leads to an up-regulated IL-1β gene 
expression and an increased concentration of pro-inflammatory 
cytokines (TNF-α and IL-6) when stimulated by mCRP (100 µg/mL) for 
24 hours.  
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• The data herein reported corroborate that mCRP is not able to increase 
the release of IL-10 anti-inflammatory cytokines. A possible explanation 
may be that mCRP polarize the macrophage maturation towards the 
M1-like pro-inflammatory phenotype (Trial et al., 2016). 
 
• The ELISA assay confirmed that mCRP stimulation increased TNF-α 
and IL-6 production but that anti-FCγR antibody stimulation does not 




Platelets can dissociate nCRP into mCRP during AD activation causing its 
accumulation in ischemic tissue (McFadyen et al., 2018). mCRP is capable of 
increasing in monocyte adhesion and the formation of ROS species when it 
binds with the FCγI (CD64), FCγIIa (CD32), FCγIII (CD16) receptors on ECs 
(Eisenhardt et al., 2009b). Knowing that the FC-γ receptors are also present 
in macrophages (Satpathy et al., 2012), the macrophages were stimulated with 
anti- FCγI (CD64) anti- FCγII (CD32) and anti- FCγIII (CD16) antibodies, to 
determine whether these receptors mediated the mCRP pro-inflammatory 
activity. 
 
The experiments reported herein demonstrated that although mCRP have a 
strong pro-inflammatory activity, anti-FCγRs antibodies cannot reduce it. 
Therefore, mCRP may provoke pro-inflammatory activity by binding to other 
cellular portions (Ji et al., 2009; Jia et al., 2018). Further studies could hopefully 
clarify if there are any pathways that may be associated with pro-inflammatory 
activity, aimed at determining whether there are any antibodies and/ or SMIs 
capable of mitigating the mCRP pro-inflammatory action. This could be useful 
in order to block or at least limits the mCRP pro-inflammatory activity reported 
in several chronic inflammation condition (Schwedler et al., 2003; Eisenhardt 
et al., 2009b; Slevin et al., 2015). 
  
146 | P a g .  
   
 
 
CHAPTER 5 RESULT:  
Investigating the potential 
Acetylcholine anti-






147 | P a g .  
   
CHAPTER 5: Investigating the potential Acetylcholine (ACh) 
and Nicotine anti-inflammatory activity on monocyte 
differentiated macrophages against mCRP.  
 
As previously mentioned in chapter 1 paragraph 1.1.1, inflammation is a well 
regularised process useful to avoid substantial blood, fluid loss and potential 
infections (Weiss, 2008; Gurtner et al., 2008). Endothelial cells (ECs) increase 
the expression of both cell adhesion molecules (Martin, 1997) and chemokines 
(Deshmane et al., 2009) during the first phase of inflammation, recruiting 
neutrophils and monocytes (Rodero et al., 2014; Gonzalez et al., 2016). Once 
recruited, monocytes differentiated into naïve M0 macrophages which express 
specific surface makers (Murray and Wynn, 2011) that are capable of 
recognising Damage Associated Molecular Patterns (DAMPs) and Pathogen 
Associated Molecular Patterns (PAMPs) (Geissmann et al., 2010; Malissen et 
al., 2014; Orekhov et al., 2019). DAMPs, PAMPs and inflammatory stimuli bind 
with the M0 macrophages (Ramadan et al., 2017; Roh and Sohn, 2018), 
activating the MAPKs (JNK1/2, MAPKp38 and ERK 1/2), facilitating NF-KB 
phosphorylation which polarizes M0 macrophages into a pro-inflammatory M1 
phenotype (Trial et al., 2016; Liu et al., 2017a; Liu et al., 2017c; Atri et al., 
2018; Neamatallah, 2019). The polarization of M0 macrophages towards a 
pro-inflammatory M1 phenotype facilitates pro-inflammatory cytokine release 
(Scull et al., 2010; de Oliveira et al., 2017). When the pro-inflammatory 
cytokines bind with the the vagus nerve (VN), afferent fibres modulate the VN-
efferent-fibre activity (Pavlov and Tracey, 2012). This neuromodulation leads 
to a cholinergic anti-inflammatory pathway (CAIP) activation, followed by an 
increase in non-neuronal Acetylcholine serum (Zhang et al., 2016; Han et al., 
2017). ACh binds directly to the macrophages through the nicotinic 
acetylcholine receptors (nAChRs) (Rosas-Ballina et al., 2011). This binding 
reduces the NF-KB nuclear translocation (Fig 5.1) and limits the release of 
pro-inflammatory cytokines (Borovikova et al., 2000; Baez-Pagan et al., 2015).  
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Fig 5.1. The protective effect of Acetylcholine (ACh). The efferent VN increases the activity of the spleen, liver and intestine, which, in turn increases ACh release. 
The anti-inflammatory activity is triggered when ACh binds with the α7 nicotinic acetylcholine receptor (α7nAChR) (expressed on macrophages or other immune 
cells), which regulates the NF-КB and STAT3 activity, reducing the pro-inflammatory cytokine release. Source: Adapted from Pavlov VA, Tracey KJ. The vagus nerve 
and the inflammatory reflex - Linking immunity and metabolism. Nature Reviews Endocrinology. 2012;8(12):743-54. 
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AChRs are cysteine-loop ligand-gated ion channel (cys-loopLGIC) receptors 
such us the γ-aminobutyric acid type A receptors (GABAA) and the serotonin 5-
HT3 receptors (Cockcroft et al., 1990; Karlin, 2002; Le Novere et al., 2002). 
Several nAChR have been recognised in monocyte and macrophage (Galvis et 
al., 2006a; Chernyavsky et al., 2010). For example, Galvis et al. (2006b) reported 
that mice primary macrophages possess the α3, α4, α5, α7, α9, α10, β2, β3, and 
β4 subunit receptors and Chernyavsky et al. (2010) showed the presence of α1, 
α4, α5, α6, α7, α9, α10, β1, β2, β3, and β4 subunits on the U937 monocyte cell 
line. The specific activation of the α7nAChR subunit expressed on macrophages 
has been associated with strong anti-inflammatory activity (Nathan, 2002; 
Tracey, 2002; Wang et al., 2003; de Jonge et al., 2005; Saeed et al., 2005; 
Tracey, 2007). A recent study by Xu et al. (2019) reported on 35 preeclamptic 
pregnant women who had a downregulated α7nAChR in peripheral blood 
monocytes which led to a higher NF-KB transcription activity. This finding was 
also associated with an increase in the release of pro-inflammatory cytokines and 
a more severe clinical profile (Xu et al., 2019). More recently, the anti-
inflammatory activity of α7nAChR have also been associated to an another 
α7nAChR agonist, i.e., Nicotine (Quik et al., 2015). As does ACh, this natural 
compound binds to α7nAChR, suppressing the NF-KB transcriptional activity 
which also reduces TNF-α pro-inflammaotry cytokine release (Yoshikawa et al., 
2006b).  
 
Although none of the SMIs under study blocked the dissociation from nCRP into 
mCRP, as reported in chapter 3 (Fig. 3.5 and Fig 3.6), the strong anti-
inflammatory activity of ACh and Nicotine, prompted the evaluation of whether 
the use of ACh or Nicotine could be adopted as a therapeutic approach to block 
the detrimental pro-inflammatory effect of mCRP. Tests were also carried out 
during this project as to the possibility that ACh and Nicotine anti-inflammatory 
activities could potentially be mediated by the α7nAChR receptors. 
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Aim and objectives: To establish whether and how ACh and Nicotine could exercise 
anti-inflammatory activity against mCRP in monocyte-differentiated macrophages.  
 
This was addressed by the following objectives:  
 
• It was demonstrated in chapter 3 that neither ACh nor Nicotine were able 
to block nCRP-mCRP dissociation. However, recent studies have reported 
that both ACh and Nicotine treated macrophages release fewer pro-
inflammatory cytokines (Borovikova et al., 2000; Tsoyi et al., 2011; Ren et 
al., 2017). As macrophages increase the release of pro-inflammatory 
cytokines when mCRP stimulated (chapter 4), the first objective was to 
determine whether ACh and/or Nicotine activity is able to block the mCRP 
pro-inflammatory process.  
 
• As previously mentioned in chapter 1 paragraph 1.2.2.1, when monocytes 
differentiate into M0 resting macrophages (Ramadan et al., 2017; Roh and 
Sohn, 2018) they can polarise into an M1 pro-inflammatory phenotype (Atri 
et al., 2018; Neamatallah, 2019). mCRP might also be responsible for this 
process (Trial et al., 2016), increasing secretion levels of both TNF-α and 
IL-6 but not IL-10 anti-inflammatory cytokines (see chapter 4 paragraph 
4.6). Pro-inflammatory mediator release in both monocytes and 
macrophages is downstream of mitogen-activated protein kinase (MAPKs) 
p38, Janus kinase/signal transducer and activator of transcription (JAK-
STAT), extracellular signal-regulated kinases 1 and 2 (ERK1/2) and NF-
KB (Moens et al., 2013; de Oliveira et al., 2017; Lim et al., 2018). However, 
whilst a study carried out in 2011 did not detect any critical intrinsic 
pathways activated by mCRP on THP-1 macrophages (Eisenhardt et al., 
2011), further  findings have reported that mCRP can increase the IL-6 
concentration when both MAPKp38 and NF-KB signalling pathways are 
involved in ECs (Li et al., 2014). Thus, a second objective was to 
determine whether the MAPKs and NF-kB intrinsic pathway could be also 
activated in U937monocyte-differentiated macrophages by mCRP 
stimulation. 
 
• It has been demonstrated that both ACh and Nicotine are capable of 
reducing the phosphorylation of MAPKs and of avoiding the nuclear 
translocation of NF-KB (Borovikova et al., 2000; Sun et al., 2013a; 
Yoshikawa et al., 2006b). That is why the third objective was to evaluate 
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whether when ACh and/or Nicotine reduce the MAPK and NF-KB intrinsic 
pathways, they also reduce the mCRP pro-inflammatory activity.  
 
• The anti-inflammatory activity of ACh and Nicotine is triggered when they 
bind to α7nAChR (Sargent, 1993; Alkondon et al., 1997; Liu et al., 2012), 
α7nAChR is highly expressed in both monocyte and macrophage cells 
(Yoshikawa et al., 2006a; Hoover, 2017). When α7nAChR is activated it 
induces a strong anti-inflammatory activity (Sun et al., 2017; Ulleryd et al., 
2019; Gowayed et al., 2019). This finding explains why this receptor is now 
indicated as a potential therapeutic drug for several medical conditions 
(Han et al., 2017; Xu et al., 2019). That is why the fourth objective was to 
assess whether ACh and Nicotine anti-inflammatory activity is mediated 
by α7nAChR. On the basis of the aforementioned, a specific α7nAChR 
antagonist was used to this aim. 
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5.1 Cytotoxicity evaluation of small molecule inhibitor (SMI) in U937-
derived macrophages.  
 
As aforementioned, ACh, and Nicotine have been shown to have anti-
inflammatory properties (Han et al., 2017). However, investigation into their 
toxicity is a prerequisite before they may be proposed as a therapy against 
inflammation. Cell viability (Alamar Blue cell viability assay) and cell apoptosis 
assays (Annexin-V Fluorescein isothiocyanate apoptosis detection kit) were 
carried out after 24 hours of ACh and Nicotine stimulation (the best time-point for 
mCRP and LPS was obtained in experiment 4.5). On the basis of literature data, 
ACh was tested at several concentrations (from 0 to 250 μM) (Borovikova et al., 
2000) and Nicotine (Mayer and Mayer, 2014) at its highest concentration of 150 
ng/mL (Fig 5.2).  
 
As reported in Fig 5.2, the Alamar Blue cell viability assay evidenced no 
cytotoxicity for ACh in the range of 0-250 μM. Table 5.1 reports the percentage 
of viable cells for ACh. Also, Nicotine (between 0-150 ng/mL) did not show any 
cytotoxic effects. All the results are summarised in Fig 5.2 and Table 5.2. 
 
The cell viability test was followed by an apoptosis assay. ACh was tested at 100 
μM and Nicotine at 150 ng/mL. These concentrations were selected on the basis 
of data from previous studies where they were used as inhibitors, in both 
macrophages and glial cells (Shytle et al., 2004; Park et al., 2007; Borovikova et 
al., 2000). No apoptotic effect was observed with 100 µM of ACh or 150 ng/mL of 
Nicotine (0.93 µM), as reported in Fig 5.3 and Table 5.3. These results provided 
working concentrations for ACh (100 and 10 µM) and Nicotine (150 and 75 
ng/mL) so as to evaluate SMI anti-inflammatory potential.  
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Fig 5.2. Cytotoxicity evaluation of small molecule inhibitor (SMI) in U937-derived macrophages. In this experiment a cytotoxic test was performed on ACh or Nicotine 
to evaluate any cytotoxic effects that might lead to cell death. After differentiation, monocyte differentiated macrophages were exposed to a media containing RPMI 
1640 with L-glutamine (1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and ACh (from 3.9 μM to 250 μM) or Nicotine (from 2.34 to 150 ng/mL) for 
24 hours. Ethanol (20% total volume for 24 hours) was used as a positive control. Cell viability was evaluated by a CellTiter-Blue® Cell Viability Assay (Promega). The 
results are shown as the average ± SD. ****P-value < 0.0001. The ANOVA One-way and Tukey's post-hoc tests confirmed a statistically significant difference (P-
value<0.0001) between the positive control (20% Ethanol) and all the groups stimulated with ACh (P-value<0.0001), or all the groups stimulated Nicotine (P-value<0.0001) 
(n=3).  
154 | P a g .  
   
 
Fig 5.3. Cell apoptosis evaluation of small molecule inhibitor (SMI) U937-derived macrophages. After differentiation, monocyte-differentiated macrophages were 
cultured in media containing RPMI 1640 with L-glutamine (1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and ACh (100 μM) or Nicotine (150 
ng/mL) for 24 hours. Ethanol (20% total volume for 24 hours) was used as a positive control. Apoptosis was evaluated by Annexin-V Fluorescein isothiocyanate (FITC) 
apoptosis detection kit (Bioscience), according to the manufacturer’s instructions. The results are shown as the average ± SD. ****P-value < 0.0001. The ANOVA one-
way and Tukey's post-hoc tests confirmed a statistically significant difference (P-value<0.0001) between the untreated macrophage and the positive control (20% 
ethanol). The same results were confirmed by comparing the positive control with the group treated with SMIs (P-value<0.0001). No statistically significant difference 
(P-value=0.9678) was observed between the untreated macrophage and selected SMIs. The results confirmed that ACh (100 µM) and Nicotine 150 ng/mL (0.93 µM) did 
not lead to apoptotic body development (lower left quadrant of the AV/PI plot) in the U937 monocyte-differentiated macrophages (n=3). 
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ACh Alamar Blue Cell Viability Assay 
ACh 
Concentration 
 Posi.Con Neg. Con 
(0) 3.9 μM 7.8 μM 15.6 μM 31.2 μM 62.5 μM 125 μM 250 μM 
% Viable Cells  14.8% 100% 99.44% 98.45% 99.35% 91.70% 95.10% 97.65% 93.84% 
Table 5.1. ACh Alamar Blue Cell Viability Assay. This table reports the percentage of viable cells after a cell viability assay was performed on U937 macrophages. 
Differently to the positive control (20% Ethanol), the SMI tested (ACh) was safe up to 250μM. (n=3). 
Nicotine Alamar Blue Cell Viability Assay 
Nicotine 
Concentration 
 Posi. Con 
Neg. Con 
(0) 
2.34 ng/ml 4.68 ng/m 9.37 ng/mL 
18.75 
ng/mL 
37.5 ng/mL 75 ng/mL 150 ng/mL 
% ViableCells   5.83% 100% 98.68% 97.38% 98.22% 98.79% 98.44% 101.48% 96.24% 
Table 5.2. Nicotine Alamar Blue Cell Viability Assay. This table reports the percentage of viable cells after a cell viability assay was performed on U937 
macrophages. Differently to the positive control (20% ethanol), the SMI tested (Nicotine) was safe up to 150 (0.93 µM) ng/mL. (n=3). 
SMI Cell Apoptosis Assay 
Cell apoptosis assay  Neg Annexin 
V Neg PI 
Pos Annexin 
V Pos PI ACh 100 µM 
Nic 150 
ng/mL 
% Viable Cells  97.15% 93.81% 12.18% 5.38 % 94.67% 87,.29% 
 
Table 5.3. SMI Cell Apoptosis Assay. A test was performed to assess whether the SMIs showed any cytotoxic effects that could lead to cell death. Cell viability 
was unaffected by ACh at 100 μM and Nicotine at 150 ng/mL.  Only one concentration for each compound was used in this cell apoptosis assay. The percentage 
of viable cells expressed is the average of three different experiments. (n=3). 
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5.2 The effect SMIs have on inflammation in U937 macrophages.  
 
The previous experiments allowed for the determination of the best working 
SMI concentrations to use without triggering cytotoxic effects that might lead 
to cell death. Therefore, ACh was used at concentrations of 100 μM and 10 
μM and Nicotine at 150 and 75 ng/mL (0.93 and 0.46 µM respectively). These 
concentrations for the same reason described in paragraph 5.1 (Borovikova et 
al., 2000; Shytle et al., 2004; Park et al., 2007). The next step was to determine 
that selected SMIs did not effectively induce any pro-inflammatory effects in 
U937 macrophages. In the experiments described as follows the pro-
inflammatory effects of the anti-mCRP 3H12 antibody was also investigated. 
LPS at 10 ng/mL was used as a positive control, as previously optimized in 
chapter 4 paragraph 4.4. Macrophages were exposed to SMIs in the 
aforementioned concentration for 24 hours (see experiment paragraph 5.1). 
TNF-α, IL-6, or IL-10 were selected as targets as described in the experiments 
in chapter 4, paragraph 4.6.  
 
As reported in (Fig 5.4 and Fig 5.5) enzyme-linked immunosorbent assays 
(ELISA) were carried and demonstrated that SMIs alone did not increase the 
macrophage cytokine release. An assessment and comparison (Fig 5.4) was 
made of the TNF-α protein concentrations for the untreated macrophage 
group, the positive control group and the group stimulated with ACh (100 μM 
and 10 μM) or Nicotine (150 ng/mL and 75 ng/mL) at 24 hours. No statistically 
significant difference was observed between the untreated group and the 
groups stimulated with ACh at 100 μM or 10 μM and Nicotine at 150 ng/mL 
and 75 ng/mL. Whereas, there was a statically significant difference between 
the untreated macrophage group vs the positive control group, as was 
observed in the positive control vs the other the groups stimulated with ACh at 
at 100 μM or 10 μM and Nicotine at 150 ng/mL and 75 ng/mL. Furthermore, a 
statistical difference was confirmed between the untreated macrophage group 
and the group treated with the 3H12 anti-mCRP antibody.  
 
As shown in Fig 5.4, assessment and comparison was made of the IL-6 protein 
concentrations in the untreated macrophage group, the positive control and 
157 | P a g .  
   
the group stimulated with ACh (100 μM and 10 μM) or Nicotine (150 ng/mL 
and 75 ng/mL) at 24 hours. No statistically significant difference was observed 
between the untreated macrophage group the ACh and Nicotine groups. 
Whilst there was a significant difference between the untreated macrophage 
group and the positive control group, as well as the positive control group and 
the other the groups stimulated with ACh at ACh at at 100 μM or 10 μM and 
Nicotine at 150 ng/mL and 75 ng/mL. Furthermore, concentrations also 
differed between the untreated macrophage group and the group treated with 
the 3H12 anti-mCRP antibody. 
 
As shown in Fig 5.5 assessment and comparison was made of the IL-10 
protein concentrations in the untreated macrophage group, the positive control 
group and the groups stimulated with SMIs at 24 hours. No statistically 
significant difference was observed between the untreated macrophage group 
and the ACh and Nicotine groups, nor was there a statistically significant 
difference between the ACh and Nicotine groups. 
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Fig 5.4. SMIs did not induce pro-inflammatory effects on U937 macrophages. After differentiation (PMA 50 ng/mL for 72 hours), the macrophages were treated with 
LPS at 10 ng/mL (positive control) or ACh (100 and 10 μM) or Nicotine (150 and 75 ng/mL) or anti-3H12 antibody (1/10 total volume), for 24 hours. The TNF-α (A)-
and IL-6 (B) production was quantified by the ELISA assay (R&D System). The results are shown as the average ± SD. ****P-value <0.0001. *P-value<0.001. There was 
an increase of the TNF-α (A) concentration and IL-6 (B) pro-inflammatory cytokines in the positive control group. The absence of statistical differences (P-
value=0.3157) between the untreated macrophage group and SMIs groups (A) was confirmed by the One-way ANOVA test, followed by Tukey’s post-doc test, with a 
99.9% CI and a 0.01% α error. A statistically significant difference was observed when the positive control and the SMI groups were compared (P-value<0.0001) and 
when the untreated macrophage group (P-value=0.0230) and the group treated with the 3H12 anti-mCRP antibody (244.6 vs 1011 pg/mL respectively), were 
compared. A similar result was also confirmed with IL-6. No statistical differences (P-value> 0.9999) between the untreated macrophage group and the SMIs groups 
(B) were observed, as confirmed by the One-way ANOVA test, followed by Tukey’s post-doc test, with a 99.9% CI and α error fixed at 0.01%. The only statically 
significant difference was observed (P-value<0.001) when the untreated macrophage group and the anti-3H12 antibody group (9.797 vs 172.5 pg/mL respectively) 
were compared. (n=3).  
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Fig 5.5. SMIs did not increase the release of IL-10 anti-inflammatory cytokine. After 
differentiation (PMA 50 ng/mL for 72 hours), the macrophages were treated with LPS at 10 ng/mL 
(positive control), ACh (100 and 10 μM), Nicotine (150 and 75 ng/mL) or anti-3H12 antibody (1/10 
total volume), for 24 hours. The production of IL-10 anti-inflammatory cytokines was quantified 
by ELISA assay (R&D System). The results are shown as the average ± SD. ****P-value <0.0001. 
*P-value<0.001. The One-way ANOVA test, followed by Tukey’s post-doc test, with a 99.9% CI and 
a 0.01% α error, confirmed there were no statistically significant differences (P-value=0.3157) 
amongst the groups (P-value=0.7063) (n=3).  
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5.3 Testing the anti-inflammatory activity of SMIs on LPS-
stimulated macrophages. 
 
After having demonstrated that SMIs did not induce pro-inflammatory activity 
on macrophages, the general anti-inflammatory properties of the SMIs (ACh 
and Nicotine) were evaluated (Han et al., 2017; Yamada and Ichinose, 2018). 
The SMIs were tested against the positive control (LPS at 10 ng/mL) for 24 
hours. TNF-α, IL-6 and IL-10 were selected as markers as reported in chapter 
4, paragraph 4.6. The macrophages were pre-treated with SMIs for 2 hours as 
this pre-treatment time point had been demonstrated to be the best time-point 
(experiment 5.4). 
 
There was a statistically significant increase in the IL-6, IL-10 and TNF-α level 
in macrophages following stimulation with LPS at a concentration of 10 ng/mL.  
 
As reported in Fig. 5.6 and Fig. 5.7, the trend here reported showed that the 
use of SMIs did not reduce this release. SMIs were not found to be 
characterised by any general anti-inflammatory effects. 
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Fig 5.6. None of the SMIs showed anti-inflammatory properties. Monocyte differentiated macrophages were pre-treated with ACh (100 and 10 µM) or Nicotine (15 and 75 ng/mL) 
for 2 hours and then stimulated by LPS (10 ng/mL) for 24 hours. LPS alone (10 ng/mL) was used as a positive control, for 24 hours. The pro-inflammatory cytokines TNF-α and IL-6 
were assessed by ELISA assay (R&D System). Stimulation by LPS, at 10 ng/mL for 24 hours led to a substantially increased production of both TNF-α (A) and IL-6 (B) in the macrophages 
and this cytokine release remained extremely high even after the use of SMIs (n=1 2 technical replicates). 
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Fig 5.7. SMIs did not reduce the IL-10 anti-inflammatory cytokines release. The macrophages were pre-treated with ACh (100 and 10 µM) or Nicotine (150 and 75 ng/mL) for 2 hours 
and then stimulated by LPS (10 ng/mL) for 24 hours. Only LPS (10 ng/mL) was used for 24 hours as a positive control. The anti-inflammatory cytokines IL-10 was assessed by ELISA 
assay (R&D System). Stimulation by LPS, at 10 ng/mL for 24 hours, led to a substantially increased production of IL-10 in macrophages and this cytokine release remained extremely 
high even when the macrophages were pre-stimulated by SMIs (n=1 2 technical replicates). 
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5.4 Evaluation of the incubation time-point for SMIs, aimed at the 
inhibition of mCRP pro-inflammatory activity. 
 
After observing that the SMIs did not induce pro or anti-inflammatory effects on 
LPS-stimulated macrophages, assessment was made as to whether SMIs could 
limit or block mCRP inflammatory activity. To this aim, it was necessary to 
optimise the SMIs in terms of time points. The same SMI concentrations as that 
used in experiment 5.2. were adopted. The mCRP concentrations and time-
points were the same as those in experiment 4.6. TNF-α, was selected based on 
the same concepts expressed in chapter 4, paragraph 4.6 and were used to 
evaluate the SMI anti-inflammatory proprieties. The TNF-α, cytokine 
concentration was quantified by the ELISA assay. 
 
As shown in Fig 5.8, the trend showed a statistically significant difference 
between the TNF-α expression level in the untreated macrophage group and 
macrophages stimulated with mCRP (18.71 vs 1203 pg/mL). It was observed that 
a four-hour pre-treatment with Nicotine 150 ng/mL (0.93 µM) or 3H12 was able 
to reduce TNF-α release (1203 vs 480 pg/mL and 1203 vs 943.3 pg/mL 
respectively). 
  
A comparison between ACh and mCRP groups indicated that the levels of TNF-
α in U937-monocyte differentiated macrophages pre-stimulate for two hours with 
ACh both at 100 and 10 μM was lower than that in the mCRP group alone (1203 
vs 639 pg/mL and 1203 vs 651.1 pg/mL respectively). Similarly, all groups that 
had been pre-treated for 2 hours with Nicotine (150 ng/mL) and antimCRP-3H12 
antibody (1:10) had a reduction in mCRP pro-inflammatory activity.  
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Fig 5.8. Time-point evaluation activity for SMIs, aimed at the inhibition of mCRP pro-inflammatory activity. After differentiation (PMA exposure 50 ng/mL for 72 
hours) monocyte differentiated macrophages were pre-treated with ACh (100 and 10 μM), Nicotine (150 and 75 ng/mL) or antimCRP-3H12 antibody (1:10) for 30 
minutes 1, 2 and 4 hours respectively, followed by stimulated with mCRP (100 µg/mL) for 24 hours. LPS (10 ng/mL for 24 hours) was used as a positive control. The 
pro-inflammatory cytokine TNF-α was estimated by ELISA assay (R&D System). Fig (A-B) mCRP stimulation at 100 µg/mL increased TNF-α production. The trend 
showed that pre-stimulation with ACh (100 and 10 μM) led to anti-inflammatory activity. B) The trend showed that pre-stimulation with Nicotine (150 and 75 ng/mL) 
or antimCRP-3H12 antibody (1:10) led to anti-inflammatory activity. Two hours was the optimum time-point to reduce the TNF-α release for all conditions. At 4 hours 
the SMI inhibitors began to lose their efficacy. (n=1 2 technical replicates). 
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5.5 Studying the SMI-ACh anti-inflammatory effect against mCRP. 
Previous research demonstrated that, after binding with macrophages, both 
ACh and Nicotine have strong anti-inflammatory activity (Boras et al., 2014; 
Han et al., 2017). This experiment assessed the anti-inflammatory effect of 
SMIs against mCRP, i.e., its ability to reduce pro-inflammatory effects. The 
U937-derived macrophages were incubated for 2 hours (see 5.4 for time point 
experiment) with ACh (100 and 10 μM), Nicotine (150 and 75 ng/mL) or the 
antimCRP-3H12 antibody (1:10). The concentrations were the same as those 
reported in 5.2 and 5.4 for all the SMIs. After this initial pre-treatment, the 
macrophages were exposed to 100 μg/mL mCRP for 24 hours (see experiment 
4.6). TNF-α, IL-6 and IL-10 were selected, according to the results obtained in 
chapter 4 paragraph 4.6, as cytokines of interest. The cytokine concentrations 
were quantified by ELISA assay.  
ELISA assay was carried out in order to evaluate the TNF-α releases after 
mCRP stimulation. It was observed that mCRP increased the release of TNF-
α (P-value<0.0001). The mCRP pro-inflammatory effect was comparable to 
that of the positive control group (LPS 10 ng/mL). No statistically significant 
differences were observed between the positive control group and the one 
stimulated by mCRP (Fig 5.9). The small molecule (ACh and Nicotine) and 
anti-mCRP3H12 antibody anti-inflammatory activity were also investigated. 
Pre-treatment with ACh at 100 μM (P-value<0.0001) and 10 μM (P-
value=0.0110) significantly reduced TNF-α release. No statistically significant 
differences were observed between the mCRP stimulated group and all other 
groups that had been pre-stimulated with Nicotine or the 3H12 antibody.  
 
The ELISA assay quantified the IL-6 releases after mCRP stimulation. The 
mCRP stimulation increased the release of the IL-6 pro-inflammatory cytokine 
(P-value<0.0001). The IL-6 cytokine release is similar to that observed in the 
positive control group (LPS 10 ng/mL). There were no statistically significant 
differences between the positive control group and the one stimulates by 
mCRP. The SMIs ACh, Nicotine, and anti-mCRP3H12 antibody anti-
inflammatory activity was also assessed. Only the pre-treatment with ACh at 
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100 μM was capable of reducing IL-6 production (P-value<0.0001). No 
statistically significant differences were observed in any of the other groups 
stimulated by ACh (10 μM), Nicotine (P-value 0.9810) or the 3H12 antibody 
(P-value 0.9810). 
 
The ELISA assay quantified the IL-10 releases after mCRP stimulation. As 
shown Fig 5.10, contrary to mCRP, LPS stimulation increased the anti-
inflammatory cytokine IL-10 secretion significantly (P-value 0.0305). There 
were no statistically significant differences (P-value 0.9830) in any of the other 
groups that had previously been stimulated by SMIs (ACh or Nicotine) or the 
3H12 antibody. Fig 5.10 reports the results.  
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Fig 5.9. ACh reduced the concentration of 
both TNF-α and IL-6 cytokines. After 
differentiation (PMA 50 ng/mL for 72 
hours) the macrophages were pre-treated 
with ACh (100 and 10 μM), Nicotine (150 
and 75 ng/mL), or anti-mCRP3H12 antibody 
(1:10) for 2 hours. This was followed by 
mCRP stimulation at 100 μg/mL for 24 
hours. LPS (10 ng/mL for 24 hours) was 
used as a positive control. The TNF-α 
production was quantified by ELISA assay 
(R&D System). The results are shown as the 
average ± SD. ****P-value < 0.0001. *P-
value<0.05. As shown in figure (A), the 
ANOVA One-way test, followed by Tukey's 
post-hoc test, with a 99.9% CI and a 0.001% 
α error (P-value<0.0001), evidenced a 
statistically significant difference between 
the untreated macrophage group and the 
one stimulated by mCRP (132 vs 1128 
pg/mL respectively). The same tests 
determined there were no statistically 
significant differences between the 
positive control group (LPS 10 ng/mL) and 
the one stimulated by mCRP (1247 vs 1128 
pg/mL respectively). The ANOVA One-way test also showed that there were statically significant differences (P-value<0.0001) in the TNF-α expression level between 
the groups where the macrophages had been stimulated by mCRP alone and those where mCRP had previously been incubated with ACh at 100 μM (1128 vs 298.4 
pg/mL respectively) and 10 μM (1128 vs 581.7 pg/mL respectively). The TNF-α reduction in macrophages previously treated with SMI ACh (both 100 and 10 µM) was 
so significant that the ANOVA One-way did not report any statistical differences between the untreated macrophage group and the ACh stimulated groups (P-value 
0.0573). As reported in figure (B), the ANOVA One-way test, followed by Tukey's post-hoc test, with a 99.9% CI and a 0.001% α error, evidence a statistically significant 
difference (P-value <0.0001) between the untreated macrophage group and the mCRP stimulated macrophages (72.32 vs 756.6 pg/mL respectively). The same tests 
evidenced no statistically significant differences (P-value >0.9999) between the positive control group and the mCRP stimulated macrophages (732.4 vs 756.6 pg/mL 
respectively). However, significant differences (P-value<0.0001) were observed between the mCRP-stimulated macrophages and the groups where the mCRP had 
previously been incubated with ACh at 100 μM (756.6 vs 251.7 pg/mL respectively). This reduction was so significant that the ANOVA One-way test did not report 
any statistically significant differences between the untreated macrophage group and the group pre-stimulated with ACh 100 µM (P-value =0.4548) (n=3). 
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Fig 5.10. ACh did not affects the release of IL-10 anti-inflammatory cytokine. The macrophages 
were pre-treated with ACh (100 and 10 μM), Nicotine (150 and 75 ng/mL), or anti-mCRP3H12 
antibody (1:10) for 2 hours. This was followed by mCRP stimulation, at 100 μg/mL, for 24 hours. 
LPS (10 ng/mL for 24 hours) was used as a positive control. The production of IL-10 was quantified 
by ELISA assay (R&D System). The results are shown as the average ± SD. ****P-value<0.0001. 
*P-value<0.05. The ANOVA One-way test, followed by Tukey's post-hoc test, with a 99.9% CI and 
a 0.001% α error, evidenced no statistically significant difference (P-value= 0.9994) between the 
untreated macrophage group and the mCRP stimulated groups (1190 ± 231.2 vs 929 ± 120.9 
pg/mL respectively). The ANOVA One-way test also confirmed a statistically significant difference 
(P-value= 0.0305) between the positive control group and the mCRP stimulated groups (2249 vs 
929 pg/mL respectively). No statistical differences (P-value=0.9830) were observed in any of the 
other groups that had previously been stimulated by SMIs (ACh or Nicotine) or the 3H12 antibody 
(n=3). 
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5.6 The role of both mitogen-activated protein kinases (MAPKs) and 
NF-KB pathways in response to mCRP pro-inflammatory activity.  
 
After having determined that mCRP has a pro-inflammatory activity, the 
possible signalling pathways were investigated. As previously reported in 
chapter 1 paragraph 1.1.9, literature has reported that the activation of  
MAPKp38, JNK and ERK1/2 facilitates pro-inflammatory cytokine release 
(Kyriakis and Avruch, 2001). It was reported by de Oliveira et al. (2017) that 
when macrophages were treated by LPS, they up-regulated the 
MAPKp38/JNK/NF-KB intrinsic pathways through an increase in pro-
inflammatory cytokines, such as IL-1β and TNF-α levels. Lim et al. (2018) 
reported that LPS-induced phosphorylation of both ERK and JNK but not 
MAPKp38 in BV-2 Microglia. It is known that mCRP pro-inflammatory activity 
in both leukocytes and ECs is triggered when MAPKs or NF-KB are activated 
(Tarek et al., 2002; Tarek et al., 2004; Tarek et al., 2006; Turu et al., 2008). 
However, to the best of my knowledge, no studies have been able to detect 
any critical intrinsic pathways activated by mCRP on macrophages (Eisenhardt 
et al., 2011). Thus, a western blot assay was carried out to study whether 
activation of MAPKp38, JNK, ERK 1/2 and NF-KB through their 
phosphorylation, were linked to mCRP pro-inflammatory activity in monocyte 
U937 differentiated macrophages. Next, ACh and Nicotine were also tested 
before incubation with mCRP to assess whether they were capable of reducing 
MAPKp38, JNK, ERK 1/2 and NF-KB phosphorylation in agreement with data 
from international literature (Yoshikawa et al., 2006b; Sun et al., 2013a; Lim et 
al., 2018).  
 
The results reported in Fig 5.11 showed that LPS, at 10 ng/mL and the use of 
mCRP alone, at 100 μg/mL, increased the phosphorylation level of ERK 1/2, 
JNK 1/2, MAPKp38 and NF-KB. These results (Fig 5.11) also confirmed that 
both ACh, at 100 and 10 μM and Nicotine alone at 150 ng/mL, do not increase 
the phosphorylation of ERK 1/2 and JNK 1/2 but they do increase the release 
of MAPKp38. The NF-KB phosphorylation was also increased when the 
macrophages were exposed to ACh (100 and 10 μM) alone. The resulting data 
also showed that when macrophages were pre-treated with ACh (100 and 10 
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μM) or Nicotine (150 ng/mL) both the SMIs were also able to reduce the ERK 
1/2, JNK 1/2 and NF-KB phosphorylation induced by mCRP (100 μg/mL). 
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Fig 5.11. The role of both MAPKs and NF-KB pathways in response to mCRP pro-inflammatory 
activity. Following differentiation (PMA 50 ng/mL for 72 hours), monocyte-differentiate 
macrophages were stimulated by ACh (100 and 10 µM), or Nicotine (150 ng/mL) whether or not 
mCRP (100 μg/mL) was present for eight minutes. LPS (10 ng/mL) for 8 minutes was used as a 
positive control. After disposal of the medium, the macrophages were washed twice with PBS, 
followed by addition of 250 μl of lysis buffer containing a protease inhibitor and phosphatase 
inhibitor cocktails. Lane 1, untreated macrophage; Lane 2, LPS (10 ng/mL); Lane 3 mCRP (100 
μg/mL); Lane 4 ACh (100 μM) + mCRP (100 μg/mL); Lane 5 ACh (10 μM) + mCRP (100 μg/mL); 
Lane 6 Nicotine (150 ng/mL) + mCRP (100 μg/mL); Lane 7 ACh (100 μM); Lane 8, ACh (10 μM) 
alone; Lane 9, Nicotine (150 ng/mL) alone. The mCRP induced phosphorylation of ERK1/2 (B), JNK 
1/2 (C), NF-КB (D) and MAPKp38 (E). When the macrophages were pre-treated with ACh (100 and 
10 μM) or Nicotine (150 ng/mL) for 8 minutes, there was a reduced ERK1/2, JNK 1/2 and NF-КB 
phosphorylation (n=2). 
173 | P a g .  
   
5.7 RT-PCR data demonstrated that macrophage pre-stimulation 
with SMI (ACh and Nicotine) was not able to reduce the mCRP 
induced cytokine RNA expression. 
 
After confirming the activation of the intrinsic pro-inflammatory pathway, the 
next step was to determine whether the ACh was capable of reducing the 
release of pro-inflammatory cytokines, downregulating both the IL-1β and IL-6 
gene expression. The gene expression of pro (IL-1β and IL-6) and anti (IL-10) 
inflammatory cytokines was determined by RNA isolated from the samples and 
analysed by RT-PCR. In this experiment, the TNF-α gene expression was 
replaced by the IL-1β gene expression, due to the short TNF-α mRNA life-span 
(even when there was a high TNF-α cytokine secretion), as reported in a 
previous study (Mijatovic et al., 2000). LPS, mCRP and SMI concentrations 
and time-point were the same of experiment 5.5.  
 
As expected, there was a statistically significant upregulation of IL-1β in the 
mCRP-stimulated group, after 24 hours (Fig 5.12). Furthermore, the average 
IL-1β gene expression was higher in the experimental group (mCRP alone) 
than in the untreated macrophage and positive control group (LPS 10 ng/mL). 
None of the inhibitors under investigation were able to reduce this increase.  
 
There was a statistically significant upregulation of IL-6 in the mCRP-
stimulated group after 24 hours. The average IL-6 gene expression was higher 
in the experimental group (mCRP alone) than in the untreated macrophage 
group and the positive control group. No statistically significant differences 
were observed between the mCRP group and the group that had previously 
been treated with SMIs. Fig 5.13 reports the results. 
 
The ELISA assay data (chapter 4, paragraph 4.6) evidenced that there was no 
statistically significant upregulation of IL-10 in the mCRP-stimulated group 
after 24 hours. The data on the IL-10 gene are in line with the previous ELISA 
assay, which confirm that there were no differences in the IL-10 cytokine 
release between the untreated macrophage group and the groups stimulated 
with mCRP (P-value=0.3301). Fig 5.14 reports the results. 
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Fig 5.12. Pre-stimulation with SMIs (ACh and Nicotine) did not reduce the mCRP-induced mRNA-
IL-1β expression. Following differentiation (PMA 50 ng/mL for 72 hours), the monocyte 
differentiate macrophages were pre-treated with ACh (100 and 10 μM) or Nicotine (150 and 75 
ng/mL) for 2 hours. This was followed by mCRP stimulation at 100 μg/mL, for 24 hours. LPS (10 
ng/mL for 24 hours) was used as a positive control. The IL-1β gene expression was quantified by 
both the TaqMan™ Fast Advanced Master Mix and the TaqMan® Gene Expression Assays. The 
results are shown as the average ± SD. *P-value < 0.05. The One-tailed unpaired t-test, with a 95% 
CI and a α error fixed at 5%, evidenced a statically significant difference (P-value<0.0296) between 
the untreated macrophage group and the group stimulated with mCRP. The ANOVA One-way test 
did not evidence any statistically significant differences between the untreated macrophage 
group and the mCRP group (P-value=0.7768). The ANOVA One-way test also confirmed that there 
were no statistically significant differences between the mCRP group alone and all the other 
groups previously stimulated by ACh or Nicotine (P-value=0.9944) (n=3). 
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Fig 5.13. Pre-stimulation with SMI (ACh and Nicotine) did not reduce the mCRP-induced mRNA-
IL-6 expression. Following differentiation (PMA 50 ng/mL for 72 hours), the monocyte 
differentiate macrophages were pre-treated with ACh at 100 and 10 μM or Nicotine at 150 and 
75 ng/mL for 2 hours. This was followed by mCRP stimulation at 100 μg/mL, for 24 hours. LPS (10 
ng/mL for 24 hours) used as a positive control. The IL-6 gene expression was quantified by both 
the TaqMan™ Fast Advanced Master Mix and the TaqMan® Gene Expression Assays. The results 
are shown as the average ± SD. **P-value<0.01 *P-value < 0.05. The One-tailed unpaired t-test, 
with a 95% CI and a α error fixed at 5%, evidenced a statistically significant difference (P-
value<0.0014) between the untreated macrophage group and the mCRP group. A statistically 
significant difference (P-value=0.0077) was observed between the positive control group and the 
mCRP group. The ANOVA One-way test did not evidence any statistically significant differences 
between the untreated macrophage group and the mCRP group (P-value= 0.7768). The ANOVA 
one-way test also evidenced that there were no statistically significant differences between the 
mCRP group alone and all the other groups that had previously been treated with ACh or Nicotine 
(n=3). 
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Fig 5.14. Pre-stimulation with SMI (ACh and Nicotine) did not affects the mCRP-induced mRNA-
IL-10 expression. Following differentiation (PMA 50 ng/mL for 72 hours), the monocyte 
differentiate macrophages were pre-exposed to ACh (100 and 10 μM) or Nicotine (150 and 75 
ng/mL) for 2 hours. This was followed by mCRP (100 μg/mL) stimulation for 24 hours. LPS (10 
ng/mL for 24 hours) was used as a positive control. The IL-10 gene expression was quantified by 
both the TaqMan™ Fast Advanced Master Mix and the TaqMan® Gene Expression Assays. The 
results are shown as the average ± SD.*P –value < 0.05. The ANOVA One-way test, followed by 
Tukey's post-hoc test, with a 99.9% CI and an α error of 0.001%, did not evidence any statistically 
significant differences (P-value<0.0001) amongst all the groups. Furthermore, the average IL-10 
gene expression was lower in the experimental groups (mCRP alone) than in the untreated 
macrophage group (n=3).  
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5.8 Methyllycaconitine (MLA) citrate toxicity analysis on U937-
derived macrophages. 
After observing that ACh had anti-inflammatory effects, the next step was to 
evaluate whether its anti-inflammatory activity was due to α7nAChR. As 
reported in literature, MLA is a selective α7nAChR antagonist (Sun et al., 
2013a; Krafft et al., 2017; Patel et al., 2017; Zou et al., 2017). To support the 
aforementioned, MLA was used to block the α7nAChR activation.  
 
MLA cytotoxic activity was evaluated first. A cell viability assay was performed 
to determine whether MLA had cytotoxic effects that could lead to cell death 
after 24-hours of stimulation. The macrophages were incubated with MLA for 
24 hours, in a range between 0 and 200 μM, i.e., two-fold the highest ACh 
working concentration (100 μM) used in the previous experiments to determine 
a safe MLA concentration.  
 
As reported in Fig 5.15 and Table 5.4, MLA did not show any cytotoxic effects 
in a range between 0-200 μM. Therefore, on the basis of these results, a 
working concentration of 200 μM was selected to assess whether MLA alone 
or in combination with ACh and Nicotine, induced pro-inflammatory effects on 
U937 macrophages.  
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% Viable cells  5.20 99.99 104.43 105.93 104.43 101.84 101.88 102.82 103.09 104.91 
 
Fig. 5.15. and Table 5.4. Methyllycaconitine (MLA) citrate toxicity analysis on U937-derived 
macrophages. Following differentiation (PMA 50 ng/mL for 72 hours), the monocyte differentiate 
macrophages were pre-exposed to a media containing RPMI 1640 with L-glutamine (1640 
medium Lonza), supplemented with 10% FBS (F9665 Sigma®) and MLA (from 1.5 μM to 200 μM). 
Ethanol (20% total volume for 24 hours) was used as a positive control. Cell viability was evaluated 
by the CellTiter-Blue®Cell Viability Assay (Promega). The results are shown as the average ± SD. 
****P-value< 0.0001. The results herein reported confirm that MLA did not have cytotoxic effects 
in a range between 0-200 μM. The ANOVA One-way test, along with Tukey's post-hoc test, 
confirmed that there was a statically significant difference (P-value<0.0001) between the positive 
control group (20% Ethanol) and the untreated macrophage group. There was no statistically 
significant difference between the untreated macrophage group and all groups stimulated by 
MLA, at a concentration ranging from 0 µM to 200 µM (P-value =0.8943). (n=3).  
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5.9 ACh and Nicotine with and without MLA as a method to evaluate 
pro-inflammatory effects on U937 macrophages.  
 
After having determined that MLA had no cytotoxic effect, MLA alone or 
together with SMIs (ACh and Nicotine), were tested to corroborate that they 
did not induce any pro-inflammatory activity on U937 macrophages. The MLA 
working concentration used for these experiments, i.e., 200 and 100 μM were 
based on the previous experiment reported in chapter 5, paragraph 5.8. These 
two MLA concentrations were identical or two-fold the highest ACh working 
concentration of 100 μM used in the previous experiment. The ACh and 
Nicotine concentration and time-points were the same as those in experiment 
5.4. The TNF-α pro-inflammatory cytokine level was evaluated by ELISA 
assay. The TNF-α pro-inflammatory cytokine was selected on the basis of the 
same concepts expressed in chapter 4, paragraph 4.6.  
 
As reported in Fig 5.16, the TNF-α cytokine concentrations between the 
untreated macrophage, positive control and the MLA stimulated groups at 200 
μM and 100 μM, with or without ACh (100 μM and 10 μM) or Nicotine (150 
ng/mL and 75 ng/mL) after 24 hours, were evaluated. No statistically significant 
difference was observed between the untreated macrophage group and the 
groups stimulated by MLA alone or in combination with both ACh or Nicotine. 
There was a statistically significant difference between the untreated 
macrophage group and the positive control, as well as the positive control and 
the SMI groups.  
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Fig 5.16. MLA alone or together with SMIs did not induce any pro-inflammatory activity on U937 
macrophages. The macrophages were pre-exposed to a media containing RPMI 1640 with L-
glutamine (1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and MLA (200 
and 100 μM), for 2 hours. This was followed by ACh stimulation at 100 and 10 μM, or Nicotine, at 
150 and 75 ng/mL, for 24 hours. LPS alone (10 ng/mL) was used as a positive control for 24 hours. 
The TNF-α production was quantified by ELISA assay (R&D System). The results are shown as the 
average ± SD. ****P-value< 0.0001. The One-way ANOVA test, followed by Tukey’s post-doc test, 
with a 99.9% CI α error fixed at 0.001%, evidenced no statistically significant differences between 
the untreated macrophage group and groups stimulated by MLA alone or in combination with 
both ACh or Nicotine. The only statistically significant difference (P-value<0.0001) was observed 
between the positive control group and all the other groups. (n=3). 
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5.10 MLA did not have any general LPS anti-inflammatory effect on 
macrophages. 
 
After having demonstrated that MLA at 200 and 100 μM did not have any pro-
inflammatory activity on macrophages and before testing MLA specific activity 
to block α7nAChR activation, it became essential to assess whether MLA was 
characterised by anti-inflammatory proprieties. In this experiment the U937 
differentiated macrophages were treated with LPS at 10 ng/mL, both with or 
without 200 µM of MLA, for 24 hours. The MLA concentration was selected on 
the basis of the data obtained in experiment 5.9. An MLA pre-treatment time 
point of 2 hours was the best time-point obtained in experiment 5.4. The TNF-
α pro-inflammatory cytokines used were selected on the basis of the same 
notions expressed in chapter 4, paragraph 4.6. The TNF-α production in 
macrophages was assessed after LPS stimulation at a concentration of 10 
ng/mL, for 24 hours.  
 
The ELISA assay demonstrated that MLA alone did not reduce the TNF-α in 
pro-inflammatory cytokine release. As shown in Fig 5.17, there was no 
statistically significant difference amongst the LPS group and the groups with 
or without pre-MLA treatment. The MLA activity effects were neither pro-
inflammatory nor anti-inflammatory. 
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Fig 5.17. MLA did not reduce lipopolysaccharide (LPS) inflammatory effect in macrophages. The 
monocyte differentiated macrophages were pre-exposed to a media containing RPMI 1640 with 
L-glutamine (1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and MLA (200 
μM) for 2 hours, then stimulated by LPS (10 ng/mL), for 24 hours. LPS alone, at 10 ng/mL, was 
used for 24 hours as a positive control. The pro-inflammatory cytokine TNF-α was estimated by 
ELISA assay (R&D System). The results are shown as the average ± SD. ****P-value<0.0001. The 
One-way ANOVA test evidenced a statically significant difference (P-value<0.0001) amongst the 
untreated macrophage group and the LPS stimulated groups (442.2 vs 1030 pg/mL). No 
statistically significant difference was observed amongst the LPS stimulated groups, with and 
without pre-MLA treatment (P-value= 0.9989). (n=3). 
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5.11 Studying the MLA association according to the pro-inflammatory 
response. 
 
The effect MLA had on inflammation was also tested by the western blot assay. 
To this aim, the MLA-response activation of MAPKp38 and NF-KB was 
evaluated. This was based on the data reported in paragraph 5.6, which 
confirmed that when macrophages were stimulated by ACh and Nicotine only, 
there was an increase in MAPKp38 and/or NF-KB phosphorylation. 
 
As shown in Fig 5.18, LPS stimulation increased the phosphorylation of both 
MAPKp38 and NF-KB. Whereas in all the MLA stimulated groups, with or 
without SMIs (ACh or Nicotine), phosphorylation was minimal or completely 
absent. 
 
The trend herein reported evidenced that MLA alone or in combination with 
ACh or Nicotine was not able to activate any signalling pathways that may 
have been associated with a pro-inflammatory response.  
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Fig 5.18. MLA alone or in combination with ACh or Nicotine did not activate any signalling 
pathways. Macrophages were pre-stimulated with a media containing RPMI 1640 with L-
glutamine (1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) with or without 
MLA (200 μM), ACh (100 and 10 μM) or Nicotine (150 and 75 ng/mL), for 8 minutes. LPS alone at 
10 ng/mL for 8 minutes, was used as a positive control. Lane 1, untreated macrophage; Lane 2, 
LPS (10 ng/mL); Lane 3 and 4, MLA (200 and 100 µM) Lane 5 (MLA 200 + ACh100 µM), Lane 6 
(MLA 200 + ACh10 µM), Lane 7 (MLA 200 + Nic 150 ng/mL), Lane 8 (MLA 200 + Nic 75 ng/mL). As 
reported in this figure, phosphorylation was minimal or completely absent in all groups treated 
with MLA (with or without SMIs ACh or Nicotine). (n=1).  
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5.12 MLA did not reverse ACh anti-inflammatory capacity but did reduce 
TNF-α release. 
Therefore, so as to determine if the anti-inflammatory effects of ACh were 
mediated by α7nAChR, the next step involved assessing whether MLA could 
reverse the ACh anti-inflammatory activity. MLA and the SMIs (ACh or 
Nicotine) were incubated together to analyse whether MLA was able to block 
or reduce the anti-inflammatory activity of a selected ACh SMI. 
 
The macrophages were stimulated by MLA (200 µM) for 2 hours and then ACh 
(100 and 10 µM) or Nicotine (150 and 75 ng/mL) and mCRP 100 µg/mL. Both 
SMIs and mCRP at the same time-point and concentration as those used in 
experiment 5.5. The TNF-α cytokine concentration was quantified by ELISA 
assay. The TNF-α pro-inflammatory cytokines were chosen on the basis of the 
same notions expressed in chapter 4, paragraph 4.6. 
 
As reported in Fig 5.19, mCRP increased the TNF-α release substantially. 
There was a substantial TNF-α inhibition in the group pre-stimulated by ACh 
at 100 µM. Surprisingly, the results of this experiment evidenced that not only 
did MLA and ACh used together (100 and 10 µM) not reverse ACh anti-
inflammatory capacity, but rather emphasised it. Fig 5.19. reports the results.  
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Fig 5.19. MLA did not reverse ACh anti-inflammatory capacity however it did decrease TNF-α 
release. Macrophages were pre-stimulated with a media containing RPMI 1640 with L-glutamine 
(1640 medium Lonza) supplemented with 10% of FBS (F9665 Sigma®) and MLA (200 μM) for 2 
hours followed by another 2 hours of SMI stimulation (ACh or Nicotine). Then, macrophages were 
stimulated by mCRP (100 μg/mL), for 24 hours. LPS at a concentration of 10 ng/mL for 24 hours 
was used as a positive control. The TNF-α production was quantified by ELISA assay (R&D System). 
The results are shown as the average ± SD. ****P-value < 0.0001, **P-value < 0.01. As reported 
in the figure, surprisingly MLA did not reduce ACh anti-inflammatory activity but rather led to an 
increase. The One-way ANOVA test, followed by Tukey’s post-doc test confirmed a statistically 
significant reduction (P-value=0.0078) in TNF-α release when MLA (200 µM) and ACh (100 and 10 
µM) were combined. (n=3). 
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5.13 Discussion. 
 
It has been reported that monomeric-CRP (mCRP) is generated by activated 
platelets near the atherosclerotic plaques when nCRP bind to membrane lipids 
and come into contact with derivates of phosphatidylcholine (PC) exposed on 
the cell membrane (Eisenhardt et al., 2009b). This mCRP has been observed 
close to inflammation tissue (Eisenhardt et al., 2009b; Slevin et al., 2010), 
along with an increase in CD68+ monocytes/macrophages (Thiele et al., 
2014a), associated to a strong pro-inflammatory activity and pro-inflammatory 
cytokine release (Slevin et al., 2015; McFadyen et al., 2018). An increase in 
pro-inflammatory cytokines is frequently associated to an increase in non-
neuronal serum Acetylcholine (ACh) (Zhang et al., 2016). CAIP release ACh 
to attenuate the pro-inflammatory mediator release (Duris et al., 2017) and 
counterbalance the potential negative effects of the pro-inflammatory cytokine 
release during the acute-phase response (Gruys et al., 2005; Jain et al., 2011). 
Therefore, this project aimed at evaluating the mCRP immune regulatory 
properties. This was done by using an in vitro inflammation model with 
monocyte-like U937 cells differentiated into macrophages. Furthermore, taking 
into consideration that both ACh and Nicotine showed anti-inflammatory 
effects (Lakhan and Kirchgessner, 2011; Han et al., 2017), a series of 
experiments were carried out during this project to establish whether and how 
ACh or Nicotine could reduce mCRP pro-inflammatory activity. 
 
The results reported during this PhD project showed that, (I) ACh and Nicotine 
were not cytotoxic to the U937-derived macrophages, (II) did not increase 
cytokine release, and (III) did not activate any signalling pathways that could 
have been associated with a pro-inflammatory response. However, the results 
of the experiments carried out in this project are in disagreement with data 
from studies which report that both ACh and Nicotine have strong anti-
inflammatory proprieties in LPS stimulated macrophage cells (Yoshikawa et 
al., 2006b; Liu et al., 2015a), as reported in Fig. 5.6 and Fig. 5.7. This 
discrepancy might be explained by the fact that the LPS and SMI 
concentrations and time-point stimulation in these two studies differed 
substantially (Yoshikawa et al., 2006b; Liu et al., 2015a). 
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Literature data report that once MAPKp38, JNK1/2, ERK1/2 and NF-KB are 
activated they increase pro-inflammatory mediator release (Kyriakis and 
Avruch, 2001; de Oliveira et al., 2017; Lim et al., 2018). Some findings also 
indicate that when ECs are stimulated by mCRP (Li et al., 2014), these cells 
increase the secretion of some pro-inflammatory mediators, such as IL-6, 
ICAM-1 and VCAM-1, through the activation of MAPKs and NF-KB intrinsic 
pathways (Yang et al., 2008; Eisenhardt et al., 2009b; Yong and Cao, 2020). 
However, a previous study did not identify any intrinsic pathways triggered by 
mCRP on macrophages (Eisenhardt et al., 2011). This led to the assessment 
of whether these signalling pathways could also be triggered in U937 
monocyte-differentiated macrophages after mCRP treatment, in this project.  
 
The results herein reported are in agreement with the statement that mCRP 
increases pro-inflammatory levels of TNF-α and IL-6 cytokines (Fig 5.9) 
through ERK 1/2, JNK 1/2, MAPKp38 and NF-КB phosphorylation (Fig 5.11). 
ACh alone, at 100 and 10 µM, increase MAPKp38 and NF-КB phosphorylation. 
Nicotine alone at 150 ng/mL, increases only the MAPKp38 phosphorylation. 
However, none of the aforementioned SMIs were associated with an increase 
in JNK1/2 and ERK1/2 phosphorylation or pro-inflammatory cytokine release 
(Fig 5.11). Furthermore, although pre-treatment with either ACh or Nicotine 
was able to reduce ERK1/2, JNK1/2 and NF-KB phosphorylation caused by 
mCRP, ACh was the only SMI capable of limiting the increase of mCRP 
induced pro-inflammatory cytokines (Fig 5.11).  
 
The RT-PCR experiments herein reported showed that mCRP increases the 
IL-1β and IL-6 gene expression. However, none of the SMI inhibitors under 
study were able to reduce significantly either the IL-1β or IL-6 RNA expression 
in this model of inflammation (Fig 5.12 and Fig 5.13). All results presented 
during this project validated that SMIs were able to reduce IL-1β gene 
expression, even if statistical significance was not reached. This was also 
observed when ACh was used at a concentration of 100 µM (24.79 % the 
highest reduction). Of particular interest is that fact that although ACh is able 
to reduce the pro-inflammatory protein concentration, it does not downregulate 
IL-1β and IL-6 gene expression. A possible explanation for this can be found 
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in the literature. Indeed, Clark et al. (2009) reported that when inflammatory 
stimuli, such as IL-1, TNF, or LPS, activate the transforming growth factor β–
activated kinase 1 (TAK1) this macro complex protein triggers the MAPKp38 
signalling pathway. Once MAPKp38 is activated, it is able to increase the 
MK2/3 and the mRNA decay-promoting protein tristetraprolin (TTP) 
phosphorylation (Hitti et al., 2006). Moreover, it has been reported that TTP 
phosphorylation leads to the loss of binding to AU-rich elements (AREs), 
increasing cytokine mRNA stability and translation (Khabar, 2014). Borovikova 
et al. (2000) reported that ACh reduced pro-inflammatory cytokine release 
through a post-transcriptional event, whilst Waldburger et al. (2008) stated that 
ACh reduced the half-life of IL-6 mRNA from 13.8 hours to 6.5 hours. 
Therefore, taking in consideration that both ACh and Nicotine were able to 
reduce the ERK and JNK intrinsic pathway (Fig 5.11), without reducing the 
MAPKp38 phosphorylation or the interleukin gene expression (Fig 5.11), the 
reduction of the protein cytokine concentration might well depend on the 
capacity ACh has to intervene at a post-transcriptional level (Fig 5.20), through 
the involvement of microRNA-132 (miR-132), in line with  what was previously 
reported by Liu et al. (2015c).  
 
Although ACh and Nicotine have been reported to have anti-inflammatory 
proprieties (Lakhan and Kirchgessner, 2011; Mihara et al., 2017) the results of 
the experiments carried out in this project showed that only ACh was able to 
reduce mCRP pro-inflammatory activity (Fig 5.9). Nicotine did not play an anti-
inflammatory role. This is most likely connected to the fact that Nicotine itself 
can increase nCRP expression through the nAChR and nAChR-MAPK 
signalling pathways on U937-monocyte differentiated macrophages (Mao et 
al., 2012). This increase may also interfere with the potential anti- inflammatory 
activity of Nicotine against the mCRP (Fig 5.21). 
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Fig 5.20. ACh reduced the pro-inflammatory cytokines concentration due to its ability to reduce the phosphorylation of the ERK/JNK/ NF-KB intrinsic pathway. 
Monomeric-CRP promote the activation of the (TAK1) signalling complex. TAK1 then activates MKK3 and IKK. MKK3 then lead to MAPKp38 phosphorylation, which, 
in turn induce MK2/3 phosphorylation and the nuclear translocation of the transcription factor NF-KB. mCRP can also promote MEKK1 activation. MEKK1 then 
activates JNK 1/2. Then JNK 1/2 phosphorylated cause the nuclear translocation of the NF-KB transcription factor. mCRP can also trigger the Ras-Raf-MEK-ERK1/2 
pathway. When ERK1/2 are activated this activation facilitates the nuclear translocation of the NF-KB transcription factor. NF-KB increase the mRNA expression of 
several pro-inflammatory cytokines, which can be translate into protein when MK2/3 (previously phosphorylated by MAPKp38) and TTP also become phosphorylated. 
The use of ACh to block JNK1/2 and ERK1/2 phosphorylation can also reduce the nuclear translocation of the NF-KB transcription factor. ACh is not able to block 
MAPKp38 phosphorylation, which promotes NF-KB nuclear translocation. However, although NF-KB increase the pro-inflammatory gene expression (mRNA), ACh can 
intervene at a post-transcriptional level, reducing the life of mRNA.  
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After observing ACh anti-inflammatory effects, the next step was to evaluate 
whether ACh anti-inflammatory activity could be triggered through the 
activation of α7nAChR. Over the past few years, numerous studies have 
postulated that the activation of α7nAChR and/or the use of the α7nAChR 
agonist (ACh and Nicotine) could be a useful and innovative treatment for 
several medical conditions (Liu et al., 2015b; Lombardo and Maskos, 2015; 
Han et al., 2017; Xu et al., 2019). For example in stroke, where the presence 
of mCRP has been confirmed (Slevin et al., 2010), an in vivo study also 
reported that α7nAchR activation could reduce sensorimotor deficits, lesion 
size, neural decease, the presence of CD68+ cells, the ratio between M1 and 
M2 microglia and the NF-KB activity (Han et al., 2014).  
 
So as to evaluate α7nAchR activation, methyllycaconitine (MLA), recognised 
as a selective α7nAchR antagonist (Carroll et al., 2007; Patel et al., 2017; Krafft 
et al., 2017; Zou et al., 2017), was tested to observe whether it could reduce 
ACh anti-inflammatory properties. The results confirmed that (I) in appropriate 
concentrations (from 0 to 200 μM) MLA was not cytotoxic to the U937 derived 
macrophages (II) alone or in combination with ACh and Nicotine MLA did not 
induce any pro or anti-inflammatory effects on U937 macrophages. However, 
contrary to expectations, MLA did not reverse the ACh anti-inflammatory 
capacity but enhanced the ACh anti-inflammatory proprieties, reducing TNF-α 
release even further Fig 5.19. These results suggest that MLA could also 
potentially play an anti-inflammatory role, as previously reported for microglia 
cells (Thomsen and Mikkelsen, 2012). Therefore, as the data from the 
experiments showed that both ACh and MLA had the same anti-inflammatory 
activity on macrophages, the idea that α7nAchR is in some way involved in the 
ACh anti-inflammatory activity cannot be rejected as both ACh and MLA bind 
to α7nAchR. Moreover, it may be that the anti-inflammatory activity of ACh is 
mediated by another receptor, i.e., the muscarinic Acetylcholine receptor 
(mAChR) (Fujii et al., 2017).  
 
Muscarinic receptors are extensively diffused in human body tissue and 
facilitate various physiological tasks, depending to their location and  
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Fig 5.21. Nicotine did not reduce the pro-inflammatory cytokines concentration due to its ability to activate nAChR-MAPK signalling pathways. As herein reported, 
it is most likely that Nicotine does not reduce pro-inflammatory cytokine release, as by the activation of the TAK1-MEKK3-MAPKp38-NF-KB signalling pathway it is 
able to synthesis and release nCRP.  
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receptor subtype (Caulfield and Birdsall, 1998). Literature reports that there 
are 5 different mAChR subtypes (from M0 to M5) (Bonner, 1989), which allow 
the neurotransmitter ACh to bind and carry out their physiological functions 
(Kellar et al., 1985) and that the mAChR subtypes are also associated with a 
strong anti-inflammatory and antioxidant activity (Frinchi et al., 2019). All five 
mAChRs have been confirmed in immune system cells, such as B cells, 
macrophages and DCs (Kawashima et al., 2007). Indeed, Koarai et al. (2012) 
reported that human monocytes express all 5 mAChR subtypes but that the 
expression of M1, M2 and M3 receptors on monocyte-differentiated 
macrophages are considerably higher than on monocytes. Therefore, the 
current bibliography could support the hypothesis that the anti-inflammatory 
effect of ACh may not only be mediated by the α7nAchR, but also by at least 
one of the aforementioned mAChR.  
 
5.14 Key findings: 
 
The key findings of the experiments described in this chapter are: 
• Before testing the anti-inflammatory activity of both ACh and Nicotine, 
these two SMIs were tested by a cell viability and cell apoptosis assay, 
to assess whether SMIs had cytotoxic effects that might lead to cell 
death. It was observed that neither ACh nor Nicotine triggered pro-
inflammatory activity on monocyte U937-differentiated macrophages.  
 
• The second step was that of carrying out experiments to assess 
whether mCRP pro-inflammatory activity could be blocked, or at least 
reduced, by one of these two SMIs or by the use of the anti-mCRP 
antibody. The result herein reported confirmed that the mCRP pro-
inflammatory activity were limited when the macrophages were 
previously pre-treated with ACh, at concentration of 100 µM.  
 
• The activation of MAPKp38, JNK, ERK1/2 and NF-KB are strong 
players involved in the increase of pro-inflammatory cytokines on 
macrophages (Liu et al., 2003; Moens et al., 2013; de Oliveira et al., 
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2017; Lim et al., 2018). The results herein reported showed that mCRP 
is able to increase the phosphorylation of ERK1/2, JNK, MAPKp38 and 
NF-KB. Furthermore, although both ACh and Nicotine reduced ERK 
1/2, JNK 1/2, NF-KB phosphorylation, only ACh was able to reduce the 
pro-inflammatory cytokine release through a pre- and post-
transcriptional event.  
 
• Another objective of this study was to assess whether ACh had anti-
inflammatory activity on macrophages through the activation of the 
α7nAchR. To this aim α7nAchR antagonist MLA was used. Contrary to 
expectations, this α7nAchR antagonist did not reduce the ACh anti-
inflammatory activity but rather exacerbated it.  
5.15 Summary. 
 
During the first phase of the inflammation process the increase in pro-
inflammatory cytokines has been associated with an increase in non-neuronal 
serum ACh, due to the activation of CAIP. Several studies have confirmed that 
this neurotransmitter has anti-inflammatory properties, during the last few 
years. This prompted the study of whether, two cholinergic compounds, i.e., 
ACh and Nicotine, were able to reduce the mCRP pro-inflammatory effects. 
 
The aforementioned experiments showed that mCRP has pro-inflammatory 
activity and that its capacity to increase pro-inflammatory cytokine release is 
associated with an increase in the phosphorylation of both the MAPK and NF-
KB signalling pathways. Contrary to Nicotine, the SMI ACh exerted anti-
inflammatory activity against mCRP and these anti-inflammatory proprieties 
have been associated with the capacity of ACh to intervene at both a pre- and 
post-transcriptional level. 
 
In conclusion, specific molecules, such as ACh or other SMIs of similar 
structure, potentially have a role as inhibitors for mCRP pro-inflammatory 
activity. 
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CHAPTER 6: GENERAL DISCUSSION. 
 
The research carried out during this project focused on obtaining a better 
understanding of the pro-inflammatory role of mCRP, as well as its 
downstream inflammasome signalling pathways and potential treatments. A 
series of experiments were carried out to establish if and how mCRP is able to 
promote inflammation activity. The experiments described ranged from dot blot 
analysis to in vitro studies and analyses as to potential signalling on monocyte-
derived macrophages, through analyses of the genetic effects of mCRP. This 
project provided novel data on the effects of mCRP isoform in an inflammation 
model, based on monocyte-derived macrophages and the potential 
contribution of the small molecule inhibitor Acetylcholine (ACh) as a possible 
inhibitor of inflammatory mCRP.  
 
6.1 How ACh affects the dissociation of nCRP to mCRP. 
Inflammation is the first stage of the wound healing process (Chen et al., 2018) 
which induces an increase of several pro-inflammatory mediators (Freire and 
Dyke, 2013; Čejková et al., 2016) and APPs, like nCRP (Gans et al., 2015; 
Zhou et al., 2016). nCRP is a protein, made up of five different monomers 
(Osmand et al., 1977), assembled through disulfide bonds (Goodman et al., 
1996) and symmetrically positioned around a central hole (Thompson et al., 
1999; Pepys and Hirschfield, 2003; Du Clos and Mold, 2004). Under 
physiological conditions, nCRP maintains its pentameric form (Eisenhardt et 
al., 2009a). However, recent literature has reported that the stability of nCRP 
could be alternated in some in vitro and in vivo conditions (Salazar et al., 2014). 
This prompted the study of two different dissociation methods for nCRP in 
mCRP. 
 
The results reported in chapter 3 evidence that the stability of nCRP is 
compromised when it is immersed in a buffer (Fig. 3.2) with a high urea 
concentration (8 M) in the presence of EDTA (10 mM) (Potempa et al., 1983; 
Potempa et al., 2015). Moreover, as previously reported by Taylor and Van 
Den Berg (2007), the results confirmed that the dissociation from nCRP to 
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mCRP could also be acquired by warming the nCRP to a temperature of +70 
°C for one hour (Fig. 3.3). However, it was observed that warming the nCRP 
had a strong influence on the capacity the anti-mCRP3H12 antibody had to 
bind to the mCRP pro-inflammatory form (Fig. 3.3).  
 
The last decade has witnessed the publication of several studies reporting that, 
when nCRP is dissociated into mCRP, the monomer obtained has strong pro-
inflammatory proprieties (Tarek et al., 2006; Molins et al., 2008; Potempa et 
al., 2015), potentially associated with chronic kidney disease (Schwedler et al., 
2003), thrombosis in atherosclerosis (Eisenhardt et al., 2009b) and 
neurological degradation and/or dementia (Slevin et al., 2015) and macular 
degeneration (Chirco et al., 2016). The well-defined connection between 
nCRP-mCRP dissociation and inflammation implies that inhibition of this 
separation is a realistic pharmacological approach for a wide spectrum of 
disorders correlated to mCRP and inflammation (Thiele et al., 2015). 
Previously published results state that 1,6-bis(phosphocholine)-hexane (1,6-
bis-PC) is the only nCRP-mCRP dissociator inhibitor (Thiele et al., 2014a). 
Experiments were carried out to determine whether the use of the 
neurotransmitter ACh, which is similar in structure to 1,6-bis-PC (Slevin et al., 
2018), is able to prevent this dissociation. This hypothesis was further 
supported by a previous study which confirmed that nCRP induced lower ACh 
levels in plasma via a capture process (Nazarov et al., 2007). 
 
The results herein confirmed that ACh was not able to block nCRP-mCRP 
dissocation (Fig. 3.4 and Fig. 3.5). This most likely occurred as the SMIs might 
bind to nCRP at a site where dissociation does not take place. Furthermore, in 
the computational docking analysis, it appears that the SMIs tested were not 
able to inhibit the nCRP dissociation in subunits. This might be due to a lower 
binding activity or because the SMIs are sequestered in a different binding 
pocket as shown in Fig. 3.4. Furthermore, it seems that the energy bond of 
ACh compared to 1,6-bisPC, is insufficient for a stable interaction, despite its 
similarity with 1,6-bisPC. This limitation and the difficulty of finding other SMIs 
that might be able to avoid the nCRP-mCRP dissociation, as reported by 
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Pepys et al. (2006) and Caprio et al. (2018) prompted the assessment of the 
potential anti-inflammatory activity of both ACh and Nicotine, that Borovikova 
et al. (2000) and Rosas-Ballina and Tracey (2009) confirmed to exert a strong 
anti-inflammatory activity on monocyte-derived macrophages.  
 
6.2 Assessment of whether mCRP stimulation induces monocyte-derivate 
macrophage pro-inflammatory activity. 
Over the years several studies have confirmed the finding of local deposits of  
mCRP, monocytes and macrophages in ischemic stroke (Slevin et al., 2010; 
Chiba and Umegaki, 2013), chronic kidney disease (Schwedler et al., 2003; 
Lee et al., 2013; Guiteras et al., 2016) Alzheimer (Feng et al., 2011; Slevin et 
al., 2017; Mammana et al., 2018) and infarcted myocardial tissue (Nahrendorf 
et al., 2010; Thiele et al., 2014b; O'Rourke et al., 2019). This promoted a series 
of experiments to determine whether mCRP could be involved in the 
physiopathology of the aforementioned pathologies, by increasing the U937 
monocyte and U937monocyte-derived macrophage pro-inflammatory cytokine 
production. 
 
The data reported in chapter 4 suggested that monocytes are immune system 
cells that duplicate very quickly (Fig. 4.1). However, these cells do not release 
pro-inflammatory TNF-α cytokines when stimulated by LPS (Fig. 4.2). 
Furthermore, even if some authors have shown that mCRP is able to bind with 
both αvβ3 and α4β1 integrins expressed on the U937 monocyte cell line (Fujita 
et al., 2014), the results obtained in this study indicate that this binding did not 
increase the pro-inflammatory TNF-α cytokine concentration (Fig. 4.2). This 
most likely takes place because, as previously reported, monocytes are unable 
to release pro-inflammatory cytokines (Wang et al., 1997; Hur et al., 2004). 
Therefore, it was decided to differentiate the monocytes into U937 monocyte 
derived macrophages to produce a valid in vitro inflammation model. 
 
The results herein reported showed that U937 monocytes can differentiate into 
macrophages when treated with PMA at a concentration of 50 ng/mL for 72 
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hours (Fig. 4.3, Fig. 4.4 and Fig. 4.5). After differentiation, macrophages 
increase pro-inflammatory cytokine secretion (Fig. 4.6 and Fig. 4.7). 
Moreover, these cells were able to up-regulate IL-1β gene expression when 
they were exposed to mCRP, at a concentration of 100 µg/mL, for 12 and 24 
hours (Fig. 4.8). The increase in IL-1β gene expression was found to be 
directly related to an increase in pro-inflammatory cytokines, i.e., TNF-α and 
IL-6 (Fig. 4.9) but not IFN-γ (Fig. 4.10). Indeed, IFN-γ is not released even 
after LPS stimulation (Fig. 4.10) probably due to the fact that this pro-
inflammatory cytokine is mainly released by T and natural killer (NK) cells 
(Kulkarni et al., 2016), or as it can be released by macrophages only when 
they have previously been co-stimulated by both IL-12 and IL-18 (Darwich et 
al., 2009). Furthermore, the research carried out during this PhD shows that 
when U937-derived macrophages were stimulated by mCRP, these cells were 
not able to increase the release of IL-10 anti-inflammatory cytokines (Fig. 
4.10). This result could indicate that mCRP has the potential to polarize 
macrophages towards an M1 pro-inflammatory phenotype (Trial et al., 2016), 
probably through the activation of the STAT-1/IRF-1/iNOS/NO intrinsic 
pathway, which was previously reported to be able to polarize several immune 
system cells towards an M1 pro-inflammatory phenotype (Jaruga et al., 2004; 
Lohoff and Mak, 2005; Xie et al., 2016). This hypothesis is not only supported 
by other previous studies, which confirm that mCRP is capable of generating 
NO (Mills et al., 2000; Mills, 2001; Sproston and Ashworth, 2018; Yao et al., 
2019), but may also have some clinical value in pathologies where the 
accumulation of monocytes/macrophages and mCRP has been confirmed in 
the same tissue (Schwedler et al., 2003; Eisenhardt et al., 2009b; Slevin et al., 
2015). Indeed, when this concomitant accumulation occurs, mCRP facilitates 
the macrophage polarization towards an M1 pro-inflammatory phenotype, this 
protein acerbates the inflammation by increasing the production of some pro-
inflammatory cytokines (Fig. 4.9) and reduces the release of some growth 
factors and anti-inflammatory cytokines (King et al., 2014; Gilbert et al., 2016) 
which are specifically synthesized  by the M2 anti-inflammatory phenotype (Liu 
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et al., 2018a; Krzyszczyk et al., 2018) where their presence may be 
compromised when mCRP binds with these immune system cells.  
 
During the last few decades, several studies have reported that the mCRP pro-
inflammatory activity is FCγR-mediated (Eisenhardt et al., 2009b; Okun et al., 
2010; Thiele et al., 2014a; Thiele et al., 2015; Mkaddem et al., 2019). Knowing 
that these receptors are also expressed on macrophages (Satpathy et al., 
2012; Chiba and Umegaki, 2013; Bain and Mowat, 2014; Vogelpoel et al., 
2015), it was reasonable to study whether the mCRP-macrophage pro-
inflammatory activity was mediated by the FCγRs. The results herein reported 
show that the FCγR antibodies did not increase the pro-inflammatory cytokine 
concentration on U937 macrophages (Fig 4.11 and Fig 4.12). Furthermore, it 
did not provoke the phosphorylation MAPK or NF-KB signalling pathways (Fig 
4.13). However, FCγR antibodies are unable to reduce mCRP pro-
inflammatory activity in U937 monocyte-derived macrophages (Fig 4.15). The 
fact that the FCγR antibodies cannot limit mCRP might depend on the capacity 
mCRP has to bind with the lipid raft microdomain or cholesterol binding 
sequence (CBS), rather than on its binding to FCγRs (Ji et al., 2009; Jia et al., 
2018).  
 
The significance of understanding the involvement of FCγRs with mCRP pro-
inflammatory activity was also linked to the potential biological effects that 
mCRP may have on other immune system cells, such as microglia. Microglia 
are tissue-resident macrophage cells that derive solely from the yolk-sac 
(Davies et al., 2013) and play a crucial role in brain inflammatory responses 
(Stephenson et al., 2018). It has recently been reported that microglia also 
express FCγRs (Fuller et al., 2014), which contributes substantially to 
microglia activation (Komine-Kobayashi et al., 2004) in Alzheimer’s disease 
(AD) (Fuller et al., 2014).  
 
Taking into consideration that two previous studies already confirmed that the 
presence of mCRP in the brain is associated to stroke-induced vascular 
dementia or AD (Slevin et al., 2015; Slevin et al., 2017), it would be interesting 
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to study whether the monomeric CRP forms could have a strong pro-
inflammatory activity in this immune system cell. 
 
6.3 Investigating the potential Acetylcholine anti-inflammatory activity on 
mCRP-stimulated monocyte-derivate macrophages. 
After showing that macrophages are able to release pro-inflammatory 
cytokines when stimulated by mCRP, another key purpose of this project was 
to evaluate which type of inflammatory pathway the mCRP was able to trigger. 
Therefore, western blot experiments were carried out to determine which 
macrophage intrinsic pathways are triggered.  
 
Recent studies have reported that when ECs are stimulated by mCRP, the 
activation of both MAPKs and NF-KB induces an increase in both the ICAM-2 
and VCAM-1 release (Li et al., 2014; Yong and Cao, 2020). The results herein 
reported evidenced that both the MAPK (ERK1/2, JNK1/2, MAPKp38) and NF-
KB intrinsic pathways were also activated in U937monocyte-derivated 
macrophages when these immune system cells were stimulated by mCRP at 
a concentration of 100 µg/mL (Fig. 5.11). Knowing that these signalling 
pathway activities can be limitated by Nicotine and ACh (Yoshikawa et al., 
2006a; Sun et al., 2013b), which would substantially reduce the pro-
inflammatory cytokine release (Han et al., 2017; Jiang et al., 2017a; Delgado-
Velez and Lasalde-Dominicci, 2018), it was assessed whether both ACh and 
Nicotine could be used as a potential SMI against mCRP pro-inflammatory 
activity, by binding with the U937 monocyte-derivate macrophages. 
 
The data reported in chapter 5 evidenced that neither ACh nor Nicotine were 
cytotoxic to the U937-derived macrophages (Fig. 5.2 and Fig 5.3) and did not 
trigger signalling pathways that could have been associated to a pro-
inflammatory response (Fig. 5.11). Furthermore, when the macrophages were 
stimulated by these two SMIs, these immune system cells did not increase the 
pro-inflammatory cytokine secretion (Fig. 5.4 and Fig 5.5) nor did they have 
other general anti-inflammatory proprieties (Fig. 5.6 and Fig. 5.7) differently to 
what was reported in some studies (Yoshikawa et al., 2006a; Liu et al., 2015a). 
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However, even if neither ACh nor Nicotine were able to block the dissociation 
from nCRP into mCRP (Fig. 3.4 and Fig. 3.5), the results herein reported 
showed that ACh was the only selected small molecular inhibitor able to reduce 
the mCRP induced increase in pro-inflammatory cytokines (Fig. 5.9). ACh 
reduced the concentration of both TNF-α and IL-6 cytokines, due to its ability 
to reduce the phosphorylation of the ERK/JNK/ NF-KB intrinsic pathway (Fig. 
5.11). 
 
As ACh is able to reduce IL-6 and TNF-α synthesis, down-regulating MAPK 
and NF-KB phosphorylation, there is the possibility that other MAPK and NF-
KB small molecule inhibitors may also be useful in blocking or reducing the 
mCRP pro-inflammatory cytokine release. For example, Tectorigenin (TEC), a 
natural element derived from the Belamcanda chinensis (Zhang et al., 2017a), 
that has both anti-inflammatory and antioxidant proprieties (Wang et al., 2017), 
could reduce the inflammation activity by reducing the activation of the MAPK 
and NF-KB intrinsic pathways (Yang et al., 2012; Zeng et al., 2018). Indeed, 
Lim et al. (2018) also published evidence of its anti-inflammatory proprieties 
and reported that TEC is able to reduce the IL-6 and TNF-α synthesis, through 
the down-regulation of the ERK, JNK and NF-KB phosphorylation, which are 
the same intrinsic pathways reported in this study.  
 
Resveratrol is another natural compound with anti-inflammatory activity and 
has been documented to be one of many strong bioactive polyphenol elements 
that can protect against CVD (Singh et al., 2015; Stephan et al., 2017) and 
stroke (Singh et al., 2013; Lopez et al., 2015). As aforementioned, ischemic 
stroke is a neurological medical condition where an accumulation of both 
mCRP and macrophages has been confirmed in the ischemic brain (Slevin et 
al., 2010; Chiba and Umegaki, 2013). An in vivo study reported that 
Resveratrol was able to reduce infarct size, ischemic injury, microglia 
activation and IL-1β, TNF-α and ROS concentration after a transient MCAO in 
both male and female C57BL/6 mice (Shin et al., 2010). Another study reported 
that Resveratrol was able to reduce both nCRP and triglyceride concentrations 
without any changes in weight, waist circumference or blood pressure (Bo et 
al., 2013). Later on, another two studies reported that, as Resveratrol reduced 
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ERK1/2, JNK and NF-КB phosphorylation and also decreased the TNF-α, IL-
1β, IL-6 and NO synthesis and release (Shao et al., 2014a; Zhang et al., 2015). 
Therefore, taking into consideration the potential Resveratrol has to reduce 
nCRP levels, as well as the fact that its anti-inflammatory activity is similar to 
that of ACh, it can be hypothesized that this bioactive polyphenol compound 
may have a specific protective function against mCRP deleterious activity. 
Moreover, these two compounds may also exert some anti-inflammatory 
activities, without increasing NF-KB phosphorylation. This is what occurred 
when ACh was used alone in the experiments herein reported (Fig. 5.11) and 
this may be attributed to an activation of muscarinic acetylcholine receptors 
(mAChR), as previously reported by Profita et al. (2008).  
 
mAChRs are widely distributed throughout human tissue (Caulfield and 
Birdsall, 1998) and are also expressed in both monocytes and macrophages 
(Kawashima et al., 2007) and allow ACh to exert its strong anti-inflammatory 
and antioxidant activity (Frinchi et al., 2019). However, in the last two decades, 
numerous studies have reported that the anti-inflammatory activity of ACh and 
Nicotine depends mainly on the capacity these two compounds have to 
specifically activate α7nAchR (Nathan, 2002; Tracey, 2002; Wang et al., 2003; 
de Jonge et al., 2005; Saeed et al., 2005; Pavlov and Tracey, 2005; Tracey, 
2007; Ren et al., 2017; Han et al., 2017), which has also been reported to be 
strongly expressed on macrophages (Nathan, 2002; Tracey, 2002; Wang et 
al., 2003; de Jonge et al., 2005; Saeed et al., 2005; Tracey, 2007).  
 
Differently to what has been reported in literature (Ren et al., 2017), i.e., that 
both ACh and Nicotine are able to bind to α7nAchR, the results obtained in this 
study evidenced that only ACh had anti-inflammatory activity against mCRP 
(Fig. 5.9). Nicotine did not reduce pro-inflammatory cytokine secretion, maybe 
due to the fact that Nicotine itself increases nCRP expression when it binds to 
nAChR and activates the nAChR-MAPK signalling pathways on U937-
monocyte-derived macrophages (Mao et al., 2012). This is confirmed by the 
activation of the MAPKp38 intrinsic pathway reported in Fig 5.11, which may 
also interfere with the anti-inflammatory activity of Nicotine against mCRP. 
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As ACh anti-inflammatory activity has been associated with α7nAchR 
activation, methyllycaconitine (MLA), a known selective α7nAchR antagonist 
(Carroll et al., 2007; Patel et al., 2017; Krafft et al., 2017; Zou et al., 2017), was 
used to assess whether ACh anti-inflammatory activity depends on the 
capacity of ACh to activate α7nAchR. The results evidenced that MLA does 
not induce any cytotoxic activity on U937-derived macrophages, either alone 
or in combination with SMIs (Fig 5.15), nor did MLA trigger any pro-
inflammatory activity on U937 macrophages (Fig 5.16) or phosphorylate the 
MAPK or NF-KB signalling pathways (Fig 5.18). However, surprisingly, MLA 
did not reverse the ACh anti-inflammatory proprieties but rather increased 
them (Fig 5.19). These results are similar to other previous findings, which 
reported that MLA may play an anti-inflammatory role, as previously reported 
for microglia (Thomsen and Mikkelsen, 2012). A possible explanation for this 
could be that this α7nAchR antagonist does not increase the MAPKp38 or NF-
KB intrinsic pathways (Fig. 5.18), differently to what has been evidenced when 
macrophages are stimulated by ACh or Nicotine alone (Fig. 5.11).  
 
  
205 | P a g .  
   
6.4 Conclusions. 
A series of experiments were performed in this project to establish if and how 
monomeric-CRP might trigger or increase inflammation. The data obtained 
confirmed that the pentameric nCRP protein can be dissociated into a 
monomeric-CRP form (mCRP) and the use of two different cholinergic 
compounds, i.e., ACh and Nicotine does not block this dissociation. 
Furthermore, it was observed that macrophages up-regulate IL-1β and IL-6 
gene expression when stimulated by mCRP at a concentration of 100 µg/mL. 
This up-regulation was also associated with an increase in the release of pro-
inflammatory TNF-α and IL-6 cytokines through the activation of the ERK1/2, 
JNK1/2, MAPKp38 and NF-KB signalling pathways. The results also evidence 
that ACh plays a strong anti-inflammatory role against mCRP pro-inflammatory 
activity by working at both a pre- and post-transcriptional level (Fig 6.1).  
 
In conclusion, the experiments carried out during this project evidenced that 
ACh, or other small molecule inhibitors with a similar structure, may be useful 
in blocking the mCRP pro-inflammatory activity that may be important in some 
chronic inflammatory medical conditions.  
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Fig 6.1. ACh decreases monomeric c-reactive protein pro-inflammatory activity. When 
monomeric-CRP activates the MAPKKK/MAPKs/MAPKs intrinsic pathways this leads to the 
nuclear translocation of the NF-KB. Transcription factor NF-KB increases the mRNA and protein 
expression of several pro-inflammatory cytokines. ACh is unable to block MAPKp38 
phosphorylation, which promotes the NF-KB nuclear translocation associated with an increase of 
pro-inflammatory cytokine release. However, the use of ACh to reduce MAPKs (JNK1/2 and 
ERK1/2) and NF-KB phosphorylation, limits the pro-inflammatory cytokine release which is more 
elevated when macrophages are stimulated with mCRP alone. Furthermore, ACh may also be able 
to reduce the pro-inflammatory cytokine release by intervening at a post-transcriptional level, 
thus reducing the life of mRNA. 
207 | P a g .  
   
6.5 Limitations. 
• Even if U937 cells have previously been used in other chronic 
inflammatory conditions, such diabetes, stroke, obesity and chronic 
kidney disease (Jain et al., 2002; Power et al., 2003; Yamagata et al., 
2010; Fuggetta et al., 2019; Brito et al., 2020), none of these 
experiments provided evidence that the U937 monocytes, which 
differentiated into macrophages after PMA induction, behaved like 
primary circulating macrophages. 
 
• As aforementioned, when monocytes differentiate into macrophages, 
they extravasate to the surrounding area and express specific surface 
markers, such as FCγR (Murray and Wynn, 2011; Satpathy et al., 
2012). It has been reported that nCRP-mCRP dissociation led to an 
increase in monocyte adhesion and ROS, which is abolished when 
CD64 (FCγI), CD32 (FCγIIa), CD16 (FCγIII) receptors are blocked 
(Eisenhardt et al., 2009b). However, none of these experiments were 
aimed at assessing whether PMA could affect the expression of these 
receptors or whether antibodies were able to identify receptors on 
monocyte differentiated macrophages.  
 
• A total of 24/30 the experiments were repeated 3 times. The 6 
exceptions were optimization experiments which were carried out only 
once. This was because previous work in this group already had other 
similar complementary definitive results, i.e., the experiments reported 
in chapter 3.2 and 3.3 complemented the results obtained by the 
Surface plasmon resonance technique and published by Slevin et al. 
(2018) 
 
• All the results herein reported are based on an in-vitro model. The main 
drawback of this experimental model is that it is challenging to obtain 
the same or similar results in an in vivo model. 
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6.5 Future Work. 
Further studies could be carried out on the basis of the findings herein reported  
 
• Previous studies reported that mCRP stimulation of ECs triggers the 
activation of both MAPKp38 and NF-KB signalling pathways (Li et al., 
2014). Literature confirmed that when mCRP activates these signalling 
pathways there is an increase in the concentration of IL-6, ICAM-1, 
VCAM-1, which is associated to an elevated migration and recruitment 
of several immune system cells, such as monocytes, macrophages, 
natural killer cells and dendritic cells (Yang et al., 2008; Eisenhardt et 
al., 2009b; Yong and Cao, 2020). It has also been reported that ACh is 
able to bind with ECs (Shao et al., 2014b). Furthering these findings, a 
recent publication from this work, reported that ACh can limit (even if 
not significantly) the mCRP-mediated adhesion of EC to monocytes 
(Slevin et al., 2018). Future studies may be able to reach statistical 
significance, if ACh were used together with the SMI 6877002. Indeed, 
a recent study reported that when SMI 6877002 binds to monocytes it 
is able to: (I) reduce pro-inflammatory cytokine secretion; (II) increase 
the IL-10 anti-inflammatory cytokine release; (III) and reduce trans-
endothelial monocyte migration (Aarts et al., 2017). Therefore, it is 
reasonable to presume that a combined stimulation with both ACh and 
SMI 6877002 may significantly reduce the mCRP pro-inflammatory 
activity in endothelial cell/macrophage co-cultures in in-vitro models. 
This could be useful in those pathologies were the endothelial, 
monocyte and mCRP interactions play a significant role in the 
development of pro-thrombotic and pro-inflammatory events (Molins et 
al., 2008; Eisenhardt et al., 2009b), which are often associated with 
medical conditions like arteriosclerosis or ischemic stroke (Badimon 
and Vilahur, 2014; Simons et al., 2015). 
 
• ACh is able to reduce the mCRP pro-inflammatory activity, thus 
reducing ERK1/2, JNK1/2 and NF-kB phosphorylation. Knowing that 
both MAPK and NF-KB transcription factors regulate the expression of 
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genes involved in both acute and chronic inflammatory responses, it is 
may also be that other MAPKs and NF-KB SMIs could be used to block, 
or at least reduce, mCRP pro-inflammatory activity. Amongst the MAPK 
and NF-KB inhibitors, both Tectorigenin (TEC) and Resveratrol may be 
the most efficient candidates for this role due to their capacity to limited 
both MAPK and NF-KB activity.  
 
• In the last few decades several studies have highlighted a number of 
common features in stroke and AD. (Desmond et al., 2002; Arbel-
Ornath et al., 2013; Weinstein et al., 2013; Pase et al., 2017). After an 
ischemic stroke (IS) event, Howard (2016) advised that the first medical 
intervention after IS onset should be targeted towards restoring blood 
flow. However, the ischemia/reperfusion injury can exacerbate organ 
injury, allowing both nCRP and mCRP to penetrate the reperfused 
tissue (McFadyen et al., 2018). Other authors reported a strong link 
between this phenomenon and the increase of dementia incidence 
(Slevin et al., 2015; Slevin et al., 2017; Mammana et al., 2018), although 
the underlying mechanisms are still to be fully clarified. Based on the 
data presented herein, it would be interesting to study whether the 
binding of mCRP with microglia triggers a pro- inflammatory activity. 
Furthermore, it would also be of interest to assess whether the 
stimulation of ACh or Nicotine could be used as a potential 
therapeutically approach in microglia, based on fact that both of them 
have already been proposed as potential pharmacological treatment for 
several neurological diseases (Han et al., 2017). 
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